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Abstract 
 
The infectious disease tuberculosis (TB) remains the leading cause of death worldwide by a single 
infectious agent, despite significant advances in biomedical sciences. The idea that host genetics 
plays a role in the development of disease was proposed by Haldane in 1949. The observation that 
only 10% of immunocompetent individuals develop disease while others are able to successfully 
contain it, further suggests that host genetics plays an important role. TB is thus a complex 
disease, with the causative bacterium, Mycobacterium tuberculosis, host genetic factors and 
environment all contributing to the development of disease. To date several genes have been 
implicated in TB susceptibility, albeit with small effect.  
 
Genome-wide association studies (GWAS) offer the means to identify novel susceptibility variants 
and pathways through their ability to interrogate polymorphisms throughout the genome without 
being limited by our understanding of the immune processes involved in TB infection and disease 
progression. TB and sarcoidosis are both granulomatous diseases, and we therefore hypothesized 
that the genes and their associated variants identified in recent GWAS conducted in West Africa 
for TB, and Germany for sarcoidosis, could alter susceptibility to TB in the South African Coloured 
(SAC) population. In the sarcoidosis GWAS, ANXA11 was shown to alter susceptibility to 
sarcoidosis; whereas in the TB GWAS, CADM1 was found to alter susceptibility to TB. 
 
This study tested the association with TB of 16 polymorphisms in 5 potential TB host susceptibility 
genes in the SAC population. A well designed case-control study was employed, using the 
TaqMan® genotyping system to type the various polymorphisms. Any polymorphism that was 
found to be significantly associated with susceptibility to TB was then subjected to further analysis 
to determine the functional effect of the polymorphism. Promoter methylation patterns were also 
investigated in ANXA11 as another mechanism to elucidate its role in TB susceptibility. 
 
A 3’ UTR ANXA11 polymorphism was found to be strongly associated with susceptibility to TB, 
including 3 haplotypes. The gene expression analysis identified differential transcriptional levels 
between individual with the different genotypes, with individuals homozygous for the A-allele 
exhibiting a 1.2-fold increase in gene expression relative to those homozygous for the G-allele. 
Methylation analysis however found no differences between cases and controls. In addition, 16 
novel polymorphisms were also identified, 15 of which occurred in the 3’UTR of ANXA11. The 
mechanism of action of ANXA11 in TB susceptibility is hypothesised to be in the area of 
endocytosis, autophagy or apoptosis. 
 
A weak association was noted with one of the 5’ UTR polymorphisms of CADM3, which did not 
hold up to further analysis in the GWAS study, and no functional work was therefore done. 
 
This work facilitates our understanding of the role of host genetics in susceptibility to TB and adds 
to the growing amount of information available. Proper understanding of the role that host 
genetics plays in TB susceptibility could result in better treatment regimens and prediction of 
individuals who are at a greater risk of developing TB, a disease that still kills millions of individuals 
annually. 
 
 
 
 
 
 
 
Opsomming 
 
Tuberkulose is verantwoordelik vir meer sterftes as enige ander aansteeklike siekte, ten spyte van 
die voortuitgang wat die Biomediese Wetenskappe tans beleef.  In 1949 het Haldane voorgestel 
dat die genetiese samestelling van die gasheer ‘n rol speel in vatbaarheid vir aansteeklike siektes.  
Vir tuberkulose word hierdie aanname gesteun deur die feit dat slegs 10% van individue wat 
geïnfekteer word aktiewe simptome ontwikkel, terwyl 90% die siekte suksesvol sal afweer.  
Tuberkulose is dus ‘n komplekse siekte wat veroorsaak word deur Mycobacterium tuberculosis, 
maar wat beïnvloed word deur genetiese sowel as omgewingsfaktore.  Verskeie gene is al 
geïdentifiseer wat ‘n rol speel in vatbaarheid vir tuberkulose, tog is hul invloed betreklik klein. 
 
Genoom-wye assosiasiestudies (GWAS) bied unieke geleenthede vir die identifisering van nuwe 
polimorfismes wat genetiese vatbaarheid kan beïnvloed.  Hierdie tegniek kan die hele genoom 
fynkam, sonder dat enige vooropgestelde idees oor die immuunrespons teen tuberkulose ‘n 
invloed sal hê.  Tuberkulose en sarkoïdose is albei siektes wat die vorming van granulomas 
veroorsaak. Verskeie gene met hul geassosieerde variante is geïdentifiseer in ‘n onlangse GWAS, 
wat gefokus het op populasies in Wes-Afrika en Duitsland. Ons hipotese was dat die polimorfismes 
wat in hierdie studie geïdentifiseer is, ‘n invloed kan hê op genetiese vatbaarheid vir TB in die 
Suid-Afrikaanse Kleurlingbevolking (SAK). Die sarkoïdose GWAS het bevind dat ANXA11 
vatbaarheid vir die siekte beïnvloed, terwyl CADM1 in die tuberkulose GWAS geïdentifiseer is. 
 
Die studie het die assosiasie tussen 16 variante en tuberkulose vatbaarheid ondersoek in die SAK 
populasie.  Die variante strek oor 5 potensiële tuberkulose vatbaarheidsgene.  Goedbeplande 
pasiënt-kontrole assosiasiestudies is gedoen en die polimorfismes is gegenotipeer deur gebruik te 
maak van die TaqMan® genotiperingsisteem. Enige polimorfisme wat beduidend met tuberkulose 
geassosieer was, is verder geanaliseer om die moontlike funksionele invloed daarvan te bepaal.  
Promotormetileringspatrone van ANXA11 is ook geanaliseer, om ‘n addisionele meganisme in 
tuberkulose vatbaarheidheid te ondersoek.  
 
Na genotipering van die polimorfismes is ‘n 3’ UTR ANXA11 variant geïdentifiseer wat beduidend 
met tuberkulose vatbaarheid geassosieer was.  Drie haplotipes is ook geïdentifiseer.  
‘Geenuitdrukkingsanalise het aangedui dat verskille in transkripsie vlakke voorkom in individue 
met verskillende genotipes. Individue wat homosigoties was vir die A-alleel het ‘n  verhoging van 
1.2 in geenuitdrukking gehad, relatief tot individue wat homosigoties was vir die G-alleel.  
Metileringsanalise het egter geen verskil aangedui tussen pasiënte en kontroles nie.  Addisioneel, 
is 16 nuwe variante ontdek, waarvan 15 in die 3’UTR van ANXA11 geleë was.  Die meganisme 
waarmee ANAX11 genetiese vatbaarheid vir tuberkulose beïnvloed, blyk in die area van 
endositose, apoptose of outofagie, te wees. 
 
‘n Swak assosiasie is gevind vir ‘n 5’ UTR variant van CADM3 en is nie verder opgevolg in die GWAS 
nie.  Gevolglik is geen funksionele studies op hierdie polimorfisme gedoen nie.   
 
Hierdie studie dra by tot ons kennis oor die rol wat die genetiese samestelling van die gasheer 
speel in vatbaarheid vir tuberkulose.  Indien die rol van mensgenetika in tuberkulose vatbaarheid 
korrek verstaan word, kan behandeling van die siekte verbeter word en kan individue wat  ‘n hoër 
risiko loop om tuberkulose te ontwikkel geïdentifiseer word. 
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Chapter 1: Tuberculosis 
 
 
 
 
 
The capacity to blunder slightly is the real marvel of DNA.  Without this special 
attribute, we would still be anaerobic bacteria and there would be no music.   
 
Lewis Thomas 
 
 
 
 
 
 
 
 
 
 
 
1 
 
1.1 A Brief History of Tuberculosis 
 
Tuberculosis (TB) has recently re-emerged as a major global health concern. However, TB has been 
plaguing humanity for centuries before this, with the earliest documentation of TB occurring in 
Egypt as early as 5000 years ago, based on the isolation of Mycobacterium tuberculosis (M. 
tuberculosis) DNA from mummies 1, 2. Earlier names for TB included phthisis, which means 
consumption or to waste away, and was identified as the most rife disease of the times by 
Hippocrates3. He also noted that the disease occurred more frequently in individuals between the 
ages of 18 and 25 years old, and almost always resulted in death. It was Clarissimus Galen, a Greek 
physician, who described phthisis as an “ulceration of the lungs, chest or throat, accompanied by 
coughs, low fever, and wasting away of the body because of pus”; and described it as a disease of 
malnutrition4. 
 
With the commencement of the 17th century, Europe was struck by a TB epidemic which lasted for 
200 years, and was later known as the “Great White Plague” 3. It is believed that overcrowding and 
poor sanitary conditions that were characteristic of the rapidly growing cities of the Western 
World provided the necessary milieu for the spread of this airborne pathogen. Due to the 
exploration and colonization that was typical of this period, the TB epidemic slowly consumed the 
colonized nations as well 5. Although it is believed that TB existed in America and Africa before the 
arrival of the Europeans, the disease was very rare among the indigenous people, but after contact 
with the Europeans, the mortality rate due to TB rapidly increased within these native 
populations. 
 
Even though 17th century Europe was plagued with TB disease, it is the century during which 
scientists began to unravel the mysteries of the disease and its causative agent 1, 5, 6. It was 
Franciscus Sylvius de la Böe of Amsterdam who was the first to identify the presence of tubercles 
in the lungs of TB patients as a characteristic of the disease, and this finding was later 
corroborated by the English physician Richard Morton 3. Both de la Böe and Morton also believed 
that the disease was hereditary; however, Morton also considered transmission by intimate 
contact as a possible mechanism. Later it was shown by Gaspard Laurent Bayle that the tubercles 
noted by de la Böe and Morton were not the products of the disease but the actual cause, which 
gave rise to the name of the disease used today: tuberculosis. 
 
During the 18th and 19th centuries, various physicians and epidemiologists made scientific 
breakthroughs in that they finally discovered that the causative agent of TB was a microorganism, 
and that it could be transmitted between individuals and between humans and various other 
mammal species. In 1882, Robert Koch made his famous presentation, in which he showed that 
the bacterium, M. tuberculosis, was the causative agent of tuberculosis disease 2, 3. Towards the 
end of the 19th century, Koch announced the isolation of a compound that inhibited the growth of 
the tubercle bacilli when administered to guinea pigs both pre- and post-exposure. This compound 
was called ‘tuberculin’, and soon after its discovery it was used as a therapeutic vaccine in a 
clinical trial, the results of which were extremely disappointing. However, it was found to be 
valuable in the diagnosis of TB, and later gave rise to the currently used Tuberculin Skin 
Test/Mantoux test, which is used for diagnosis of latent TB. 
 
The 20th century brought with it the advent of the first successful vaccine and the use of 
chemotherapy in the fight against TB. At the beginning of the century, Albert Calmette and Camille 
Guérin successfully created the attenuated strain of M. bovis, Bacille Calmette-Guérin (BCG), 
which was avirulent in cattle, horses, rabbits and guinea pigs 1. In 1943, the first antibiotic, 
2 
 
streptomycin, was isolated by Selman A. Waksman and Albert Shatz from Streptomyces griseus. 
The drug was effective against M. tuberculosis in vitro, and post-infection in guinea pigs. In 1944, 
the first human was treated with the drug and two clinical studies followed, one in Europe and the 
other in the United States of America. It was noted that individuals who were treated with 
streptomycin exhibited a substantial improvement in the outcome of disease. The findings of 
these studies were however of a “double-edge sword” nature, in that the investigators also noted 
that following the first months of treatment, some patients’ disease status began to worsen; from 
which they concluded that the pathogen was able to develop resistance to the drug 7. This was 
soon followed by the administration of para-aminosalicylic acid (PAS) as an oral therapy 3. PAS 
therapy was successful in treating TB, and unlike streptomycin, it was non-toxic and the bacterium 
was not able to develop resistance to the drug easily. In the late 40’s, researchers noted that when 
TB patients were treated with both streptomycin and PAS, the disease outcome was much more 
favourable than when patients were treated with only one of the drugs. The 1950’s saw the 
introduction of isoniazid (INH) as a chemotherapeutic agent against TB. Unfortunately, however, 
like its predecessor streptomycin, it was found that M. tuberculosis was able to easily develop 
resistance to this drug. On the positive side, treatment with streptomycin, PAS and INH was found 
to be highly effective in the treatment of TB, and for the first time TB was curable. This lead to a 
wave of new drugs being developed for the treatment of TB, including rifampicin, pyrazinamide, 
ethambutol, cycloserine and ethionamide; all of which are still in use today for the treatment of 
TB. However, the problem of drug resistance acquisition continues. 
 
TB has had a long history, claiming millions of victims during the ages and taking more lives than 
any other microbial disease. Due to this, TB has left its mark on humanity; in music, art and 
literature and playing a major role in the advancement of biomedical sciences and healthcare. So 
what does the 21st century hold for this highly efficient pathogen? 
 
1.2 Global Epidemic 
 
 In 1993, the World Health Organization (WHO) declared TB a global health emergency 8. 
Approximately one-third of the world’s population is infected with M. tuberculosis, with the WHO 
estimating that 9.27 million people developed TB in 2007, with around 2 million deaths. Most TB 
incident cases were from developing countries, predominantly Asia and Africa (Figure 1) with 
India, China, Indonesia, Nigeria and South Africa rated as the five countries with the highest TB 
burden respectively. 
 
TB is the world’s second most common cause of death by an infectious agent, after the human 
immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS). Although TB is “under 
control” in developed nations, it remains a major health threat in third world countries. This is 
predominantly due to high HIV infection rates, poor health care, poor socio-economic status and 
the development of drug resistant strains of M. tuberculosis. 
 
1.3 South African Perspective 
 
TB has been a long-standing health issue in South Africa and with the current HIV epidemic 
sweeping the nation, the fight for the eradication of TB has become even more difficult, with a HIV 
prevalence rate of 18.1% (2007) in South African adults 10. As mentioned previously, South Africa is 
currently ranked 5th in the world with regards to TB burden, with TB treatment success rates 
remaining low due to the high number of deaths due to TB, an increase in relapses due to poor 
adherence to treatment therapy and the spread of multidrug-resistant (MDR) and extensively drug  
3 
 
 
 
 
Figure 1: Estimated TB incidence rates by country, 2007 (Reproduced 8) 
 
 
 
            Figure 2: Estimated TB incidence rates in South Africa and its provinces, 1999 – 2006 9 
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resistant (XDR) TB 11. 
 
Of the South African provinces, the Western Cape has maintained a consistently high TB incidence 
rate 1 030 per 100 000, only surpassed in 2006 by the Kwa-Zulu Natal Province with 1 076 per 
100 000. The current incidence rate for TB in South Africa is 948 per 100 000 individuals 9 (Figure 
2). 
 
1.4 Mycobacterium tuberculosis – clinical features and pathogenesis 
    
   1.4.1 Structure 
 
TB is a result of infection by the pathogen, M. tuberculosis, although other members of the 
Mycobacterium tuberculosis complex are also known to result in TB, including M. africanum, M. 
bovis and M. microti 12, 13. These bacteria are rod-shaped (Figure 3), non-spore-forming, aerobic, 
Gram-positive bacteria. Mycobacteria usually measure 0.5 µm x 0.3µm and are classified as acid-
fast bacilli due to the difficulty with which dyes are removed from the cell wall with the treatment 
of acid-alcohol after the staining of the cell wall 14, 15. 
 
 
Figure 3: Scanning electron micrograph image of M. tuberculosis. Courtesy of the Centre for Disease Control.  
 
The cell wall structure of M. tuberculosis is essential for the survival of this pathogen intracellularly 
14. The cell wall of M. tuberculosis is comprised of mycolic acid (fatty acid) which is covalently 
bound to arabinogalactan (peptidoglycan-bound polysaccharide) which gives rise to the 
bacterium’s extraordinary lipid barrier. This lipid barrier is largely responsible for the ability of M. 
tuberculosis to develop resistance to antibiotics and evade the host’s defence mechanisms. The 
presence of lipoarabinomannan on the cell wall of the bacterium confers upon it its immunogenic 
properties, allowing the bacterium to survive within macrophages, while the composition and 
quantity of the bacterium’s cell wall components directly influences its pathogenicity and growth 
rate.  
   
 1.4.2 Mode of Transmission 
 
M. tuberculosis is an airborne pathogen with transmission as the result of the spread of small 
airborne droplets, droplet nuclei, usually generated by coughing, sneezing or talking of an infected 
person with pulmonary tuberculosis 2. Due to the small size of these droplets, they are able to 
remain airborne for long time periods. When these droplet nuclei enter the lungs of an uninfected 
individual various outcomes are possible. Depending on the pathogenicity of the M. tuberculosis 
strain and the host’s immune response 16, the newly infected individual can go on to develop 
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active TB disease, prevent the growth and spread of the bacteria or immediately kill the bacteria. 
Various factors can influence the transmission of M. tuberculosis, including the number of bacilli 
contained within the droplet nuclei, virulence of the bacilli and ventilation. 
 
   1.4.3 Host Immune Response 
 
Cell-mediated immunity is the primary response employed by the host to fight off M. tuberculosis 
infection 12. TB infection starts when the bacteria reach the alveoli and are phagocytosed by 
alveolar macrophages or dendritic cells 17. Depending on the virulence of the infecting strain and 
the immune system of the host there are two possible outcomes 15, 17, 18. Firstly, as occurs in most 
individuals, phagocytosis of the bacteria by macrophages results in the initiation of a strong host 
immune response and the subsequent death of the mycobacteria. However, if the host is unable 
to contain the growth of the bacteria the formation of granulomas will follow. They have the 
effect of limiting the growth and further spread of the bacilli and are formed by macrophages, T 
lymphocytes, B-lymphocytes and fibroblasts 17. The T lymphocytes, which surround the infected 
macrophages, release various cytokines including interferon gamma (IFN-γ) which activates the 
macrophages to destroy the bacterium. In most cases however, the bacteria are not killed but 
become dormant resulting in latent infection17, 19. At this stage of infection, the immune system 
effectively contains the infection. However, if it is unable to, the bacteria will begin to actively 
replicate, resulting in necrosis of the infected lung tissue and further spread of the bacteria to 
other body organs (extrapulmonary TB) or to new hosts. 
 
   1.4.4 Clinical Manifestation and Diagnosis 
 
Based on the immune response that is elicited at the point of infection, TB disease can manifest in 
various forms; including latent infection, primary disease, active TB disease and extrapulmonary 
TB disease (Table 1). Each stage of disease can be characterised by its own set of symptoms and 
means of diagnosis14.  
 
In summary, latent TB occurs when the host immune system is unable to completely eliminate the 
bacterium after infection but is able contain its growth within an enclosed location. Although 
these bacteria are viable and are able to persist for many years, they do not result in active TB 
disease and therefore no symptoms are experienced and these individuals are not infectious. In 
the past, latent TB was diagnosed by means of the tuberculin skin test (TST), however, due to 
false-negative (immunocompromised or malnourished individuals) and false-positive (response to 
BCG vaccination) skin tests, this method has been replaced by the QuantiFERON-TB Gold test 
which is thought to be more sensitive and time efficient (Table 2). 
 
Active TB disease occurs when the immune response initiated by the host is unable to control the 
infection, resulting in the active growth of the bacterium in the lungs of the infected individual. 
These individuals experience various symptoms which are indicative of active TB disease. These 
include fatigue, weight loss, fever, extensive coughing, night sweats and anaemia. These 
individuals are highly infectious. Diagnosis of active TB usually involves chest X-rays in addition to 
sputum smears and sputum cultures (the “gold standard”). However, recent advances in 
molecular biology have allowed for the development of faster diagnostic tests. Amplification of 
DNA and RNA now allows for rapid detection of microorganisms (Table 2). 
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Table 1: Different stages of TB infection  
Early Infection 
Early Primary Progressive 
(active) 
Late Primary 
Progressive (active) 
Latent 
Immune system fights 
infection 
 
Infection generally 
proceeds without signs 
or symptoms 
 
Patients may have 
fever, paratracheal 
lymphadenopathy, or 
dypsnea 
 
Infection may be only 
subclinical and may not 
advance to active 
disease 
Immune system does not 
control initial infection 
 
Inflammation of tissue 
ensues 
 
Patients often have 
nonspecific signs or 
symptoms (e.g., fatigue, 
weight loss, fever) 
 
Non-productive cough 
develops 
 
Diagnosis can be difficult: 
findings on chest 
radiographs may be 
normal and sputum 
smears may be negative 
for mycobacteria 
Cough becomes 
productive 
 
More signs and 
symptoms as disease 
progresses 
 
Patients experience 
progressive weight loss, 
rales, anaemia 
 
Findings on chest 
radiograph are normal 
 
Diagnosis is via cultures 
of sputum 
Mycobacteria persist in 
the body 
 
No signs or symptoms 
occur 
 
Patients do not feel sick 
 
Patients are susceptible 
to reactivation of 
disease 
 
Granulomatous lesions 
calcify and become 
fibrotic, become 
apparent on chest 
radiographs 
 
Infection can reappear 
when 
immunosuppression 
occurs 
 
Finally, extrapulmonary TB occurs when the infection can no longer be contained within the lungs 
and the bacterium enters the blood system (miliary TB) and is able to infect other organs. The 
most seriously infected region is the central nervous system, which results in tuberculosis 
meningitis (TBM). This form of TB is often fatal and is usually characterized by headaches and 
mental instability. Miliary TB on the other hand is much more difficult to diagnose, due to the 
nonspecific symptoms experienced by these individuals; including fever, weight loss and 
weakness. 
 
Table 2: Diagnostic tests currently employed in TB 
Variable 
Sputum 
smear 
Sputum culture 
Polymerase 
chain 
reaction 
(PCR) 
Tuberculin 
skin test 
QuantiFERON-
TB test 
Chest 
radiography 
Purpose of 
test study 
Detect 
acid-fast 
bacilli 
Identify M. tb Identify M. 
tb 
Detect 
exposure to 
mycobacteria 
Measure 
immune 
reactivity to 
M. tb 
Visualize 
lobar 
infiltrates 
with 
cavitation 
 
Time 
required 
for results 
 
<24 hours 
 
3-6 weeks with 
solid media, 4-
14 days with 
high-pressure 
liquid 
chromatography 
 
Hours 
 
48-72 hours 
 
12-24 hours 
 
Minutes 
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1.4.5 Treatment 
 
The advent of sanatoria represented the first widely used treatment for the fight against TB 1, 3. 
Treatment was rather simple, with infected individuals receiving good nutrition and maximum 
exposure to fresh air. However, with the discovery of the antibiotics, streptomycin and PAS in the 
1940’s, current TB treatment has altered drastically 3. Today, treatment goals include curing 
infected individuals and limiting the chance of relapse, stopping transmission and preventing the 
development of drug resistance and death 20. 
 
Current TB drug treatments require extended time periods (usually six months) of medical drug 
use 20. TB treatments are usually composed of 2 phases, namely an initial phase (2 months) and a 
continuation phase (4-7 months). During the initial phase infected individuals receive four first-
line* drugs (Table 3); while during the continuation phase these individuals receive only isoniazid 
(INH) and rifampicin (RIF). However, due to this long treatment plan, poor treatment adherence is 
observed which leads to the development of drug-resistant TB. In this case, patients are treated 
with second-line drugs (Table 3) for an extended time period. 
 
Table 3: Anti-TB drugs currently in use. 
First-line drugs Second-line drugs 
Isoniazid* Cycloserine 
Rifampicin* Ethionamide 
Ethambutol* Levofloxacin 
Pyrazinamide* Moxifloxacin 
 Gatifloxacin 
Rifapentine p-Aminosalicylic acid 
Rifabutin Streptomycin 
 Amikacin/Kanamycin 
 Capreomycin 
*
First-line drugs by default 
 
Although TB treatment plans are broadly applicable, treatment modifications should be made 
under certain conditions; including HIV infection, drug-resistance, pregnancy and the treatment of 
children. 
 
1.5 TB – Future Prospects and Fatal Alliances 
    
   1.5.1 Drug-Resistant TB 
 
The development of resistance in M. tuberculosis to various anti-TB drugs is considered one of the 
draw-backs of the use of chemotherapy to fight TB disease 21. Drug resistance is defined as the 
inability of otherwise effective drugs to kill the bacterium and is a result of drug misuse and 
mismanagement. This includes poor treatment adherence, incorrect prescriptions by health-care 
workers (wrong treatment, dosage, and treatment period), the unavailability of drugs and drugs of 
poor quality. 
 
There are currently two forms of drug-resistant TB, namely multidrug-resistant TB (MDR TB) and 
extensively drug resistant TB (XDR TB) 22, 23. MDR TB is defined as TB that is resistant to at least 
two of the most efficient first line drugs, INH and RIF. These TB cases are usually much more 
difficult to treat, with a mortality rate of approximately 40% - 60%. XDR TB on the other hand is TB 
that is resistant to both INH and RIF, in addition to any fluoroquinolone and at least one of the 
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three injectable second-line drugs (amikacin, capreomycin or kanamycin) 20. This form of TB is 
much harder to treat, mainly due to the resistance of the pathogen to most first- and second-line 
anti-TB drugs, resulting in poorly effective treatment options and outcomes. 
 
   1.5.2 HIV and TB 
 
With the global spread of the HIV/AIDS epidemic, controlling TB disease has become exceedingly 
difficult. Due to the immunocompromising effect of HIV infection, TB disease prognosis has 
worsen, with noted increasing risks for reactivation of latent M. tuberculosis  infection and rapid 
disease progression 24, 25. It has also been noted that individuals only infected with M. tuberculosis 
exhibit lifetime risks of developing TB of between 10% and 20%, while individuals infected with 
both M. tuberculosis and HIV have an annual risk of developing TB greater than 10%. 
 
 
Figure 4: Estimated HIV prevalence in new TB cases, 2007 8 
 
Southern Africa currently has the highest prevalence of HIV infection in new TB cases (Figure 4), 
with more than 50% of new TB cases being co-infected with both organisms 11. 
 
1.6 Other Risk Factors for the Development of TB 
    
   1.6.1 Host Genetic Factors 
 
There is clear evidence that host genetic factors play a crucial role in the development of active 
clinical tuberculosis and that pathogenic factors, although important, is not the sole deciding 
factor in who progresses to disease and who does not. Current global TB statistics highlight the 
important fact that of the one-third of the world’s population infected with TB; only 10% will go on 
to develop active disease. This clearly shows that host genetic factors are extremely important in 
the outcome of this infection. 
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To support this idea, various classical studies have been conducted on the effects of host genetics 
in infectious diseases; these include numerous twin and adoption studies. Twin studies have been 
used to determine how susceptibility to infectious diseases differs between monozygotic and 
dizygotic twins 26-28. All of these studies found that monozygotic twins, who share the exact 
genetic make-up, have a higher concordance for disease than dizygotic twins, whose genetic 
make-up differs from each other (Table 4). This illustrates that host genetic factors are major 
contributors to the development of TB since twins generally share the same environment. 
Adoption studies have also been conducted, which have conclusively shown that adopted children 
are more likely to die from an infectious disease if their biological parents died from an infectious 
disease compared to their adoptive parents, again highlighting the importance of host factors over 
environment in the outcome of disease 29-32.  
 
Table 4: Twin studies investigating the heritability of TB. 
Study 
Number of Twins % Concordance 
Reference 
Monozygotes Dizygotes Monozygotes Dizygotes 
Diehl et al, 1936 80 125 65 25 33 
Uehlinger et al, 1938 12 34 58 6 34 
Kallmann et al, 1943 78 230 62 18 27 
Harvald et al, 1965 135 513 37 15 35 
Comstock et al, 1978 54 148 32 14 26 
Simonds, 2004 55 150 32 14 28 
van der Eijik, 2007 54 148 21 19 36 
 
Other evidence supporting the idea that host genetics plays an important role in susceptibility to 
TB, include the rather unfortunate event which occurred in Lübeck, Germany in 1926, where 251 
newly born infants were mistakenly vaccinated with a live virulent strain of M. tuberculosis rather 
than an attenuated strain 37. Of the 251 babies; 47 went on to develop latent TB disease, 77 died 
from TB, and 127 had radiological signs of TB but later recovered. This incident demonstrates that 
certain individuals in a population have an efficient innate immune response to TB. Another event 
which gives credence to the role of host genetics in susceptibility to TB comes from the initial 
exposure of a population to M. tuberculosis. This was particularly seen in the Qu’Appelle Indians 
who, when first exposed to the bacterium, had a high annual TB mortality rate (10%), but after 40 
years, the annual death rate due to TB dropped significantly (0.2%) 38. This incident can be 
interpreted as illustrating the effects of strong selection pressures against those genes that confer 
susceptibility to TB, and that the causative genetic variants within these genes are selected against 
and not transmitted to subsequent generations, resulting in less susceptible future populations. 
This effect of natural selection can also be seen in other populations. In the case of Europeans and 
Africans, it appears that individuals from Europe are less susceptible to TB infections, whereas 
individuals from Africa seem to be more prone to infection by M. tuberculosis. It is believed that 
this is due to European populations having been exposed to M. tubercuslosis for centuries (White 
Plague, 17th century), resulting in a more resistant population 31. In Africa on the other hand, 
exposure to M. tuberculosis occurred rather recently and with the availability of drugs to fight M. 
tuberculosis infection, natural selection has not been able to remove susceptibility genetic variants 
from the population. Although environmental and socio-economic factors differ immensely 
between these two populations, they alone cannot account for this population variation. This has 
been shown in a study conducted in a USA nursing home which found that individuals of African 
ancestry were twice as likely to be infected with M. tuberculosis compared to individuals of 
European ancestry, even though they shared the same environment 39. 
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All these studies and historical incidents clearly demonstrate that human genetic variation plays a 
key role in the disease outcomes. 
 
   1.6.2 Environmental Factors 
 
Environmental factors also play an important role in the outcome of TB disease, and these factors 
include socio-economic, nutrition, smoking and alcohol abuse.  
 
Various studies have showed that disadvantaged communities tend to have a higher incidence of 
TB, which is mainly attributable to poverty and the associated overcrowded living conditions 40, 41. 
This can be seen in a report (1995) which listed “high risk environments” for TB, in which prisons, 
nursing homes and homeless shelters were included. The role of overcrowded living conditions in 
TB development was also highlighted when it was noted that there was a higher incidence of TB in 
monasteries and refugee camps, which became overcrowded due to the flight of refugees during 
the Chinese occupation of Tibet. This has also been seen in America, where racial segregation 
resulted in over-crowding and limited health care access in minority areas. A study done by Farmer 
(1997) also showed that treatment compliance was essentially determined by economic factors 42. 
 
As mentioned previously, nutrition is another environmental factor that plays an important role in 
disease development. In 2004, Cegielski et al. conclusively showed for the first time the 
relationship between malnutrition and TB, based on studies in humans and experimental animals. 
Malnutrition may alter cell-mediated immunity, which is the principle host defence mechanism 
against TB 43. In the guinea pig TB model, various studies have also shown that chronic protein 
energy malnutrition (PEM) has a negative effect on the immunity to M. tuberculosis. PEM results 
in significantly reduced lymphocyte stimulation, in addition to low level secretion of the Th1 
cytokines IL-2, IFN-γ and TNF-α. Additionally, it was noted that PEM animals generated 
macrophages which produced higher levels of transforming growth factor β (TGFβ), which results 
in the suppression of T cells and inflammation 44. With regards to vegetarianism and the risk of 
developing TB, Finch et al., (1991) showed that in a retrospective study of TB in an Indian 
subcontinent population, Hindu Asians were at a greater risk for developing TB when compared to 
Asian Muslims with an overall incidence ratio of 4.5 45. Strachan et al., (1995) using a case-control 
study technique in the same population, showed that this increased risk for developing TB was in 
fact due to diet and not religion, since vegetarianism was common practice in Hindus but not 
Muslims 46. After adjusting for diet (vegetarianism) other factors such as socioeconomic status, 
migration, lifestyle choices, age and sex made little difference to the relative risk of developing TB 
in this population. They also showed that individuals who were lactovegetarians had an 8.5 fold 
risk of developing TB when compared with daily meat/fish eaters. From this they concluded that a 
vegetarian diet is an independent risk factor for developing TB, and postulated that it could be due 
to impairment of the immune system through the deficiency of micronutrients. One of these 
micronutrients is vitamin D 47, 48, which has been shown to have an immunoregulatory role in both 
lymphocytes and monocytes and a deficiency in vitamin D could lead to an impaired host defence 
to M. tuberculosis 49. 
 
Both smoking and alcohol abuse contribute to the development of TB disease 50-53. It has also been 
shown that children who live with adults who previously had TB and were exposed to second hand 
cigarette smoke were at a higher risk of developing TB 53. Interestingly, in India, it was found that 
individuals with TB were three times more likely to be smokers when compared to the rest of the 
population. Smokers tend to have faster TB disease progression, poor treatment adherence and 
are more likely to relapse. For alcohol abuse, it has been noted that such individuals have a 
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relative risk of 3 (95% CI: 1.89-4.59) with regards to developing TB 51. This is believed to be due to 
the pathogenic impact of alcohol on the immune system. Alcohol abuse can alter the 
pharmacokinetics of the medication used in the treatment of TB, as well as resulting in higher 
rates of re-infection and treatment defaults which also increases the risk of developing drug-
resistant TB. Analysis of current data also indicates that approximately 10% of the global TB cases 
are attributable to heavy alcohol consumption 50-52. 
 
These risk factors indicate the complexity of TB disease, and show that although M. tuberculosis is 
necessary, it is not sufficient for the development of clinical TB disease. It also highlights the 
necessity of integration of epidemiology, host genetics and environmental factors if we are to 
successfully eradicate this disease.  
 
 
 
 
 
 
 
 
 
 
Chapter 2: Approaches in 
Disease Gene Identification 
 
 
 
 
 
Science is facts; just as houses are made of stones, so is science made of facts; but a pile of 
stones is not a house and a collection of facts is not necessarily science. 
 
Henri Poincaré 
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2.1 Current Approaches 
 
There are two chief approaches currently being used in the identification of susceptibility genes 
for human TB, namely population-based gene association studies and family-based linkage 
analysis (Figure 5) 32. However, both study designs have advantages and disadvantages, with the 
use of both methodologies combined being most likely to yield success. Identification of genes 
involved in complex diseases can either be based on a hypothesis (association studies) or not 
(linkage studies) 54. 
 
 
Figure 5: Current strategies for the identification of TB susceptibility genes 32 
 
However, recent advances in genotyping techniques and molecular biology have resulted in the 
introduction of novel techniques for the identification of susceptibility genes for TB. These include 
genome-wide association studies (GWAS) 55, the use of admixture mapping 32 and epigenetic 
studies 56. 
 
2.2. Linkage Studies 
 
Linkage studies are used to identify chromosomal regions that contain TB susceptibility genes by 
testing for co-segregation between a genetic marker and a possible disease locus. This method of 
gene identification requires a large number of families with affected children 37. The advantage of 
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this method lies in that it can evaluate the entire genome or focus on a specific region in the 
genome. The former allows for the identification of novel genes and pathways that would 
previously not have been considered. Linkage studies are based on the assumption that 
chromosomal regions and the disease of interest segregate non-randomly, allowing for the 
identification of these regions in large affected families. Once linkage has been identified in a 
region, further studies are conducted to narrow down the interval on the chromosome so that the 
gene can be identified, possibly by positional cloning 57. Recent advances have allowed researchers 
to employ fine-mapping for the identification of the susceptibility gene. Fine-mapping involves the 
use of gene-associated markers (single nucleotide polymorphisms, SNPs) and whether or not they 
are transmitted with the disease in affected offspring 58. There are however disadvantages to this 
method 37. Firstly, genome-wide linkage analysis requires large number of families with at least 
two affected children, which is not easily attainable. This method also has lower statistical power 
compared to association studies, mainly due to the difficulty of attaining multi-case families than 
random cases, and is therefore likely to identify regions containing genes with modest effects. This 
method is also better suited for gene identification of monogenic diseases in that it is able to 
identify a single chromosomal region which can be narrowed down to identify the causative gene 
32. Complex diseases such as TB on the other hand, which involves numerous genes, may not be 
best suited for gene identification using this method. 
 
To date, seven genome-wide linkage studies have been conducted to identify genes associated 
with varied susceptibility to TB (Table 5). The first genome-wide linkage scan was conducted in the 
Gambian and South African populations using sib pairs 59. This study identified the Xq and 15q 
chromosomal regions in the respective populations. Fine-mapping of chromosome 15q11-13 
region identified the ubiquitin protein ligase E3A (UBE3A) or another closely linked gene as a 
possible susceptibility gene for TB 58. The identification of the Xq chromosomal region in Gambians 
as a region containing a possible susceptibility gene for TB is also interesting, as current statistical 
data shows that males have a higher incidence of developing TB 60. This effect however could be 
attributable to other non-genetic factors as well 59. To date, one gene on the X chromosome has 
been found to be associated with susceptibility to TB in the general population, namely toll-like 
receptor 8 (TLR8 in Indonesia and Russia) 61. A genome-wide linkage scan conducted in the 
Ugandan population identified four chromosomal regions, of which two were found to contain 
regions, 2q21-q24 and 5p13-5q22, associated with a persistently negative tuberculin skin test 
(PTST-) 62. Interestingly, the most recent genome-wide linkage scan conducted in the South African 
population identified two chromosomal regions, 5p15 and 11p14, to be associated with various 
tuberculin skin test (TST) properties 63. The 11p14 region was found to be involved in controlling 
human resistance to M. tuberculosis infection. On the other hand, the 5p15 region was found to 
be involved in determining the extent of the TST, which supports the findings of the Ugandan 
genome-wide linkage scan that identified the 5p13-5q22 region to be involved in PTST- 62. Fine 
mapping of this 5p15 region resulted in the identification of the solute carrier family 6, member 3 
(SLC6A3) gene as a potential candidate for the regulation of TST intensity 63. 
 
Of the seven genome-wide linkage scans conducted in TB, very little overlap between the 
identified susceptibility regions has been observed 64. This could be due to differences in study 
designs, for example, low sample numbers, differences in phenotype/diagnostic criteria or 
population specificity. 
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Table 5: Chromosomal regions identified by genome-wide linkage analysis for susceptibility to TB 
Population Chromosomal region TB* phenotype              Reference 
South Africa 15q11-q13 TB 59 
The Gambia Xq TB  
Brazil 10q26.13 TB 65 
 11q12.3 TB  
 20p12.1 TB  
Morocco 8q12-q13 TB 66 
South Africa 6p21-q23 TB 67 
Malawi 20q13.31-33 TB  
Uganda 2q21-q24 PTST-• 62 
 5p13-5q22 PTST-  
 7p22-p21 TB  
 20q13 TB  
Thailand 5q23.2-q31.3 TB 68 
 17p13.3-p13.1 TB, CA†  
 20p13-p12.3 TB, CA  
South Africa 5p15 TST‡ intensity 63 
 11p14 TST positivity  
*
TB, current or previous microbiologically confirmed TB 
•
PTST-, persistently negative tuberculin skin test 
†
CA, ordered subset analysis with minimum age at onset of disease as covariate 
‡
TST, tuberculin skin test 
 
2.3 Association Studies 
 
The most commonly employed study design for the identification of genes that alter susceptibility 
to TB is candidate gene association studies 64. This study design is based on the comparison of 
allele frequencies between cases (affected individuals) and controls (unaffected individuals), 
provided the alleles are in Hardy-Weinberg equilibrium (HWE) 69. In essence, association studies 
involves the investigation of polymorphisms in a gene of interest and whether or not it occurs 
more frequently in the cases or controls when compared to each other. Association studies are 
thus hypothesis based 70. This method of gene identification has greater statistical power 
compared to linkage analysis, therefore allowing for the identification of genes with smaller 
effects, provided an adequate sample size is used 71. Another important issue to consider when 
designing population-based association studies is the type of polymorphisms that will be 
investigated in the study. It is important to select genes that are involved in the development of 
TB disease and that the polymorphisms in the candidate gene that are preferably functionally 
relevant so as to minimize the identification of false-positive associations. Due to the availability of 
the human genome sequence, selection of functionally relevant polymorphisms has now become 
possible 72. Therefore, polymorphisms that result in amino acid changes and thus alter the protein 
structure are good candidates, in addition to polymorphisms that result in frameshift mutations in 
the coding area of the gene or alter the expression of the gene 72. There are usually three reasons 
why an association is observed between a polymorphism in a candidate gene and the disease of 
interest, which include (1) the associated allele being the actual cause of the disease, (2) the 
associated allele is in linkage disequilibrium (LD) with the causative allele of the disease, (3) the 
association is an artefact of population admixture 69. It is thus of the utmost importance that 
significant associations be replicated or validated in other populations and to identify whether or 
not the population being investigated is stratified, therefore reducing the likelihood of identifying 
false-positive associations 70. 
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There are however disadvantages to this method as well. Firstly, due to the complexity of the 
disease, it is believed that numerous genes are involved in determining the outcome of the 
infection. Therefore, using the candidate gene approach could be a very laborious means of 
identifying these genes. Also, because association studies are hypothesis based, only genes that 
are known to play a role in immunity against M. tuberculosis infection are investigated and this 
may be problematic as it is possible that many susceptibility genes may not yet have been 
discovered. This issue can however be addressed by employing genome-wide association studies 
73. Secondly, when a candidate gene is selected for investigation only a select set of 
polymorphisms associated with the gene are studied 74. If these polymorphisms are found not to 
be associated with the disease it does not necessarily mean that the gene does not play a role in 
susceptibility to the disease. Thirdly, and probably the biggest concern with regards to association 
studies, the number of confirmations between studies is low 70. Associations that are identified in 
one population are often found not to be associated with the disease in other populations 75. This 
is predominantly due to differences in study design between the populations and can include 
differences in phenotype definition, experimental procedure and sample sizes 76, 77. With regards 
to sample size, more often than not, the initial study will investigate a small subset of the 
population resulting in reduced statistical power and the identification of false-positives, which is 
apparent when the initial associations are not found in validation studies using larger sample sizes. 
Finally, the association of an allele with TB is only a statistical finding and functional experiments 
are required to identify the biological impact of the associated allele with regards to TB. 
 
There are currently three variations of association studies being employed. These are population-
based case-control studies, family-based association studies and genome-wide association studies. 
 
   2.3.1 Population-based case-control association studies 
 
Population-based case-control studies are currently the most widely used form of association 
studies for the identification of genes that alter susceptibility to TB. One of the main advantages of 
the use of this method, as mentioned previously, is its greater statistical power compared to 
linkage analysis 71. However, the selection of controls should receive sufficient attention, as 
controls poorly matched to the cases could negatively affect the results of an association study. 
Controls and cases should be matched with regards to ethnicity and geographical location. 
Another confounding factor in association studies is population stratification, as a certain allele or 
haplotype may be more prevalent in one of the founder populations, which could impact 
negatively on the power of the study and result in false-positive or false-negative results. To 
overcome these factors, the use of family based association studies (transmission disequilibrium 
test, TDT) could be employed 78. This method investigates the transmission of alleles between 
heterozygous parents and affected children. Combining these two forms of association studies will 
yield better results. However, one of the drawbacks of TDT analysis is the requirement of large 
numbers of families, which is often very difficult.  To date, numerous genes and pathways have 
been studied (Figure 6) to elucidate the host genetic components involved in disease 
development. Recent association studies identified numerous polymorphisms in these genes as TB 
susceptibility factors, and some have been successfully validated in other populations (Table 6). 
 
Some of the major genes identified by population-based case-control studies include the human 
leukocyte antigen (HLA) genes, solute carrier family 11A member 1 (SLC11A1) (formerly known as 
natural resistance-associated macrophage protein 1 gene (NRAMP1)) and the pattern recognition 
receptor mannose-binding lectin (MBL) gene. 
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The HLA genes are comprised of approximately 200 genes, and are one of the most extensively 
investigated gene families 79. These genes are the most polymorphic in the human genome (3528 
alleles) and are predominantly involved in the presentation of antigens to T cells during infection 
80. Several studies investigating the role of polymorphisms in these HLA genes in susceptibility to 
TB have identified numerous alleles which alter TB disease outcome, with most of them 
highlighting ethnic differences. This is believed to be due to evolutionary selection pressures since 
the HLA genes are involved in the immune response against infectious agents 79. The HLA gene 
family was one of the first genes to be associated with TB, with the HLA-DR2 gene having been 
consistently found to be associated with susceptibility to TB in various populations such as Russia 
81, India 82, 83, Indonesia 84 and Thailand 85. 
 
Solute carrier family 11A member 1 (SLC11A1), formerly known as natural resistance-associated 
macrophage protein 1 (NRAMP1) was found to alter susceptibility to leishmania, salmonella and 
mycobacteria in inbred mouse strains (section 2.3) 86-88. Various association studies have been 
conducted on the role of SLC11A1 and its associated polymorphisms and susceptibility to TB 89-91. 
Numerous genetic variants have thus been identified that alters susceptibility to TB in various 
populations. A recent meta-analysis of these polymorphisms have shown the 5’ (GT)n variant, 
D543N (rs17235409) and the 3’ UTR (TGTG deletion) variant to be significantly associated with 
increased risk of pulmonary TB in West African, Asian and South African populations 91. 
 
The mannose-binding lectin (MBL) gene encodes the MBL protein, which plays a role in the 
promotion of phagocytosis and modulation of inflammation 92, 93. Various polymorphisms have 
been found to be associated with susceptibility to TB in various populations. Studies have shown 
that deficiencies in MBL results in increased susceptibility to various infectious diseases 94, 
including TB 95-97. This has been hypothesized to be due to the promotion of bacterial uptake into 
macrophages being advantageous to the bacterium, thus the identification of variant alleles being 
associated with protection against TB infection 95. 
 
 
   Figure 6: Current understanding of genes involved in altered susceptibility to M. tuberculosis infection 64. 
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      2.3.2 Genome-wide association studies 
 
Due to recent advancements in genotyping technology (microarray chips) and the availability of 
the human genome sequence and the HapMap Project database 97-100, genome-wide association 
studies have become possible. These studies are therefore able to investigate polymorphisms 
representative of the entire genome, one million single nucleotide polymorphisms (SNPs) in 
Caucasian populations, irrespective of the genomic location. This method is therefore not subject 
to the limitations of candidate gene association studies, in which only a few polymorphisms are 
investigated. With regards to other populations, African for example, a greater number of SNPs is 
required for complete genome coverage due to greater variation and less LD 101, 102. This method is 
therefore free of assumptions, and allows for the identification of novel genes and pathways. 
 
When conducting GWAS, study design is of the utmost importance. Currently, a two-step design is 
employed with strict significance cut-off values to limit false-positive associations 101. In the first 
stage of the study, a subset of the study population is investigated on a genome-wide level. 
Polymorphisms found to be associated with disease in the first stage are then analysed in the rest 
of the study population. Associated polymorphisms that pass this two-step study design are then 
validated in a different population in a very large sample size using a different genotyping method 
to exclude technical artefacts. Associations that remain significant throughout this entire process 
are then considered as disease susceptibility variants. 
 
There are however draw-backs to this method. Due to the extremely high significant cut-off values 
employed in this approach to limit the likelihood of false-positive associations, only SNPs that 
exhibit large effects are identified and all SNPs that demonstrate small to moderate effects are 
ignored 32. GWAS are therefore based on the “common disease, common variant” (CDCV) 
hypothesis, resulting in all rare variants being missed. There is therefore currently intense debate 
among researchers with regards to the impact of GWAS due to their basis on the CDCV hypothesis, 
as some researchers believe that susceptibility to infectious diseases could be better described by 
a combination of rare variants instead 32. GWAS also require extremely large study cohorts to 
ensure adequate power, because of the number of polymorphisms interrogated 101. 
 
GWAS have been successfully employed in identifying susceptible variants in various diseases, 
including Crohn’s disease, rheumatoid arthritis, diabetes, macular degeneration, inflammatory 
bowel disease, myocardial infarction and prostate cancer. When it comes to infectious diseases 
though, the use of GWAS has been limited. There are currently only six published GWAS that have 
been conducted in infectious diseases; namely HIV 103, Kawasaki disease 104, chronic hepatitis B 105 
and more recently leprosy 106, meningococcal disease 107 and TB 55. The recently published leprosy 
GWAS, which was conducted in the Han Chinese population of eastern China, six genes and their 
associated polymorphisms were found to alter susceptibility to infection by M. leprae 108. The 
genes identified include coiled-coil domain containing 122 (CCDC122), chromosome 13 open 
reading frame 31 (C13orf31), nucleotide-binding oligomerization domain containing 2 (NOD2), 
tumour necrosis factor [ligand] superfamily member 15 (TNFSF15), HLA-DR and receptor 
interacting serine-threonine kinase 2 (RIPK2). The first step of the study was conducted in 706 
cases and 1225 controls using the Human610-Quad BeadChip (Illumina), with the 93 associated 
SNPs identified in the first step replicated in three replication sets (first replication cohort: Han 
Chinese (eastern China), second and third replication cohort: Han Chinese and non-Han minority 
ethnic groups) comprising a total of 3254 cases and 5955 controls using the iPlex (Sequenom) and 
TaqMan assay (Applied Biosystems) systems. In the field of TB, the only GWAS to be published was 
conducted in West African populations. This GWAS was a combination of two separate studies 
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with integrated analysis. The details of this GWAS including the candidate genes investigated will 
be discussed in chapter 6. A sarcoidosis GWAS, a disease with similar pathomechanisms as TB, was 
also used to select relevant genes and will be discussed in chapter 5. 
 
    2.3.3 Linkage Disequilibrium and Haplotype analysis 
 
Linkage disequilibrium (LD) is the non-random association between two or more alleles at 
different loci within the genome, whereas haplotypes are a combination of alleles (a DNA 
sequence) at different chromosomal locations that tend to be inherited together 101. In terms of 
identifying genetic variants that are involved in disease susceptibility, a haplotype would represent 
a set of SNPs that are statistically associated with the disease. This offers a unique means by which 
to identify novel susceptibility variants as an associated haplotype block would be indicative of a 
conserved region of DNA where no recombination occurred, and would contain the causal 
polymorphism of the disease 109-111. Currently, haplotypes are predominantly inferred by means of 
statistical methods due to the high costs associated with laboratory-based haplotyping. However, 
statistical inferring of haplotypes is not as informative as determining true haplotypes and could 
result in incorrect haplotype classification 101, 112. Importantly, haplotype block structure between 
populations can differ significantly, as a result of selection, bottle-necks or admixture in the 
population 111. Taking this into consideration when comparing haplotype analysis between two 
populations is essential, as haplotype blocks identified in one population would not necessarily be 
the same in the other population 113. 
 
The sporadic nature in which mutations occur in the DNA results in the linkage of SNPs along the 
chromosome 98-100. Therefore, the presence of one allele at a given SNP could provide information 
on the alleles present at other polymorphic sites that are in LD and can thus be used for the 
identification of novel susceptibility SNPs 114. LD however also complicates disease susceptibility 
variant identification, since a SNP which is identified to be associated may in fact not be causal, 
but is instead in LD with the true disease-causing SNP. This highlights the importance of taking 
haplotypes into consideration when using LD. 
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Table 6: Association studies investigating TB susceptibility candidate genes* 
Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
HLA DQ1 India pTB 209 122  2.8 84 
 DQA India (South) pTB 38 36 NS  128 
 DQA1*0101 Mexico pTB 50 95  6.18 129 
  Iran pTB 40 100  2.66 130 
 DQA1*0301 Iran pTB 40 100  0.25 130 
 DQA1*0501 Iran pTB 40 100  0.53 130 
 DQA1*0601 Thailand pTB 82 160 0.02 (0.16) 2.1 85 
 DQB India (South) pTB 38 36 NS  128 
 DQB1*02 Poland pTB 38 58 0.01 0.39 131 
 DQB1*0301 Thailand pTB 82 160 0.01 (0.13) 0.4 128 
 DQB1*0301-0304 South Africa (Venda) TB 95 117 0.001 2.58 132 
 DQB1*0402 Mexico pTB 65 95  0.18 129 
 DQB1*05 Poland pTB 38 58 (0.002) 2.84 131 
 DQB1*0501 Mexico pTB 50 95  6.16 129 
  Iran pTB 40 100 NS  130 
 DQB1*0502 Thailand pTB 82 160 0.01 (0.13) 2.06 85 
 DQB1*0503 Cambodia pTB 126 88 0.005  133 
 DQB1*0601 India (South) pTB 126 87  2.32 83 
 DQB57 Asp/Asp Cambodia pTB 436 107 0.001 3.05 134 
 DQw1 Indonesia pTB 101 65  39% 135 
 DR2 India pTB 25 families  0.001  136 
  Russia pTB 135 130 <0.001 3.34 81 
  India (South) pTB 204 404 0.01 0.29 137 
  India (North) pTB 153 289 (0.029) 1.8 138 
  India (North) pTB 124 109 NS  136 
  India pTB 209 122  2.3 84 
  Russia (Tuvinian) pTB 96 291 <0.001 (<0.05) 3.32 139 
  Indonesia pTB 101 65  36% 135 
 DR3 Mexico pTB 51 54 Decreased in cases  140 
  Russia pTB 135 130 <0.05 0.52 81 
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Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
 DR4 Mexico pTB 65 95  0.28 129 
  Thailand pTB 35  Increased in cases  141 
  Italy cTB 54 1089 0.001 2.7 142 
 DR8 Mexico pTB 65 95  0.10 129 
 DRB India (South) pTB 38 36 NS  128 
 DRB1*13 Russia (Tuvinian) pTB 14 
pedigrees 
 Over transmitted  143 
 DRB1*07 Iran pTB 40 100  2.7 130 
 DRB1*0803 Korea DR pTB 81 200 0.047 2.63 144 
 DRB1*11 China pTB 74 90 <0.05 0.12 145 
 DRB1*13 Poland pTB 31 58 <0.001 0.04 146 
 DRB1*1302 South Africa (Venda) TB 92 117 <0.001 5.05 132 
 DRB1*14 Russia (Tuvinian) pTB 14 
pedigrees 
 Over transmitted  143 
 DRB1*15 China pTB 74 90 <0.05 2.91 145 
 DRB1*1501 Mexico pTB 50 95  7.92 129 
  India pTB 22 36 <0.05  147 
  India (South) pTB 126 87  2.68 83 
 DRB1*16 Poland pTB 31 58 <0.01 9.7 146 
 DRw53 Russia (Tuvinian) pTB 96 291 <0.001 (<0.05) 11.88 139 
 HLA Brazil pTB 98 
pedigrees 
 NS  148 
 HLA-A, -B, -C Italy TB 68 1089 NS  142 
  India (North) pTB 124 109 NS  136 
 HLA-A and –B China (Hong Kong) pTB 256 100 NS  149 
         
CCL2 -2518 China (Hong Kong) TB 412 456 NS  150 
  South Africa (SAC) pTB 431 482 NS  151 
  Russia pTB 1440 1529 NS  152 
  Ghana pTB 2010 2346 (1.8 x 10-3) 0.81 152 
  Mexico pTB 445 334 0.0003 2.43 153 
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Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
  Korea pTB 129 162 0.0001 2.63 153 
 -362C Ghana pTB 2010 2346 (2.3 x 10-4) 0.83 152 
         
CD209 -336 Columbia TB 110 229 NS  154 
  Tunisia TB 138 140 NS  155 
  Guinea-Bissau pTB 321 347 NS  156 
  India (South) TB 107 157 NS  157 
  South Africa (SAC) pTB 351 360 0.01 1.48 158 
  Gambia TB 329/347 327 0.01/0.03 0.75/0.7
9 
159 
  Republic of Guinea TB 151 180 NS  159 
  Guinea-Bissau TB 162 141 NS  159 
  Malawi TB 244 295 NS  159 
  sub-Saharan Africa TB 1233 943 0.006 0.86 159 
 -871G South Africa (SAC) pTB 351 360 8.2 x 10-4 1.85 158 
         
CXCL10 -1447 China TB 240 176 NS  160 
 -872 China TB 240 176 NS  160 
 -135 China TB 240 176 0.01 0.51 160 
         
GC Gc Brazil TB 130 78 NS  161 
  South Africa TB 281 182 NS  161 
  UK (Gujarati Asian) TB 123 140 0.009 2.81 161 
         
IFNG +874 Sicily pTB 45 97 0.02  162 
  Croatia TB 54 175 0.012 3.12 163 
  Caucasian pTB 113 207 0.0017 3.75 164 
  West Africa TB 682 619 NS  165 
  China TB 301 310 0.035 1.98 166 
  South Africa (SAC) pTB 313 235 0.0055 1.64 167 
  Turkey pTB 319 115 0.024 0.7 168 
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Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
  India (South) TB 129 127 NS  169 
  African American TB 240 174 NS  170 
  Caucasian TB 161 64 NS  170 
  USA (Houston) TB 319 98 NS  170 
  China (Hong Kong) pTB 385 451 <0.001 2.24 171 
  Croatia pTB 253 519 NS  163 
  Columbia TB 190 135 0.01  172 
  Meta-analysis TB 11 studies  0.0008 0.75 173 
 1348T/A Japan pTB 114 110 0.55  174 
 CA repeat Indonesia TB 382 437 NS  175 
 G2109A Croatia pTB 253 519 NS  163 
 rs2069718 Japan TB 87 265 NS  176 
 rs2193049 Japan TB 87 265 NS  176 
         
IL10 -1082 Ghana pTB 2010 2346 NS  177 
  Pakistan pTB 111 188 NS  178 
 -2849A/-1082A/-
819C/-592C 
Ghana TST 2010 
129 TST-
2219TST+ 
0.013 
0.017 
2.15 
2.09 
177 
         
IRF1 5 SNPs Vietnam pTB 162 132 NS  179 
 17 SNPs Indonesia pTB 192 192 NS  179 
         
MBL A/O Tanzania TB 443 426 NS  180 
 A/O and O/O Spain TB 106 344 0.02 0.58 181 
 B South Africa (SAC) TBM 91 79 0.017  95 
  African-American pTB 176 71 <0.01 0.34 182 
 C Gambia pTB 397 422 0.037 0.79 183 
 C, D African-American pTB 176 71 NS  182 
 codon 54 Turkey TB 44 99 0.01 3.9 96 
 codons 52, 54 and 57 Poland pTB 126 124 NS  184 
 HYA/HYA Italy pTB 277 288 1 x 10-8 0.09 185 
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Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
 LYB/LYD Italy pTB 277 288 1 x 10-6 49 185 
 O India pTB 202 109 0.008 6.5 186 
  USA (Houston) pTB 198 46 NS  182 
  Caucasian pTB 113 69 NS  182 
  Spain TB 106 344 0.009 0.6 181 
 O, H, L, X, Y, P, Q China pTB 152 293 NS  187 
 O, X Denmark pTB 59 250 0.03  97 
 X/O and O/O Spain TB 106 344 0.023 0.46 181 
         
NOS2A CCTTT Colombia (Paisa) pTB 114 304 0.0001 (0.001) 0.4 188 
 rs1800482 Mexico pTB 445 518 NS  153 
 rs2274894 USA (African-
American) 
pTB 279 166 0.003 1.84 189 
 rs2779249 Brazil pTB 92 
pedigrees 
 0.021 3.25 189 
 rs7215373 USA (African-
American) 
pTB 279 166 0.004 1.67 189 
 rs9282799 and 
rs8078340 
South Africa (SAC) pTB 431 482 0.011 (0.029) 1.4 
151 
 TAAA Colombia (Paisa) pTB 114 304 NS  188 
        190 
P2RX7 -1513 China (Han Chinese) TB 96 384 NS  191 
  Gambia TB >300 >160 NS  192 
  Liverpool pTB 86 167 NS  193 
  Mexico TB 94 100 0.02 5.28 194 
  Russia pTB 190 128 0.02 1.71 192 
  Sydney pTB 99 102 NS  190 
 -762 China (Han Chinese) TB 96 384 NS  191 
  Gambia TB >300 >160 0.003 0.70 193 
  Mexico TB 94 100 NS  194 
  Russia pTB 190 128 NS  190 
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Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
         
PTPN22 R263Q Morocco pTB 123 155 0.01 5.85 195 
 R620W Morocco pTB 123 155 0.01 0.14 195 
         
SLC11A1 1703G/A Japan pTB 114 110 0.144  174 
 274C/T USA (Houston) Pediatric TB 184 
families 
 0.01 1.75 196 
 3’ UTR Thailand TB 149 147 NS  197 
  Morocco pTB 116 
pedigrees 
 NS  198 
  China TB 278 282 0.0165 1.51 199 
  Korea pTB 192 192 0.02 1.85 200 
  China Pediatric TB 136 435 Associated  201 
 4 SNPs Japan TB 87 265 NS  176 
 5’ CA Tanzania TB 443 426 0.014 1.45 180 
 ATAn Gambia pTB 318 146 NS  
202 
 D543N Thailand TB 149 147 NS  197 
  China TB 278 282 NS  199 
  China pTB 61 122 NS  203 
  Cambodia pTB 358 106 0.02 0.59 204 
  Gambia pTB 410 417 0.004 1.85 89 
  China (Han Chinese) pTB 110 180  1.93 205 
  China Severe TB 127 91  2.27 206 
  China (Han Chinese) pTB 120 240  2.59 207 
  Japan cTB 95 90  5.16 208 
  Peru pTB 507 513 <0.05 1.4 209 
 GTn South Africa (SAC) pTB 265 224 0.002 0.6 
90 
  Morocco pTB 116 
pedigrees 
 NS  198 
  Poland pTB 85 93 0.03 1.69 198 
  USA (Houston) Pediatric TB 184  0.04  196 
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Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
families 
  Gambia pTB 329 324 0.024 1.4 210 
  Gambia pTB 410 417 0.008 1.45 89 
  USA (Caucasian) pTB 135 108  2.02 211 
  Japan pTB 202 267 0.0003 2.07 212 
 INT4 Russia (Slavic) pTB 58 127 NS  213 
  Taiwan pTB 49 48 NS  214 
  Guinea-Conakry pTB 44 families  0.036  215 
  Poland pTB 126 124 NS  184 
  Gambia pTB 410 417 0.006 1.83 89 
  Denmark TB 104 176 0.013 1.9 97 
  China Severe TB 127 91  2.29 206 
  China pTB 61 122  2.73 203 
  China  Pediatric TB 136 435 NS  201 
  Peru pTB 507 513 <0.05 1.72 209 
 TGTG+/d Gambia pTB 410 417 0.004 1.85 89 
  China (Han Chinese) pTB 147 145 <0.01  216 
  Cambodia pTB 358 106 0.02 0.59 204 
  China (Han Chinese) pTB 120 240  0.89 207 
  China (Han Chinese) pTB 110 180  2.22 205 
  South Africa (SAC) pTB 265 224 0.013 5.19 90 
         
SP110 rs2114592 Republic of Guinea pTB 99 families  0.009  217 
  Guinea-Bissau pTB 102 
families 
 0.002  217 
  Gambia pTB 219 
families 
 0.02  217 
  South Africa (SAC) TB 381 417 NS  218 
 rs3948464 Republic of Guinea pTB 99 families  0.015  219 
  Guinea-Bissau pTB 102 
families 
 NS  220 
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Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
  Gambia pTB 219 
families 
 0.01  217 
  South Africa (SAC) TB 381 417 NS  217 
  Russia pTB 1912 2104 NS  219 
  Ghana pTB 2004 2366 NS  217 
 rs41547617 Republic of Guinea pTB 99 families  NS  217 
  Guinea-Bissau pTB 102 
families 
 NS  217 
  Gambia pTB 219 
families 
 0.02  217 
         
TIRAP rs8177374 Gambia, Guinea-
Bissau, Republic of 
Guinea 
TB 675 605 0.04 (0.013) 0.23 221 
  Columbia TB 147 391 0.03 0.53 222 
  Russia pTB 1867 2076 NS  223 
  Indonesia pTB 611 681 NS  223 
  Ghana pTB 1913 2293 NS  223 
  Vietnam pTB 183 392 NS  224 
  Vietnam TBM 175 392 0.001 3.02 224 
         
TLR1 248S USA (African-
American) 
TB 339 194 0.009 1.63 225 
  USA TB 99 families  0.021  225 
 S602I USA (African 
American) 
TB 339 194 <0.001 2.50 225 
  USA TB 99 families  0.021  225 
TLR2 (GT)n < 16 Korea TB 176/164 196 0.047/0.02 1.41 
226 
 Arg753Gln Guinea-Bissau pTB 321 347 NS  156 
  Turkey pTB 151 116 0.022 6.04 227 
 Ins/Del (-196 to -174) Guinea-Bissau pTB 321 346 0.023 0.70 228 
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Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
  USA (African-
American) 
pTB 295 179 NS  228 
  USA (Caucasian) pTB 237 144 0.0007 0.41 228 
         
TLR4 Asp299Gly Gambia pTB 307 298 NS  229 
  Guinea-Bissau pTB 321 347 NS  156 
         
TLR8 rs3764880 Indonesia pTB 375 387 0.007 1.8 61 
  Russia pTB 1837 1779 0.03 1.2  
         
TLR9 rs352143 Guinea-Bissau pTB 321 346 NS  228 
  USA (African-
American)  
pTB 295 179 0.029 0.58 228 
  USA (Caucasian) pTB 237 144 0.017 0.53 228 
 rs5743836 Guinea-Bissau pTB 321 346 NS  228 
  USA (African-
American) 
pTB 295 179 0.014 0.63 228 
  USA (Caucasian) pTB 237 144 0.05 0.58 228 
         
TNFRSF1B rs3397 South Africa (SAC) TB 429 482 0.049 1.22 230 
  Ghana TB 640 1158 0.007 1.315 230 
         
VDR Various SNPs Japan TB 87 265 NS  176 
 ApaI Tanzania TB 443 426 NS  180 
  South Africa (Venda) TB ~85 ~88 NS  132 
  Guinea-Bissau pTB 321 347 0.03  156 
 BsmI South Africa (Venda) TB ~85 ~88 NS  132 
  India Spinal TB 64 103  2.2 231 
  Asia (Gujarati) eTB 52 116 NS  232 
 FokI Tanzania TB 443 426 NS  180 
  South Africa (Venda) TB ~85 ~88 NS  132 
 2
8 
 
 
Gene Polymorphism Population Phenotype Cases Controls P value (Pc) OR/RR Reference 
  India Spinal TB 64 103  2.4 231 
  Asia (Gujarati) eTB 52 116  2.8 232 
  China (Han Chinese) pTB 76 171  3.67 233 
  China (Han Chinese) pTB 120 240 0.03 2.35 207 
  Peru TB treatment 103 206  9.6 234 
 FokI-BsmI-ApaI-TaqI West Africa pTB 382 trios  0.009  235 
 TaqI Tanzania TB 443 426 NS  180 
  South Africa (Venda) TB ~85 ~88 NS  132 
  Cambodia pTB 358 106 NS  204 
  Asia (Gujarati) eTB 52 116 NS  232 
  Peru TB treatment 103 206  5.6 234 
  Gambia pTB 408 414 0.01 0.53 236 
*Adapted from 
32
 and 
64
. Significant associations are in bold. 
Pc, corrected P-value; OR, odds ratio; RR, relative risk; pTB, pulmonary TB; cTB, cavitary TB; eTB, extrapulmonary TB; TBM, TB meningitis; TST, tuberculin skin test; NS, not 
significant. 
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2.4 Animal Models 
 
There are currently numerous animal models; such as the fish, guinea-pig, mouse and rabbit TB 
models, which are being used to understand disease susceptibility 115. These models provide 
several advantages, in that one can control their breeding as well as the influence of 
environmental factors. Mouse models are however the most frequently used animal model, 
especially due to advances in molecular biology, allowing the creation of ‘knock-out’ (KO) mice, 
which lack genes that are important in the immune system. KO mice can illustrate the importance 
or redundancy of genes thought to alter susceptibility to TB disease. 
 
 In the 1970’s, the natural resistance associated macrophage protein (Nramp1), was identified in a 
mouse model of mycobacterial disease by positional cloning, as a gene that resulted in resistance 
to infection by various pathogens (see section 2.3.1) 116. Today, the human homologue, NRAMP1, 
is considered to be one of the first genes found to alter susceptibility to TB in humans 117. By using 
the KO method, various genes involved in the immune response to M. tuberculosis infection in the 
mouse model have been targeted, and numerous genes shown to result in increased susceptibility 
to various mycobacterial species have been identified (Table 6). 
 
Table 7: Murine genes which result in increased susceptibility to mycobacteria species when disrupted 
Gene Increased susceptibility to Reference 
Nramp1 Salmonella, Leishmania and mycobacteria species 116 
55 kD TNF receptor M. bovis (BCG) 118 
IFN-γ M. tuberculosis 119, 120 
IFN-γ Receptor M. bovis (BCG) 121 
β2-microglobulin M. tuberculosis /M. bovis (BCG) 122, 123 
MHC class II M. bovis (BCG) 123 
T cell receptor M. bovis (BCG) 124 
INF regulatory factor 1 M. bovis (BCG) 125 
IL-6 M. tuberculosis 126 
IL-12 M. tuberculosis 127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Hypothesis and Aims 
 
 
 
 
 
That is the essence of science: ask an impertinent question, and you are on the way to the 
pertinent answer. 
 
Jacob Bronowski 
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3.1 Study Hypothesis 
 
Background: A genome-wide association study is a useful technique for the identification of novel 
genes and pathways that could alter susceptibility to disease. Recent GWAS investigating various 
granulomatous diseases have identified such novel variants which could also hold true for 
susceptibility to TB.  
 
1. A GWAS conducted in a German population to identify novel susceptibility variants for 
sarcoidosis identified ANXA11 polymorphisms (Hofmann et al, 2008). Sarcoidosis shares 
various clinical features with TB pathogenesis, which makes susceptibility variants 
identified, suitable candidates for TB. 
 
2. The first GWAS in TB was conducted in a West African population and identified a novel 
susceptibility gene, CADM1 (unpublished data). A validation of these results was attempted 
in our South African Coloured (SAC) population to determine if the genes were also 
associated with susceptibility to TB in our population. 
 
Hypothesis: Genes identified in GWAS for sarcoidosis (ANXA11) and TB (CADM1) in other 
populations will be associated with TB in the SAC population. 
 
3.2 Study Aims 
 
1. To investigate whether polymorphisms found to be associated with granulomatous 
diseases in other populations are associated with susceptibility to TB in the SAC population, 
using a case-control association study. 
 
2. To determine LD patterns and identify haplotypes in the candidate genes. 
 
3. To functionally characterize any significant association identified in the case-control 
association studies. 
 
4. To understand if the methylation pattern of ANXA11 could influence TB disease outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Study Methods 
 
 
 
 
 
The most exciting phrase to hear in science, the one that heralds new discoveries, is not 
Eureka! (I found it!) but rather, "hmm.... that's funny...."        
 
Isaac Asimov 
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4.1 Reagents and Equipment 
 
All reagents and equipment used in this study are listed in the addendums 1, 2 and 3. 
 
4.2 Study Participants 
 
   4.2.1 Study Population 
 
The participants of this study belong to the South African Coloured (SAC) population, which is a 
highly admixed population with genetic contributions from African Blacks, Europeans, Khoi, San 
and Indonesia 79, 237. Due to this “mixing” of different ethnicities to form the SAC population, the 
presence of population stratification was possible, which could affect the results (false 
positives/negatives) obtained during association studies due to differential allelic-expression 
within each of the founder populations 238. 
 
To test whether the SAC population was stratified, a study in which 25 unlinked SNP markers were 
genotyped was undertaken in this population 158. No significant stratification (P = 0.26) was 
detected. Using admixed populations in association studies is highly advantageous due to the 
presence of greater number of alleles within members of this population, since their genetic 
make-up is a combination of the ancestral populations. This therefore affords us the opportunity 
to investigate unique markers with disease association within a single population 239.  
 
   4.2.2 Case-Control Samples     
 
The individuals recruited for this study were from the Ravensmead and Uitsig suburbs of the 
Western Cape province of South Africa, with approximately 98% of residents self-identifying 
themselves as SAC 237. The Western Cape has one of the highest incidences of TB in the country, 
with 967 per 100 000 in 2006 240. Individuals were therefore selected from these suburbs due to 
the high incidence of TB but low prevalence of HIV (2%) 241, 242. 
 
All study participants included in this study were unrelated. The case samples consisted of 
individuals who had bacteriologically (smear positive and/or culture positive) confirmed 
pulmonary TB. The control samples were healthy individuals with no history of TB but lived in the 
same community, and were at least 17 years of age. All study participants were HIV negative. For 
the characteristics of the case-control samples, see table 8. 
 
Table 8: Characteristics of individuals included in the case-control association studies. 
Characteristic Cases Controls 
Pulmonary TB Cohort   
Males: n (%)  200 (48%) 107 (26%) 
Females: n (%) 217 (52%) 303 (74%) 
Average age (years ±SD) 33 ±13.6 32 ±10.8 
Total number 417 410 
   
TB Meningitis Cohort   
Males: n (%) 46 (43%) 17 (23%) 
Females n (%) 61 (57%) 57 (77%) 
Average age (years ±SD) 7 ±5.2 29.7 ±7.9 
Total number 107 74 
n, number; SD, standard deviation 
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4.3 DNA Samples 
 
   4.3.1 DNA Extractions 
 
Blood samples were collected from individuals with informed written consent and approved by 
the Health Research Ethics Committee of Stellenbosch University, South Africa (Project 
registration number 95/072). DNA was extracted and purified using the Nucleon BACC Genomic 
DNA Extraction Kits (Illustra, Buckinghamshire, UK) following the manufacturer’s instructions. 
 
Once the DNA was extracted, concentration and purity was determined using the NanoDrop® ND-
1000 Spectrophotometer and the NanoDrop® v3.0.1 Software (Inqaba Biotechnology, Pretoria, 
SA). Working solutions were prepared for general PCR at a concentration of 100 ng/µl and stored 
at -20°C, while the DNA used for the TaqMan® genotyping system (Applied Biosystems, Foster City, 
USA) was diluted to a concentration of 20 ng/µl and stored in 96 deep-well plates (Eppendorf, 
Hamburg, Germany) at -20°C. DNA was diluted with milli-PORE (Massachusetts, USA) water. 
 
   4.3.2 Plate Design 
 
The 96 well plate layouts were imported into an Excel file, with each plate containing 84 DNA 
samples and 12 negative controls (distilled water). These plates were used for TaqMan® 
genotyping. For high-throughput genotyping 384 well plates were employed. Four 96 well plates 
were merged into one 384 well plate, with sample allocation determined using the Excel 7900_96 
to 384 well template (Figure 7). Each 384 well plate received a unique name which identified the 
polymorphism being investigated and the samples contained within it, example rs7071579A – 
rs7071579C. 
 
 
Figure 7: Schematic representation of sample allocation in 384 well plates.  
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7900 HT Real-Time PCR System 
4.4 Genotyping Methods 
 
   4.4.1 TaqMan® Genotyping System 
 
TaqMan® SNP genotyping is a highly efficient method for determining allelic variation. It is a one-
step PCR reaction (Figure 8) which relies on the 5’ to 3’ exonuclease activity of Taq DNA 
polymerase 243. The basic principle behind the TaqMan® genotyping system is quite simple. Firstly, 
a primer set is designed that is specific for the polymorphism and two probes which are specific 
for each allele (Figure 9). These probes contain a fluorescent dye at the 5’ end and a quencher 
molecule at the 3’ end, and as long as these two molecules are in close proximity with each other 
the fluorescence emitted by the dye is diminished 244. The 3’ end also has a minor groove binder 
attached which is responsible for the stability of the double-stranded probe structure. This results 
in an increase in the melting temperature (Tm) of the probe without increasing its length, 
augmenting the allelic discrimination capabilities of the probe. Each probe also contains a 
different fluorescent dye, which allows for the discrimination of the two alleles in a single reaction 
245. 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 8: Schematic representation of the TaqMan® Genotyping System Flowthrough. 
 
 
Figure 9: Graphical representation of the TaqMan® Genotyping Assay 246. 
epMOTION 5070 GeneAmp PCR System 9700 
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During the PCR reaction, the primers and probes are able to anneal to the template DNA (Figure 
9). If the probe recognizes the allele it will bind to the DNA allowing for the 5’ exonuclease activity 
of the Taq polymerase to cleave the fluorescent dye from the probe, allowing it to give off a 
fluorescent signal. However, if the probe is not specific for the allele it will not bind resulting in the 
fluorescent dye remaining in close proximity to the quencher molecule. Once the PCR reaction is 
complete, genotype calling is done by plotting the normalised intensity of the fluorescent dye on a 
cluster plot (Figure 10) using data analysis software. For diallelic polymorphisms, three such 
clusters are possible, with two clusters representing the homozygote genotypes (emission of only 
one of the dyes) and the third cluster representing the heterozygote genotype (emission of both 
dyes in the same sample). Finally, a fourth cluster is also identified and representative of the 
negative control samples, and usually occurs closest to the x- and y- axis intersection. 
 
 
Figure 10: Cluster plot used for the calling of genotypes 247. 
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   4.4.2 TaqMan® Protocol 
 
In this study, five polymorphisms of CADM1, one polymorphism of CADM2, three polymorphisms 
of CADM3, one polymorphism of NCAM2 and six polymorphisms of ANXA11 were genotyped using 
the TaqMan® Genotyping system (Table 9). Pipetting was done using the Eppendorf epMotion 
5070 automated pipetting system. For each 5 µl reaction, 2.5 µl TaqMan® Genotyping Master Mix 
(Applied Biosystems), 0.06 µl (40X) of TaqMan® SNP Genotyping Assay (Applied Biosystems) and 
2.4 µl of distilled water was added. To this master mix, 20 ng of DNA was added. PCR reactions 
were completed in the GeneAmp® PCR System 9700 (Applied Biosystems) machine with the 
following cycling conditions: 10 minutes at 95°C, followed by 45 cycles of 10 seconds at 95°C and 1 
minute at 60°C. The plates were analysed on the 7900 HT Fast Real-Time PCR System (Applied 
Biosystems) using the SDS v2.3 software (Applied Biosystems). 
 
Table 9: TaqMan® Genotyping Assays used in this study. 
Gene SNP Assay ID 
CADM1 
rs1460911 C_1683071_10 
rs1563899 C_7487749_10 
rs1563900 C_7487750_10 
rs2446890 C_1683096_10 
rs2515327 C_26488323_10 
CADM2 rs2324979 C_7724485_10 
CADM3 
rs12057331 C_31622088_10 
rs12068892 C_31622098_10 
rs16841729 C_33822427_10 
NCAM2 rs8184921 C_29840603_10 
ANXA11 
rs2789679 C_16108006_10 
rs7071579 C_1817519_10 
rs1953600 C_12123137_10 
rs2573346 C_1817475_10 
rs2784773 C_1817509_10 
rs1049550 C_7881261_10 
 
4.5 SNP Identification (ANXA11) 
 
We were also interested in identifying novel polymorphisms or other potential disease associated 
polymorphisms in ANXA11. We therefore sequenced 20 individuals, 10 cases and 10 controls, at 
various regions within and flanking the gene. We were interested in identifying polymorphisms 
that could be in LD with the rs1049550 (exon 5, causative allele in sarcoidosis GWAS) and the 
rs7071579 polymorphism (3’ UTR) which was associated with susceptibility to TB in the SAC 
population. Polymorphisms that occurred within a functional region (promoter, exon, exon-intron 
splice site) of the gene and had a minor allele frequency of at least 5% were subsequently 
investigated as a possible TB susceptibility variant in our SAC population. 
 
All sequencing reactions were conducted by the Central Analytical Facility (Stellenbosch 
University, South Africa), the results of which were aligned using the Sequencher v4.7 software 
(Gene Codes Corporation, Michigan, USA). All variations identified were analysed further using the 
web based program Blat (http://genome.ucsc.edu/cgi-bin/hgBlat). After inserting the flanking 
sequence of the polymorphism, Blat identified all the known polymorphisms within that region 
with their respective rs-numbers. The rs-number represents a unique ID that can be used to search 
the Single Nucleotide Polymorphism Database (dbSNP) which is hosted by the National Human 
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Genome Research Institute and the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). If no rs-number was provided and there was no 
reference to the SNP in the literature, it was considered to be novel. 
 
Four regions spanning ANXA11 were selected for sequencing, including exons 4, 5 and 6 and the 3’ 
UTR (Table 10).  
 
Table 10: Primer sets and their respective sizes used to sequence ANXA11 regions. 
Name Sequence (5’ – 3’) Size (bp) 
E4seqF TCAAATCTGGGATATGGCTCTT 
222 
E4seqR ACGTACACACCTTGATGGCTTC 
E5-6seqF CGGCATGCACGACATCTTACCT 
468 
E5-6seqR GCCTTGCCGTAAGCCGTCTTGA 
3UTRseqF TGCTGAAGATCTGTGGTGGCAATGAC 
747 
3UTRseqR ACCATTCCAGAGCTGGCTGACTCTT 
Primers were manufactured by Integrated DNA Technologies (Iowa, USA). 
 
   4.5.1 Exons 4, 5 and 6 
 
Exons 5 and 6 were sequenced in one reaction while exon 4 was sequenced on its own. Each 
sample was amplified in a total volume of 25 µl containing: 2.5 µl 10X Buffer (containing 1.5 mM 
MgCl2) (Southern Cross Biotechnologies, Cape Town, South Africa), 2 µl 1.25 mM dNTPs (Bioline, 
London, UK), 10 µM of each primer, 17.425 µl distilled water, 0.075 µl SuperTherm GOLD HotStart 
Taq polymerase and 100ng of DNA. Cycling conditions were as follows: 10 minutes at 94°C, 
followed by 35 cycles of 30 seconds at 94°C, 30 seconds at 60.6°C (exon 7 and 8)/ 54.6°C (exon 9) 
and 45 seconds at 72°C, followed by an extension step of 10 minutes at 72°C and a cooling step of 
2 minutes at 4°C. 
 
   4.5.2 3’ UTR 
 
The 3’ UTR region was amplified in a total volume of 25 µl containing: 2.5 µl 10X Buffer (containing 
1.5 mM MgCl2) (Southern Cross Biotechnologies), 2 µl 1.25 mM dNTPs (Bioline), 10 µM of each 
primer, 17.425 µl distilled water, 0.075 µl SuperTherm GOLD HotStart Taq polymerase and 100ng 
of DNA. Cycling conditions were as follows: 10 minutes at 94°C, followed by 35 cycles of 30 
seconds at 94°C, 30 seconds at 61.2°C and 45 seconds at 72°C, followed by an extension step of 10 
minutes at 72°C and a cooling step of 2 minutes at 4°C. 
 
   4.5.3 PCR Clean-Up (ExoSAP-IT) 
 
All amplified samples were electrophoresed on a 1.5% agarose gel at 150 V for 30 minutes; image 
capturing was done using the G-Box (Syngene, Cambridge, UK). All samples that were successfully 
amplified and contained no spurious amplification were subjected to a PCR clean-up using ExoSAP-
IT (USB Corporation, Ohio, USA). The clean-up reaction was done in a 16.8 µl reaction volume, 
containing 4.8 µl ExoSAP-IT and 12 µl PCR product. Cycling conditions for the clean-up process 
were as follows: 15 minutes at 37°C, 15 minutes at 80°C and 2 minutes at 4°C. Primers for 
sequencing were 1.1 µM, with each sequencing reaction requiring 5 µl. These primers and 
cleaned-up PCR products were sent for sequencing at the Central Analytical Facility (Stellenbosch 
University). Sequencing results were analysed using Sequencher v4.7 (Gene Codes Corporation, 
Michigan, USA). 
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4.6 Gene Expression Analysis 
 
   4.6.1 Sample Selection and Genotyping 
 
Heparinized venous blood was obtained from healthy volunteers after informed consent and 
approval by the Health Research Ethics Committee of Stellenbosch University, South Africa 
(Project registration number 10/08/249). These DNA samples were sequenced to determine the 
genotype for each individual at the rs7071579 polymorphic site. Individuals who were 
homozygous for the A- or G-allele were then selected to be part of the study. 
 
A primer set (Table 11) was designed to genotype the DNA samples. Each sample was amplified in 
a total volume of 25 µl containing: 2.5 µl 10X Buffer (containing 1.5 mM MgCl2) (Southern Cross 
Biotechnologies), 2 µl 1.2 5mM dNTPs (Bioline), 10 µM of each primer, 17.425 µl distilled water, 
0.075 µl SuperTherm GOLD HotStart Taq polymerase and a 100ng of DNA. Cycling conditions were 
as follows: 10 minutes at 94°C, followed by 35 cycles of 30 seconds at 94°C, 30 seconds at 52.3°C 
and 45 seconds at 72°C, followed by an extension step of 10 minutes at 72°C and a cooling step of 
2 minutes at 4°C. 
 
For sample visualization and clean-up, see section 4.5.3. 
 
Table 11: Primer set used to sequence the rs7071579 polymorphism. 
Name Sequence (5’ – 3’) Size (bp) 
rs7071579F GAGATCTAGAAAGGCCAGTCCATGCTACACATC 
286 
rs7071579R GAGAGGATCCGACTCGGTCTTGTCGGTTTCAGG 
Primers were manufactured by Integrated DNA Technologies. 
 
   4.6.2 Cell Culture 
      4.6.2.1 PBMC Isolation 
 
To isolate the peripheral blood mononuclear cells (PBMCs), four Vacuette Heparin tubes (Greiner 
Bio-One, Kremsmuenster, Austria) were filled with 10 ml blood each. Two of the blood tubes were 
transferred into one 50 ml Falcon tube and filled to 35 ml with Roswell Park Memorial Institute 
(RPMI)-1640 (Sigma-Aldrich, Missouri, USA) (two per person). In a separate 50 ml Falcon tube, 15 
ml of Histopaque (Sigma-Aldrich) was added (two per person). By holding the tube containing the 
Histopaque at an angle the blood/RPMI-1640 mixture was gently pipetted over the Histopaque, so 
as to create two layers. These 50 ml tubes were centrifuged at 400 x g for 25 minutes (no 
acceleration or brakes). This separated the tube contents into four layers. The top layer containing 
serum was discarded. The second thin layer contained the PBMCs, which were transferred to a 
new 50 ml Falcon tube and filled to 50 ml with RPMI-1640 (Sigma-Aldrich). Tubes were centrifuged 
at 250 x g for 5 minutes, the supernatant was decanted and cells were resuspended in 10 ml RPMI-
1640 (Sigma-Aldrich). After centrifuging at 250 x g for 5 minutes, the supernatant was removed 
and the cells resuspended in 4 ml complete serum. Cells were plated in 6-well plates (NUNC, 
Roskilde, Denmark) with each well containing 2 ml resuspended cells and monocytes were allowed 
to adhere to the surface for 16 hours in an incubator at 37°C and 5% CO2. Two wells were used per 
individual; one well to be subjected to BCG infection while the other would serve as a control 
 
All experiments were conducted in triplicate. 
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      4.6.2.2 BCG Infection 
 
BCG was passed fifteen times through a 1ml/cc insulin syringe (Supra Latex, Cape Town, SA) 
without creating any bubbles. BCG stock solution was diluted by adding 800 µl RPMI-1640 (Sigma-
Aldrich). After 16 hours, the media was removed and wells were washed once with 1 ml RPMI-
1640 (Sigma-Aldrich) to remove all non-adherent cells. To each BCG well, 40 µl of diluted BCG was 
added and allowed to incubate at 37°C and 5% CO2 for 4 hours. To each control well, 40 µl of 
RPMI-1640 (Sigma-Aldrich) was added. 
 
After 4 hours, all media was removed and wells were washed once with 1 ml RPMI-1640 (Sigma-
Aldrich). After the washing step, 2 ml of 10% conditioned media was added to each well. Plates 
were placed back into the incubator and 3 days post-infection a further 1 ml of 10% conditioned 
media was added. After 7 days the cells were lysed and RNA and proteins were extracted (sections 
4.6.3.1 and 4.6.4.1 respectively). 
 
BCG culture aliquots were a gift from Leanie Kleynhans (Immunology Group). 
 
   4.6.3 mRNA Expression 
      4.6.3.1 RNA Extraction 
 
RNA was extracted from the monocytes using the TRIzol® Reagent (Invitrogen, California, USA). 
Briefly, plates were placed on ice and all media was removed. Each well was then washed once 
with 1 ml RPMI-1640 (Sigma-Aldrich). Working quickly, 500 µl of TRIzol® was added to the well and 
using a scraper the cells were lysed. The cell lysate was transferred to a chilled 1.5 ml tube. This 
was repeated with a further 500 µl of TRIzol®. The cell lysate solution was then allowed to 
incubate for 5 minutes at room temperature. To allow for phase separation, 200 µl of chloroform 
was added to each 1.5 ml tube and shaken vigorously for 15 seconds and then allowed to incubate 
for 3 minutes at room temperature. Samples were then centrifuged at 12 000 x g for 15 minutes at 
4°C. After centrifugation, the solution separated into three phases, namely a lower red phenol-
chloroform phase (containing proteins), an interphase (containing DNA) and a colourless upper 
aqueous phase (containing RNA). The aqueous phase was transferred to a new 1.5 ml tube 
containing 500 µl of isopropanol and samples were allowed to incubate for 15 minutes at room 
temperature. The organic phase was stored at -80°C for protein extraction at a later time (see 
section 4.6.4.1). Samples were centrifuged at 12 000 x g for 10 minutes at 4°C. The RNA formed a 
pellet at the bottom of the tube. The supernatant was discarded and add 1 ml 70% ethanol was 
used to wash the pellet. Samples were vortexed and then centrifuged at 7 500 x g for 5 minutes at 
4°C. Ethanol was removed and RNA pellet allowed to air dry for 10 minutes (do not allow pellet to 
dry completely as this will reduce its solubility). RNA pellet was dissolved in 20 µl Diethyl 
Pyrocarbonate (DEPC) water (Ambion, Texas, USA) by pipetting or incubating for 10 minutes at 
55°C to 60°C. RNA samples were stored at -80°C. 
 
To determine the quantity and quality of RNA, we used the NanoDrop® ND-1000 
Spectrophotometer and the NanoDrop® v.3.0.1 Software (Inqaba Biotechnology). An A260/A280 
ratio < 1.6 meant that the RNA was partially dissolved. 
 
      4.6.3.2 Reverse-Transcription PCR (RT-PCR) 
 
To synthesize cDNA, RT-PCR was done using the Transcriptor First Strand cDNA Synthesis Kit 
(Roche, Mannheim, Germany), following manufacturer’s instructions. Briefly, in a 20 µl reaction 
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volume, 100ng of total RNA; 2 µl of primers (Random Hexamer Primer, 60 µM) and PCR-grade 
water (to make total volume equal 13 µl) was added to a nuclease-free PCR tube and heated for 
10 minutes at 65°C to denature the RNA-primer mixture. The following reagents were then added 
in order: 4 µl 5X Transcriptor Reverse Transcriptase Reaction Buffer, 0.5 µl Protector RNase 
Inhibitor, 2 µl 10 mM dNTPs and 0.5 µl Transcriptor Reverse Transcriptase. Tubes were placed in a 
thermal block cycler with the following cycling conditions: 10 minutes at 25°C, 30 minutes at 55°C, 
5 minutes at 85°C and then cooled down to 4°C to stop the reaction. cDNA samples were stored at 
-20°C. 
 
      4.6.3.3 Quantitative Real-Time PCR (qPCR) 
 
To conduct the qPCR experiments the LightCycler® FastStart DNA Master SYBR Green I kit (Roche) 
was used with the LightCycler® 1.5 System (Roche). Firstly, the Master Mix was prepared by 
adding 10 µl of LightCycler® FastStart Enzyme to 54 µl 10X LightCycler® FastStart Reaction Mix 
SYBR Green 1. The PCR mix was prepared by adding, in order, the following components: 13.2 µl 
PCR-grade water, 0.8 µl MgCl2, 3 µM of each primer, 2 µl Master Mix and 2 µl cDNA and pipetted 
into a precooled LightCycler® capillary. The capillaries were then centrifuged for 5 seconds at 700 x 
g. The qPCR program was as follows: Activation, 95°C for 15 minutes (ramp rate (R/R) of 20°C); 
PCR, 40 cycles of 95°C for 15 seconds (R/R of 20°C), 63°C for 15 seconds (R/R of 20°C) and 72°C for 
20 seconds (R/R of 20°C) with a single acquisition; Melt Curve, 95°C for 0 seconds (R/R of 20°C), 
60°C for 15 seconds (R/R of 20°C) and 95°C for 0 seconds (R/R of 0.1°C) with continuous 
acquisition; Cooling, 40°C for 30 seconds (R/R of 20°C). For each run a negative (no cDNA) control 
was included. For primers see Table 12. 
 
Table 12: Primer sets used for qPCR analysis. 
Type Name Sequence (5’ – 3’) Size (bp) 
Gene of interest 
ANXA11F$ AGTGCCGAGCTACCCAGGATACC 
403 
ANXA11R$ AGCGAGGATCTCAATCAGGCAGG 
Reference gene 
TubulinF* GCCAGAGCCAAGTGAC 
60 
TubulinR* CGAAGAAGGTGTTGAAGGAAT 
$
Primers from Hoffman et al 2008 
*
Primers from Roche 
 
To determine the change in gene expression the Relative Quantification method was employed. 
This method measures the difference in the threshold cycles (Cq) between the gene of interest and 
a reference gene index and is expressed as the fold difference between a test (BCG infected) and a 
control (BCG uninfected) sample. To calculate the ratio of gene expression change (R) the 
following formulae were used: 
 
ΔCq = Cq target – Cq reference ... (1) 
 
ΔΔCq = ΔCq sample – ΔCq control ... (2) 
 
R = 2-ΔΔCq  ... (3) 
 
Using equation (1) the difference in Cq was determined for each sample. Then by using equation 
(2) we determined the difference in Cq for each individual by comparing the Cq of the treated and 
control sample. Finally, R was calculated using equation (3), which is representative of the 
difference in the “corrected” number of cycles to threshold. The value of 2 is used based on the 
assumption that the product doubles with each cycle. 
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All analysis was done in duplicate. 
 
   4.6.4 Protein Expression 
      4.6.4.1 Protein Extraction 
 
To the red-phenol chloroform phase (see section 4.6.3.1) 1 ml 100% ethanol was added and 
samples mixed by inversion followed by incubation at room temperature for 2 minutes. Samples 
were centrifuged at 2000 x g for 5 minutes, all centrifugation steps at 4°C. Phenol-ethanol 
supernatant was removed and 3 ml acetone was added. Samples were mixed by inversion for 10 – 
15 seconds to obtain a homogenous solution. Samples were incubated for 10 minutes at room 
temperature and then the proteins were sedimented by centrifugation at 3000 x g for 5 minutes. 
Supernatant was discarded and pellet dispersed in 1 ml 0.3M guanidine thiocyanide in 95% 
ethanol solution. Incubation and centrifugation step was repeated. Supernatant was discarded 
and pellet washed with 1 ml 100% ethanol containing 2.5% glycerol (v/v) solution. Incubation and 
centrifugation step was repeated. Ethanol solution was decanted and pellet allowed to dry by 
inversion for 20 minutes. Pellet was resuspended in 150 µl 1% sodium dodecyl sulphate (SDS). 
 
      4.6.4.2 Standard Curve 
 
To determine the protein concentration a standard curve was created using the Dc Protein Assay 
(Bio-Rad, Johannesburg, SA). Briefly, a Bovine Serum Albumin (BSA) series dilution (standards) was 
created (0 mg/ml BSA – 1 mg/ml BSA). Since our protein was resuspended in 1% SDS, a detergent, 
20 µl of reagent S was added to each millilitre of reagent A used and relabelled reagent A’. 50 µl of 
standards and proteins (10-fold dilution) were pipetted into clean 15 ml Falcon tubes. 250 µl of 
reagent A’ was then added to each tube and vortexed. 2 ml of reagent B was added to each tube 
and vortexed immediately. After 15 minutes the absorbance was read on a spectrophotometer 
(Ultrospec 4051, LKB Biochrom, Cambridge, UK) at 750 nm. The signal was stable for 1 hour. 
 
The absorbance values of the standards were inserted into an Excel spreadsheet to generate a 
standard curve, with its associated equation (y = mx + c). This equation was used to calculate the 
concentration of each protein sample based on its absorbance value. 
 
      4.6.4.3 Western Blot 
 
After preparing a 3% stacking and 12% separating sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) gel, 10 µl of PageRuler™ Prestained Protein ladder (Fermentas, 
Ontario, Canada) and 10 µl of sample (5 µg of protein plus 5 µl of reducing buffer (RB)) was loaded 
into each well and allowed to run for 2 hours at 200V in running buffer. After completion of 
electrophoresis of the gel, the Western Blot (WB) apparatus was set-up. Briefly (per gel), two 
pieces of Western Blotting Filter Paper (Thermo Scientific, Illinois, USA) was placed in transfer 
buffer. Hybond-P PVDF (GE Healthcare, New Jersey, USA) membrane was activated in 100% 
methanol, then washed for 5 minutes in distilled water and finally allowed to equilibrate for 10 
minutes in Transfer Buffer. The WB sandwich was stacked as follows (black to red of WB casette): 
filter paper, gel, membrane, filter paper. All air bubbles were removed and the sandwich was 
placed in WB Cell System. The WB Cell System was run under cold conditions (4°C) for 1 hour at 
100V and placed on a magnetic stirrer to ensure distribution of cold transfer buffer throughout the 
run. After successful transfer of proteins from gel to membrane, the membrane was blocked 
overnight at 4°C in blocking buffer. After overnight blocking, the membrane was rinsed in TBS-T 
41 
 
buffer and then incubated with the primary antibody (Rabbit polyclonal antibody to Annexin X1, 
GeneTex®, Inc., California, USA) (1:3000) for 1 hour at room temperature. Following incubation, 
the membrane was rinsed twice in TBT-T Buffer followed by washing three times, 10 minutes 
each, in TBS-T Buffer with shaking. The membrane was then incubated with the secondary 
antibody (Goat anti-rabbit IgG-HRP, Santa Cruz Biotechnology Inc., California, USA) (1:5000) for 1 
hour at room temperature. The rinse/wash step was then repeated. To view the proteins on an 
autoradiographic film, the membrane was incubated in ECL Western Blotting Detection Fluid (GE 
Healthcare), following the manufacturer’s instructions, for 1 minute. The membrane was then 
placed between two sheets of plastic and transferred to a Hypercasette™ (Amersham Life 
Sciences, Buckinghamshire, England) with autoradiographic film for 10 minutes. The 
autoradiographic film was then developed using the Hyper Processor (Amersham Pharmacia 
Biotech, New Jersey, USA). 
 
4.7 Methylation Pattern Analysis 
 
   4.7.1 Sample Selection 
 
For the methylation experiments, eight individuals (four cases and four controls) were selected 
from the Case-Control sample set. Cases were selected based on the extent of their disease 
(number of cavities and size of cavities). Controls matching the cases in terms of age and gender 
were included. 
 
   4.7.2 Bisulfite Conversion of DNA 
 
To determine whether or not the methylation pattern of ANXA11 differs between cases and 
controls the Imprint™ DNA Modification Kit (Sigma-Aldrich) was used. This kit allows for DNA 
modification such that methylated cytosines are converted to uracil and unmethylated cytosines 
remain unchanged. Briefly, 1.1 ml of DNA Modification Solution was added to 1 vial of DNA 
Modification Powder and vortexed until the solution became clear. Once the solution was clear 40 
µl of Balance Solution was added (Solution A), followed by vortexing. To a clean 1.5 ml micro-
centrifuge tube, 500 ng of DNA was added to 110 µl of Solution A and briefly vortexed. Tubes were 
then incubated at 99°C for 6 minutes immediately followed by incubation at 65°C for 90 minutes. 
 
Following the incubation, samples were placed on ice and subjected to a Post Modification DNA 
Clean-Up. For each sample a Spin Column was inserted into a Capless Collection Tube, to which 
300 µl Capture Solution was added and allowed to incubate for 1 minute. To this the modified 
DNA solution was added. The columns were then centrifuged at 12 000 x g for 20 seconds (all 
centrifugations were at 12 000 x g) and the flow-through discarded. 200 µl of Cleaning Solution 
was then added to each column and centrifuged for 20 seconds. 50 µl of Balance/Ethanol Solution 
was added to the bottom of the column and allowed to incubate for 8 minutes at room 
temperature. Columns were then centrifuged for 20 seconds. Then 200 µl of 90% Ethanol Solution 
was added and columns were centrifuged for 20 seconds. The previous step was repeated but the 
columns were centrifuged for 40 seconds, the capless collection tube was discarded and the spin 
column placed in a clean 1.5 ml Collection Tube. 20 µl of Elution Solution was added to the bottom 
of the spin column and allowed to incubate for 1 minute followed by centrifugation for 20 
seconds. The spin column was discarded and the modified DNA stored at -80°C. The modified DNA 
was then ready for downstream applications. 
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   4.7.3 Cloning of Bisulfite Converted DNA 
      4.7.3.1 Amplification and Purification of Bisulfite Converted DNA Fragments 
 
The CpG island in the promoter region of ANXA11 was amplified using two sets of primers (Table 
13). PCR reactions were carried out in a 25 µl reaction containing: 2.5 µl 10X Buffer (containing 
1.5mM MgCl2) (Southern Cross Biotechnologies), 2 µl 1.25mM dNTPs (Bioline), 100 µM of each 
primer, 16.4 µl distilled water, 0.1 µl SuperTherm GOLD HotStart Taq polymerase and 2 µl of 
bisulfite converted DNA. The following cycling program was used: 10 minutes at 95°C, followed by 
40 cycles of 20 seconds at 94°C, 30 seconds at 55°C and 40 seconds at 72°C, followed by an 
extension step of 2 minutes at 72°C and a cooling step of 2 minutes at 4°C. PCR products were 
visualized on a 2% agarose gel. 
 
Table 13: Primers used for amplification of CpG island in promoter region of ANXA11. 
Name Sequence (5’ – 3’) Size (bp) 
Fp1 GAGGAAAGTTTTTGAAGATAG 
180 
Rp1 CTCAATCTAAACCTAAATAAAACC 
Fp2 GTTTTATTTAGGTTTAGATTG 
195 
Rp2 ACTTCCTAATTACACTACAAA 
 
The PCR products were purified by centrifugation using the Wizard SV Gel and PCR Clean-Up 
System (Promega, Wisconsin, USA) following the manufacturer’s instructions. Briefly, fragments of 
interest were cut out of the gel under UV light and placed in a clean 1.5 ml centrifuge tube. 
Membrane binding solution, the amount of which was calculated by determining the weight 
(grams) of the gel piece containing the fragment and adding 10 µl per 10 mg, was added to each 
tube. These tubes were then placed in a heating block (55°C) until the gel fragment was 
completely dissolved. The solution was then transferred to a minicolumn and allowed to incubate 
for 1 minute at room temperature. The minicolumns were then centrifuged at 14 000 rpm for 1 
minute (all subsequent centrifugations are at 14 000 rpm). The flow-through was discarded and 
the minicolumn re-assembled. The minicolumns were then washed with 700 µl of Membrane 
Wash Solution and then centrifuged for 1 minute. After discarding of flow-through and re-
assembling of minicolumns the wash step was repeated with 500 µl of Membrane Wash Solution 
and centrifuged for 5 minutes. Columns were then transferred to clean 1.5 ml centrifuge tubes, to 
which 50 µl of nuclease-free water was added to the centre of the membrane and allowed to 
incubate for 1 minute at room temperature. DNA was eluted from column by centrifugation for 1 
minute. Samples were stored at -20°C. 
 
      4.7.3.2 Ligation to pGEM®-T Easy vector 
 
The purified bisulfite converted DNA fragments were each ligated into the pGEM®-T Easy vector 
(Promega) using T4 DNA ligase (Promega). The principle behind the pGEM®-T Easy vector system is 
that the addition of adenosine bases to the 3’ end of amplified fragments facilitates its ligation to 
the 3’ tyrosine overhangs of the pGEM®-T Easy vector. This is made possible by the use of 
SuperTherm GOLD HotStart Taq polymerase which adds the adenosine bases to the 3’ ends of 
amplified fragments. The ligation reaction was done in a 10 µl reaction containing: 5 µl 2X ligation 
buffer, 1 µl pGEM®-T Easy vector, 3 µl purified PCR product and 1 µl T4 DNA ligase. Ligation 
reactions were incubated overnight at 4°C. 
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      4.7.3.3 E.coli Transformation 
 
Competent E. coli JM109 (Promega) cells were transformed by means of heat shock. In summary, 
25 µl of competent E. coli was added to 2.5 µl ligation product and allowed to incubate on ice for 
10 minutes. Cells were then heat treated at 42°C for 47 seconds and then placed on ice for a 
further 2 minutes. 900 µl of Luria-Bertani (LB) medium (4°C) was added to the transformed cells 
and cells were placed in a shaker (Orbital Shaker Incubator LM-530, Yih Der, Japan) for 60 minutes 
at 37°C. Following incubation, cells were plated onto LB agar plates supplemented with 100 µg/ml 
isopropyl β-D-1-thiogalactopyranoside (IPTG), 100 µg/ml 5-bromo-4chloro-3-indolyl β-
galactopyranoside (X-Gal) and 50 µg/ml Ampicillin (E. Coli FastGrow™ Media, Fermentas) and 
allowed to grow overnight at 37°C.  
 
      4.7.3.4 Colony PCR 
 
Due to the addition of IPTG and X-gal to the growth medium, blue and white colonies were visible 
on the plates after incubation. White colonies were indicative of cells containing the plasmid and 
were therefore selected for further investigation. Using a pipette tip, a single white colony was 
selected and transferred to 4 ml LB broth containing 4 µl of ampicillin. These cell cultures were 
then placed in the orbital shaker for 8 hours at 37°C. After the incubation, a colony PCR was 
performed to determine if the cells contained the fragment of interest. For PCR conditions see 
Section 4.7.3.1. 2 µl of cell culture was substituted for 2 µl of bisulphite converted DNA. 
 
      4.7.3.5 Small-Scale Plasmid Extraction (Miniprep) 
 
After confirmation that the cell cultures contained the correct size insert, plasmids were extracted 
using the Wizard Plus SV Miniprep Kit (Promega). Briefly, the E. coli cell cultures were pelleted by 
centrifugation for 10 minutes at 4 000 rpm and the supernatant discarded. Cells were then 
resuspended in 300 µl Cell Resuspension Solution by vigorous pipetting. Cells were then lysed by 
adding 350 µl of Cell Lysis Solution and tubes were inverted four times to mix solution. 10 µl of 
Alkaline Protease Solution was added which inhibits all endonucleases and other proteins released 
during lysis of cells, tubes were inverted four times and allowed to incubate at room temperature 
for 5 minutes. Following incubation, 400 µl of Neutralization Solution was added. After inverting 
the tubes four times they were centrifuged at maximum speed for 10 minutes (all subsequent 
centrifugations were at maximum speed). After centrifugation, the clear supernatant was 
transferred to a minicolumn and centrifuged for 1 minute. The column was then washed with 750 
µl of Membrane Wash Solution and centrifuged for 1 minute. The wash step was repeated but this 
time with 250 µl of Membrane Wash Solution and centrifuged for 2 minutes. The plasmid was 
then eluted from the column by adding 50 µl of nucleas-free water and centrifuged for 1 minute. 
Plasmid DNA concentration was determined using the NanoDrop® ND-1000 Spectrophotometer 
and the NanoDrop® v3.0.1 Software (Inqaba Biotechnology). Samples were stored at -20°C. 
 
   4.7.4 Bisulfite Sequencing (Analysis) 
 
To determine whether or not there was a difference in methylation pattern of ANXA11 between 
TB cases and controls, the purified plasmids containing the bisulphite treated DNA were sent for 
sequencing. 5 µl of 100 ng/µl DNA was sent to the Central Analytical Facility (Stellenbosch 
University) for sequencing using the universal primer SP6 (provided by the Central Analytical 
Facility). Sequencing data was analysed using the BiQ Analyzer software package (http://biq-
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analyzer.bioinf.mpi-inf.mpg.de/), which allows for visualization and quality contol of DNA 
methylation data from bisulfite sequencing. 
 
4.8 Statistical Analysis 
 
   4.8.1 Hardy-Weinberg Equilibrium 
 
The Hardy-Weinberg model is used to determine the genotypic frequencies in a population by 
using the allele frequencies 248, 249. This model however is only valid in stable populations, that is, a 
population in which no gene flow, genetic drift, mutation, natural selection or non-random mating 
is present 250. When all these assumptions hold true in a population and the population is of a 
large size, the genotypic and allelic frequencies will remain constant from generation to 
generation, resulting in a population that is in Hardy-Weinberg Equilibrium (HWE). HWE is 
therefore an important statistical tool in case-control association studies, since departure from 
HWE in the control study participants could mean that there was a genotyping error 251 or that the 
population being investigated is stratified; or in the event that the disease cases are not in HWE, 
the marker is associated with disease outcome 252. 
 
The HWE model has two equations, p + q = 1 for allele frequencies and 1 = p2 + 2pq +q2 for 
genotype frequencies, where the frequency of the one allele is p and the other is q. When one or 
both allelic frequencies are known, they can be used to determine the expected genotypic 
frequencies of the population, where p2 and q2 are the proportion of homozygotes and 2pq is the 
proportion of heterozygotes. These expected genotypic frequencies are then used to determine 
whether or not the population is in HWE by using the chi-square test (Χ2, 5.9.2). If the Χ2 value is 
less that 3.84 then the population is considered to be in HWE. HWE analysis has one degree of 
freedom (df, number of genotypes minus number of alleles).  
 
   4.8.2 Chi-square Test 
 
To test for HWE, a chi-square (Χ2) goodness-of-fit test is employed 251, 252. The Χ2 test is most 
commonly used to test if there is no association between two variables. The Χ2 value is calculated 
using the following equation:  
 
    
                                  
               
 
 
Where the expected number is the number of individuals with that genotype expected if the 
population is in HWE and the observed number is the number of individuals obtained from the 
data. When the observed and expected values are similar then the hypothesis of no association is 
held true, while if the observed and expected values differ significantly then there is an association 
between the two variables. The P-value, which is calculated from the Χ2 test and its degrees of 
freedom, is used to determine if the null hypothesis (Ho: there is no significant difference between 
the observed and expected frequencies) or the alternative hypothesis (H1: there is a significant 
difference between the observed and expected frequencies) is true. If P < 0.05 then the Ho is 
rejected and the H1 is accepted. 
 
The Χ2 value was determined using Prism v5.02 (GraphPad Software, Inc., California, USA). 
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   4.8.3 Fisher’s Exact Test 
 
Fisher’s exact test was done using Prism v5.02. This test is used to analyse 2 x 2 contingency tables 
with small sample sizes 253, and was used to calculate an exact P-value, whereas the Χ2 test is an 
approximation. 
 
   4.8.4 Haplotype and Linkage Disequilibrium 
 
Haplotype analysis was done using Cocaphase in the Unphased suite 254 and 10 000 permutation 
replicates were done to test for global significance of the estimated haplotypes. Since haplotypes 
in a haplotype block are not independent of one another the use of Bonferroni corrections would 
be too conservative, as it would result in haplotypes with moderate effect not being investigated. 
LD was evaluated using Haploview v4.1 255, with haplotype blocks being automatically selected by 
the programme, based on the block definition of Gabriel et al 109. LD was analysed in terms of D’, 
where D’ = 0 indicates no LD and D’ = 1 equals complete LD.  
 
   4.8.5 Power Calculations 
 
Power calculations were done using Epi Info 2000 (Centres for Disease Control and Prevention, 
USA). With the number of samples available we had 80% power and 95% confidence given an 
expected allele frequency of at least 5% for the SNPs genotyped to detect an odds ratio of 2.23. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: ANXA11 
 
 
 
 
 
Perfect as the wing of a bird may be, it will never enable the bird to fly if unsupported by 
the air. Facts are the air of science. Without them a man of science can never rise. 
 
Ivan Pavlov  
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5.1 Annexins 
   
   5.1.1 Annexin Gene Family 
 
The annexins are a superfamily of calcium-dependent phospholipid binding proteins that are 
stucturally related 256-258. There are currenly five classes of annexins (A – E), with human annexins 
belonging to class A, comprised of 12 annexins (A1 – A11 and A13) 257, 258. All annexins contain a 
core domain which consists of a 70 amino acid repeat, which occurs either four (35-37 kDa) or 
eight (~65 kDa) times 256, 259, 260, and is called the annexin repeat. Each annexin repeat is made up 
of five α helices and usually contains a ‘type 2’ motif 258, which is responsible for the binding 
properties of annexins to calcium (Ca2+) and phospholipids 257-259, 261, 262. These four or eight 
annexin repeats make up the C-terminal core domain and are highly conserved in all annexin 
proteins. Conversely, the N-terminal domain varies greatly between the annexin proteins, and it is 
this variability that gives rise to the functional differences in biological activities of each annexin 
protein 257, 260, 262. 
 
Annexin proteins are generally found within the cytosol, while under certain conditions some 
annexins (A2 and A11) have been found to localize in the nucleus or be expressed on the cell 
surface (A1 and A2) even though no secretory signal peptide has yet been identified 258. Annexin 
A1 (ANXA1) has been found to translocate to the cell surface after cell exposure to glucocorticoids, 
while annexin A2 (ANXA2) is constitutively expressed on vascular endothelial cells where it plays a 
role in the regulation of blood clotting 258 and maintenance of fibrinolytic homeostasis 261. Annexin 
protein expression levels and tissue distribution has been found to vary between family members, 
with some annexins being abundant and ubiquitously expressed (annexins A1, A2, A4, A5, A6, A7 
and A11), while others are selectively expressed (annexin A3 – neutrophils and annexin A8 – 
placenta and skin) or restrictively expressed (annexin A9 – tongue, annexin A10 – stomach and 
annexin A13 – small intestine) 258. 
 
Due to the ubiquitous expression of most of the annexin proteins, researchers have postulated 
that these proteins must play a fundamental role in various cellular biological processes 263 such as 
apoptosis, cell division, cell signalling, endo- and exocytosis and ion transport 257, 261, 262. With the 
use of mouse KO models, various functional insights have been identified for some annexins. For 
example, KO of ANXA1 resulted in an altered inflammatory response and glucocorticoid effects 264 
while ANXA7 null mutant mice strains were shown to be either embryonic lethal 265 or have an 
altered Ca2+ homeostasis 266. However, phenotypic changes noted in cell culture studies are not 
always seen in mice KO models, or are much more subtle, highlighting the potential functional 
redundancy of annexin proteins 258, 262. The functional role of each annexin protein has not yet 
been identified and further studies are required.                            
 
   5.1.2 Annexin A11 
 
Annexin A11 (ANXA11), is located on chromosome 10q22.3 and is considered to be the most 
evolutionary ancient member of the annexin superfamily of proteins 267. It arose from the 
duplication event of annexin A13 into ANXA7 and ANXA11 268. ANXA11 comprises a C-terminal 
core that is shared between all annexin genes and contains the Ca2+ binding domain 268, 269 and a 
unique long N-terminal domain rich in glycine, proline and tyrosine residues, which has been 
shown to contain the binding sites for the apoptotic proteins calcyclin (S100A6) and the apoptosis-
linked protein (apoptosis-linked gene-2, ALG-2) 267, 269, of which binding has been shown to be 
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calcium dependent in in vitro studies 267. In addition, it is believed that this N-terminal region is 
responsible for the protein’s autoantigenicity, nuclear localization, extracellular targeting and 
tyrosine phosphorylation properties 268, 270. Previous studies have also shown a possible role for 
ANXA11 in apoptosis, calcium signalling, cell proliferation, insulin secretion and vesicle trafficking 
267-269. Expression of ANXA11 is ubiquitous with localization predominantly in the nucleus 271. 
 
   5.1.3 Disease Mechanisms – ANXA11 
      5.1.3.1 Cancers 
 
Annexins have been studied in various cancers 272-275, and ANXA11 plays an important role in 
ovarian 269, 276 and colorectal 257 cancer. In a study conducted in 2007 by Song et al. in ovarian 
cancer patients, ANXA11 was found to be associated with the development of cisplatin 
(chemotherapeutic drug) resistance and related to tumour recurrence. It was found that in three 
cisplatin-resistant cell lines ANXA11 was continuously down-regulated when compared to the 
parental cells. They also observed normal ANXA11 expression in most “normal” human organs 
while decreased levels of ANXA11 was found in various human malignancies. Furthermore, they 
found that increased ANXA11 protein levels resulted in ovarian cancer patients being disease-free 
for longer time periods. In a 2009 follow-up study, Song et al. conducted a study to elucidate the 
mechanism by which ANXA11 suppression resulted in cisplatin chemoresistance using small 
interfering RNA. They showed that by knocking down ANXA11 expression the ability of ovarian 
cancer cell lines to proliferate and form colonies was reduced, and therefore that epigenetic 
silencing of ANXA11 conferred cisplatin resistance on these cell lines. 
 
In 2008, Duncan et al. characterised the role of annexins in colorectal cancer. By using 
comparative proteomic analysis they identified annexins A1, A2, A4 and A11 as being 
overexpressed in colorectal tumour samples. They found increased expression of ANXA11 in 
primary tumours compared to normal colon tissue, and increased ANXA11 expression correlated 
with an increase in tumour stage. They also noted that individuals who had higher annexin A4 and 
A11 expression had a lower chance of survival. They postulated that due to the role of ANXA11 in 
cell growth, dysregulation of ANXA11 could result in tumour progression. However, the 
mechanism by which the gene is regulated has yet to be elucidated.  
 
      5.1.3.3 Sarcoidosis 
 
In a recent GWAS for sarcoidosis in a German population, Hofmann et al. identified ANXA11 as a 
novel susceptibility factor 277. Sarcoidosis is a multisystem immune disease that mostly affects the 
lungs and lymphatic system 278, 279 but is of unknown aetiology 280. It is however believed that the 
causative agent could be of microbial origin and that it is airborne since the disease mostly affects 
the lungs 281, 282. As is the case with TB, sarcoidosis results in the formation of granulomas 278, 279 in 
diseased individuals with symptoms which include weight loss, extensive coughing, fever, fatigue 
and night-sweats 279, 283. Various polymorphisms associated with ANXA11 in the GWAS were found 
to alter disease outcome in sarcoidosis patients. The authors postulated that the reduction or 
presence of aberrant forms of ANXA11 could potentially alter the apoptosis pathway by destroying 
the balance between apoptosis and the survival of activated inflammatory cells in sarcoidosis 
patients 277. 
 
In the recent GWAS for novel susceptibility variants for sarcoidosis in the German population, 
ANXA11 polymorphisms were found to alter susceptibility in the population 277. Due to the 
similarity in the pathomechanisms between sarcoidosis and TB 284, we were interested in 
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identifying whether or not these ANXA11 polymorphisms could also alter susceptibility to TB in 
our SAC population. In the study by Hofmann et al., six polymorphisms (Table 14) were found to 
be in strong LD with each other, in addition to being strongly associated with sarcoidosis 
individually.       
 
Table 14: ANXA11 polymorphisms investigated as TB susceptibility variants in the SAC population. 
Polymorphism Location 
rs1049550 exon 6 
rs2784773 intron 11 
rs2573346 intron 12 
rs1953600 3’ UTR/downstream 
rs7071579 3’ UTR/downstream 
rs2789679 3’ UTR/downstream 
 
5.2 Results 
 
   5.2.1 Genotype Analysis 
 
All polymorphisms investigated by TaqMan® genotyping had a call rate ≥ 95% and were in HWE. 
Bonferroni correction for multiple testing was done by determining the number of independent LD 
blocks 285. Three LD blocks were determined for ANXA11 and a P-value < 0.017 was adopted as a 
threshold for significance. Based on this cut-off value, the 3’ UTR polymorphism rs7071579, was 
the only SNP to be significantly associated with susceptibility to TB (Table 15) with the A-allele 
being overrepresented in TB cases (OR 1.38, 95% CI 1.13-1.68). The intron 11 SNP (rs2784773) was 
found to be nominally significant with susceptibility to TB. The four remaining polymorphisms 
shared similar genotype and allele frequencies between cases and controls and were therefore 
not associated with susceptibility to TB in our population. 
 
Table 15: Statistical analysis of ANXA11 polymorphisms. 
SNP 
Allele 
Genotype frequencies 
Pgen
† Pallele
* 
OR 
[95%CI]$ 
Cases Controls 
1‡ 2 11 12 22 HWE# 11 12 22 HWE 
rs2789679 T A 0.06 0.33 0.61 0.40 0.06 0.35 0.59 0.63 0.94 0.81 
1.03 
[0.82-1.30] 
rs7071579 A G 0.33 0.45 0.21 0.11 0.25 0.45 0.29 0.080 0.01 0.0017 
1.38 
[1.13-1.68] 
rs1953600 T C 0.07 0.38 0.55 0.92 0.07 0.38 0.55 0.87 0.97 0.91 
1.02 
[0.82-1.27] 
rs2573346 A G 0.06 0.33 0.61 0.34 0.05 0.35 0.60 0.94 0.82 0.91 
0.98 
[0.78-1.24] 
rs2784773 T C 0.27 0.48 0.25 0.35 0.20 0.51 0.29 0.49 0.05 0.03 
0.80 
[0.66-0.98] 
rs1049550 A G 0.07 0.38 0.55 0.86 0.07 0.37 0.56 0.5 0.94 0.96 
1.01 
[0.81-1.26] 
‡
Minor allele in controls. 
† 
P value from a genotype-based Χ
2
-test, significant if P<0.017. 
*
 P value from an allele-based Fisher’s exact test, significant if P<0.017. 
#
Hardy-Weinberg Equilibrium. 
$
Odds Ratio and [95% Confidence Interval] 
 
 
49 
 
   5.2.2 Linkage Disequilibrium and Haplotype Analysis 
 
Haploview identified one haplotype block (Figure 11), which showed the intron 12 polymorphism 
(rs2573346) and the three 3’ UTR polymorphisms (rs1953600, rs7071579 and rs2789679) to be in 
strong to moderate LD with each other, while the exon 6 (rs1049550) and intron 11 (rs2784773) 
polymorphisms were not in LD. The Cocaphase program identified three proposed haplotypes to 
be associated with susceptibility to TB in the SAC population (Table 16). Two of these haplotypes 
contained the A-allele of rs7071579 and were more frequent in cases than controls. The global P 
value, as calculated by Cocaphase, for the estimated haplotypes was also significant (P = 0.0048). 
 
 
Figure 11: Plot of LD between the ANXA11 markers in the SAC population, generated by Haploview v4.1. 
The 5’ and 3’ ends of the genes are indicated and r2 values (%) are indicated on the squares.  The colours of 
the squares represent D’ values, with red being D’ = 1 and blue D’ = 0. 
 
Table 16: Haplotype analysis for ANXA11 polymorphisms. 
Haplotypes* Frequency 
P value OR 
rs
27
89
6
79
 
rs
70
71
5
79
 
rs
19
53
6
00
 
rs
25
73
3
46
 
rs
27
84
7
73
 
rs
10
49
5
50
 
Cases Controls 
A A C G C G 0.024 0.01 0.048 3.06 
A G C G C G 0.23 0.29 0.01 1.05 
A G C G T A 0.028 0.016 0.1 2.3 
A A C G T G 0.28 0.20 0.00037 1.8 
A G C G T G 0.17 0.21 0.1 1.1 
A A T G T A 0.027 0.022 0.5 1.5 
T A T A C A 0.19 0.20 0.4 1.2 
T A T A C G 0.026 0.019 0.4 1.7 
Global significance# 0.0048  
*
Estimated haplotypes, as produced by Cocaphase. 
#
Permutation test P value calculated from 10 000 permuations in Cocaphase, to correct for multiple testing while 
taking into account the correlation between markers and haplotypes. 
3’ 5’ 
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735bp 
   5.2.3 Sequencing 
 
Exons 4, 5, 6 and the 3’ UTR region of ANXA11 were amplified and the products visualized on a 
1.5% agarose gel (Figure 12). The PCR products were then sequenced, and the resultant 
chromatograms were analysed using the Sequencher v4.7 software. Sequencing quality was 
determined by means of background signal levels, with low levels indicative of good quality 
sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: 1.5% agarose gel with amplified PCR products. A. Exon 4 amplified products, B. Exon 5 and 6 
amplified products, C. 3’ UTR amplified products. A 100bp DNA ladder was used, size of amplified products 
are indicated below each gel. 
 
Using the Sequencher v4.7 software, the chromatograms of all the samples were aligned to each 
other and a reference sequence to identify any polymorphisms present (Figure 13). Two 
polymorphisms were identified in each of intron five and exon six of ANXA11, of which three were 
known and one was novel. For the 3’ UTR region, seventeen polymorphisms were identified, with 
two previously characterized and fifteen novel. The sequencing quality of exon 9 was not good and 
could not be analysed. For allele frequencies, chromosomal positions and rs-numbers see table 17. 
 
Figure 13: Alignment of sequence data using the Sequencher v4.7 software. 
222bp 468bp 
A
. 
B
. 
C
. 
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Table 17: Polymorphisms identified during sequencing of ANXA11 gene regions. 
Location Chromosomal Position$ rs-number Frequency* 
Intron 5 81, 916, 868 novel 0.05 
Intron 5 81, 916, 730 rs34332933 0.2 
    
Exon 6 81, 916, 698 rs2228427 0.2 
Exon 6 81, 916, 682 rs1049550 0.3 
    
3’UTR 81, 915, 479 novel 0.5 
3’UTR 81, 915, 423 novel 0.55 
3’UTR 81 ,915, 406 novel 0.6 
3’UTR 81, 915, 356 novel 0.6 
3’UTR 81, 915, 304 novel 0.6 
3’UTR 81, 915, 264 novel 0.6 
3’UTR 81, 915, 260 novel 0.6 
3’UTR 81, 915, 227 novel 0.6 
3’UTR 81, 915, 205 novel 0.6 
3’UTR 81, 915, 196 novel 0.6 
3’UTR 81, 915, 178 novel 0.6 
3’UTR 81, 915, 173 novel 0.05 
3’UTR 81, 915, 147 novel 0.55 
3’UTR 81, 915, 144 rs76487007 0.05 
3’UTR 81, 915, 136 rs2789686 0.3 
3’UTR 81, 915, 121 novel 0.6 
3’UTR 81, 915, 117 novel 0.6 
$
Position relative to chromosome 10 
*
Frequency of individuals harbouring the polymorphism, n = 20 
 
      5.2.4 Gene Expression 
 
The DNA sequence containing rs7071579 polymorphism was amplified in the DNA obtained from 
the volunteers and sent for sequencing. After analysing the sequencing data with Sequencher 
v4.7, we selected two individuals who were homozygous for the A-allele and one individual 
homozygous for the G-allele (the GG genotype is rare) for further investigation.  
 
The ANXA11 expression levels with respect to the rs7071579 polymorphism, was analysed by 
qPCR and Western Blots (WB). To measure the difference in mRNA levels between individuals with 
the different genotypes, the cDNA transcribed from the RNA of the three individuals was analysed 
by means of qPCR. The ratio of gene expression change (R) for individuals homozygous for the A-
allele was 1.28, whereas homozygosity for the G-allele resulted in R = 0.17 (Figure 14), where R = 1 
is indicative of no change in gene expression levels. PCR efficiency equalled 0.98. 
 
 
Figure 14: Differences in mRNA levels between individuals with different genotypes. 
0 0.5 1 1.5 2 2.5
Average AA
Average GG
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Unfortunately, no data was generated regarding the change in protein levels. After several rounds 
of optimization of the WB protocol, including antibody concentrations and incubation times in ECL 
detection fluid, we were still unable to generate a WB showing the ANXA11 protein. After 
consulting with experts in WB and a thorough review of our experimental technique, I think that 
the most likely reason for the failure to detect proteins on the WB was antibodies that were no 
longer active. Due to time constraints we were unable to order new antibodies and repeat the 
experiments. However, we do intend to revisit and complete this work in the future. 
 
   5.2.5 Methylation 
 
To determine the role of methylation in TB susceptibility, we investigated the DNA methylation 
pattern of the promoter region of ANXA11 in eight individuals (four cases and four controls). After 
bisulfite treatment of the DNA, it was amplified (Figure 15), purified and ligated into the pGEM®-T 
Easy vector system. E. coli JM109 cells were heat shocked to facilitate the uptake of the vector 
containing the fragment of interest. The addition of IPTG and X-Gal to the growth medium on 
which the E. coli were cultured resulted in the formation of white and blue colonies (Figure 16), 
with white colonies containing the vector. To determine if the vector contained the insert, a 
colony PCR was conducted (Figure 17). Vectors were then purified and sent for sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: 2% agarose gel with amplified bisulfite treated PCR products of the promoter region of 
ANXA11. A. Promoter region amplified with primer set 1, B. Promoter region amplified with primer 
set 2. A 100bp ladder was loaded in the first lane. Fragment sizes are indicated. 
 
 
Figure 16: Blue/White colony selection of E. coli JM109 cells. 
A 
B 
180bp 
195bp 
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Figure 17: Colony PCR of E. coli JM109 cells for the verification of DNA fragment of interest.  
A. Colony PCR with primer set 1, B. Colony PCR with primer set 2. A 100bp DNA was loaded in the 
first lane. Fragment sizes are indicated. 
 
Using BioEdit, the sequencing data was analysed, cleaned-up and aligned to the original DNA 
sequence and the “treated” DNA sequence and saved in the FASTA file format. The FASTA files 
were uploaded into the BiQ Analyzer Software package and methylation patterns of the CpG 
islands were interrogated, with no difference in methylation pattern of the ANXA11 promoter 
observed (Figure 18). Since all samples shared the same methylation pattern, only a subset of the 
data is shown in Figure 18. 
 
 
Figure 18: Lollipop diagram, with circles representative of CpGs, indicating no differential 
methylation between cases and controls. Empty circles means not methylated. 
 
5.3 Discussion 
 
In this study we identified a 3’ UTR polymorphism of ANXA11 that could alter susceptibility to TB, 
in our high incidence setting. ANXA11 and its associated polymorphisms were first identified as a 
possible susceptibility factor for sarcoidosis in a GWAS in a German population 277. In that study, 
the authors showed the rs1049550 polymorphism (P = 1.0 x 10-12, OR[95%CI] = 0.62[0.54 – 0.71]) 
to be strongly associated with sarcoidosis. The SNPs rs2784773, rs2573346, rs1953600, rs7071579 
and rs2789679 were all in strong LD with this SNP (r2 = 0.44 – 0.98). As sarcoidosis shares various 
similarities in pathophysiology to TB 284, we decided to investigate these ANXA11 polymorphisms 
as susceptibility factors for TB. In this study, we did not find the rs1049550 polymorphism to be a 
risk factor for TB. We did however observe the 3’ UTR polymorphism rs7071579 to be associated 
with TB, with the A-allele occurring more frequently in cases than controls (56% vs 48%). In the 
three estimated haplotypes shown to be significantly associated with TB, the A-allele occurred in 
two of the haplotypes more frequently in cases, further suggesting that the A-allele increases the 
risk for developing TB. A comparison of allele frequencies between the German population and 
two African populations (South African Coloured and Yoruba in Ibadan, Nigeria) shows the A-allele 
Primer 1 
A B 
180bp 195bp 
Primer 2 
Control 1 
Case 1 
Case 1 
Control 1 
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of rs7071579 to be the major allele in Germans (57%), whereas in the African populations the G-
allele is the major allele (52% and 53% respectively) (Table 18). 
 
Comparison of the LD between the South African and German populations reveals differences in 
the genetic structure of the two populations, with the German population having stronger LD (one 
LD block vs three LD blocks). This is contradictory to current opinions, since stronger LD 286 would 
be expected in the SAC population as they are a highly admixed population 237, 287. This stronger LD 
may still be true over the whole genome. The differences in allele frequencies and LD structure 
discussed above indicate that susceptibility factors identified in the German population may not 
serve as disease factors in the South African population. In addition, it has to be kept in mind that 
the two diseases, although similar, do not necessarily share the same genetic risk factors. 
 
Since an association was noted in the case-control association study, we believed that the ANXA11 
polymorphisms warranted further experimental investigation into their role in TB susceptibility. 
The expression analysis conducted in this study showed that individuals who were homozygous for 
the A-allele of rs7071579 had approximately five times higher levels of ANXA11 mRNA than 
individuals homozygous for the G-allele. This finding contradicts the initial postulation of this study 
and that of Hofmann et al. (2008). It was postulated that individuals who have lower levels or 
aberrant copies of ANXA11 would be at greater risk of developing disease, with the case-control 
study that we conducted showing the A-allele to be associated with increased susceptibility to TB. 
Due to our limited understanding of the role of ANXA11 in infectious disease mechanisms, 
particularly apoptosis, how intracellular levels of ANXA11 would alter disease processes is not 
known. It could be that the mRNA levels identified are not a true reflection of protein levels 
intracellularly 288, since other epigenetic factors could also play a role during translation. Lastly, the 
number of individuals included in this study was very small which therefore limits our confidence 
in the mRNA levels present. We are aware of the shortcomings of this study. Due to limited time, 
we were not able to address these and this study therefore serves as a pilot. We have increased 
the number of individuals of each genotype and decided to include individuals of heterozygous 
genotype and use two reference genes. 
 
DNA methylation, the most well characterised epigenetic modification process, is the process 
whereby methyl groups are added to the cytosine of CpG sites and it is known to play a role in 
transcriptional regulation 289, 290. This occurs through its ability to change the expression of genes 
by influencing the binding affinities of transcription factors or other proteins to the promoter 
region of the gene 291. Hypermethylation of the promoter region is usually associated with no 
transcriptional activity due to the tightly bound nature of the chromatin, whereas 
hypomethylation is usually associated with lower levels of transcription when compared to 
unmethylated promoter regions. In this study we were interested in identifying whether the 
promoter region of ANXA11 was differentially methylated between cases and controls, and could 
explain the difference in expression levels, but no such difference was observed in the methylation 
patterns. This however is not surprising as our laboratory previously investigated 27 578 CpG sites 
across the entire genome using the Infinium HumanMethylation27, RevB BeadChip Kit from 
Illumina. With regards to ANXA11, two CpG sites were interrogated in four samples, with no 
difference in methylation pattern observed between cases and controls (unpublished). We were 
therefore interested in whether or not differences in global methylation of the ANXA11 promoter 
were present in this study. The role of DNA methylation in infectious diseases is still unknown. 
However, in other diseases, especially cancer, the role of methylation has been well characterized 
and has led to the development of novel treatments 292. Understanding how methylation affects 
TB disease outcomes is therefore worth investigating. 
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ANXA11 has been shown to play a role in various biological processes in the cell, including 
apoptosis, cell division and vesicle trafficking. In the recent GWAS conducted by Hofmann et al. 
(2008) they postulated that reduced or aberrant forms of ANXA11 could potentially alter the 
apoptosis pathway by destroying the balance between apoptosis and the survival of activated 
inflammatory cells in sarcoidosis patients. This theory could also be applicable to TB. Tomas et al. 
(2004) showed that daughter cells in which the ANXA11 gene had been silenced using siRNA were 
unable to successfully separate from each other resulting in death by apoptosis. Recently, Song et 
al. (2009) knocked down ANXA11 expression in ovarian cancer cell lines, resulting in reduced cell 
proliferation and colony forming capability in these cells. To date, several studies have 
investigated the role of macrophage apoptosis in TB disease, with the role that it plays in the 
pathophysiology of the disease still not fully understood 293, 294. There are currently two 
hypotheses regarding the role of apoptosis in TB. The first is that macrophage apoptosis could in 
fact benefit the bacterium by inhibiting the host from eliciting an effective immune response due 
to the lack of an efficient phagosome and thus poor local inflammation 295. The current model for 
this hypothesis is based on the fact that elimination of alveolar macrophages and resultant poor 
inflammation could result in a delayed or interrupted induction of the cell mediated immune 
response. However, the second hypothesis regarding the role of apoptosis in TB is that it is 
beneficial to the host with the overwhelming amount of scientific data in favour of this. Evidence 
includes the observation that virulent mycobacterial strains (H37Rv, Erdman) are much weaker 
inducers of macrophage apoptosis compared to attenuated strains of mycobacteria (H37Ra and 
BCG) 296. This has been shown to be mediated through the ability of virulent strains to interfere 
with TNF-α signalling and upregulate the expression of Mcl-1 which has known anti-apoptotic 
properties 297-299, thus highlighting the function of TNF-α mediated apoptosis in the host defensive 
response. Interestingly, certain viruses have been shown to employ similar mechanisms to inhibit 
pro-death signals of infected cells.  
 
Much work has shown that induction of apoptosis results in a reduction in the viability of the 
mycobacteria whereas mycobacteria from macrophages undergoing necrosis exhibited no 
reduction in viability, illustrating that apoptosis exerts a direct antimicrobial effect on intracellular 
mycobacteria 296, 300-303. Other studies have shown that due to macrophage apoptosis a resultant 
altered interaction also occurs between the infected macrophages and other host defence cells. 
For example, when mycobacteria were presented to macrophages in apoptotic bodies, a reduction 
of bacterial growth of >90% was observed 304, 305 and when presented to dendritic cells adaptive 
immunity was promoted 294. Lastly, macrophage apoptosis results in less lung tissue destruction, 
and thus when it predominates over cell lysis, the lung architecture is preserved and spread of the 
bacterium to new hosts is prevented 293, 306. Therefore, knowing the importance of apoptosis in 
the outcome of diseases such as TB 294, 307, we could postulate that ANXA11 may play an important 
role in the risk of developing TB.  
 
Another mechanism whereby ANXA11 could alter susceptibility to TB is via its potential role in the 
endocytic-autophagic pathway 308-310, given a number of findings which have demonstrated a role 
of ANXA1, 2 and 6 in the endocytic pathway 259, 260. One of the hallmark features of M. tuberculosis 
is its ability to prevent phagolysosome maturation in the infected macrophage, thus enabling it to 
avoid the key bactericidal mechanism of the invaded macrophage. This results in reduced antigen 
processing and presentation 311.  
 
Autophagy is the cellular process whereby the cell degrades its own components by lysosomal 
activity, and plays an important role in cell growth, development and homeostasis 312. It has been 
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shown to be a vital survival process under starvation conditions. Recent studies have shown a role 
for autophagy in infectious diseases 313-315, especially against M. tuberculosis infection 311, 312. Its 
role in the fight against invading pathogens is two-fold. Firstly, autophagy is able to facilitate 
antigen presentation and thus enhance the immune recognition of infected cells 315. Secondly, 
although the mechanism is still unclear, it is able to kill intracellular mycobacteria. There are 
currently three potential models for how this could occur. These include: (i) the envelopment of 
the arrested mycobacterial phagosome by the autophagosome with subsequent autolysosome 
formation and degradation, (ii) the fusing of the autophagosome and mycobacterial phagosome 
followed by maturation or (iii) the activation of the endosomal system during autophagy induction 
311. In addition, IFN-γ, an important cytokine in the fight against invading pathogens, is also able to 
induce autophagy in macrophages 313. It is therefore conceivable that ANXA11, which has known 
vesicle trafficking properties 277, could also have a role in this pathway. 
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Table 18: Comparison of the allele frequencies in the German, South African Coloured and Yoruba control populations. 
SNP 
Allele frequencies in Germans277 Allele frequencies in South African Coloured Allele frequencies in Yoruba$ 
Allele Allele Frequency 
Heterozygote 
Frequency 
Allele 
Allele 
Frequency 
Heterozygote 
Frequency 
Allele 
Allele 
Frequency 
Heterozygote 
Frequency 
rs2789679 
T 0.44 
0.48 
T 0.23 
0.35 
T 0.17 
0.33 
A 0.56 A 0.77 A 0.83 
rs7071579 
A 0.57 
0.50 
A 0.48 
0.45 
A 0.47 
0.5 
G 0.43 G 0.52 G 0.53 
rs1953600 
T 0.45 
0.51 
T 0.26 
0.38 
T 0.17 
0.33 
C 0.55 C 0.74 C 0.83 
rs2573346 
A 0.45 
0.51 
A 0.23 
0.35 
A 0.12 
0.24 
G 0.55 G 0.77 G 0.88 
rs2784773 
T 0.36 
0.48 
T 0.45 
0.51 
T 0.49 
0.52 
C 0.64 C 0.55 C 0.51 
rs1049550 
A 0.41 
0.49 
A 0.26 
0.37 
A 0.17 
0.33 
G 0.59 G 0.74 G 0.83 
$
Allele frequencies for the Yoruba population were obtained from HapMap. 
  
 
 
 
 
 
 
 
 
Chapter 6: CADM gene family 
 
 
 
 
 
Knowing is not enough; we must apply. Willing is not enough; we must do. 
 
Johann Wolfgang von Goethe 
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6.1 Cell Adhesion Molecules 
   
   6.1.1 Cell Adhesion Molecule Family 
 
The immunoglobulin (Ig) superfamily of proteins is a member of the cell adhesion molecules 
(CAMs), and is the largest family with over 100 members already identified in vertebrates 
316. These IgCAMs differ from other CAM families in that they are Ca2+-independent 316-318. 
The IgCAMs consist of four main classes of molecules, incuding the NCAMs, L1 family CAMs 
and the nectins 316. All nectins are comprised of an extracellular region with three Ig-like 
loops in addition to a transmembrane- and a cytoplasmic domain 319. These nectin 
molecules are able to form homo-dimers in both the cis and trans formations which 
facilitates cell-cell adhesion.  They are also able to form hetero-trans-dimers with other 
molecules. Recently, five nectin-like (NECL) molecules have been identified based on their 
similar structure to nectins. These include NECL-1; -2; -3; -4 and -5 (Table 19). In this thesis, 
these genes will be referred to as CADM1, CADM2 and CADM3. These molecules play 
various roles in cell-cell interactions, synapse formations, target-cell recognition, neuronal 
cell migration and the formation of complex glial networks 316, 318, 320. 
 
Table 19: Various names used in the literature for the CADM genes. 
CADM1 CADM2 CADM3 
NECL-2 NECL-3 NECL-1 
TSLC1 TSLL2 TSLL1 
SynCAM1 SynCAM2 SynCAM3 
SgIGSF   
IGSF4 IGSF4D IGSF4B 
sTSLC-1   
RA175   
 
   6.1.2 CADM1 
 
CADM1 is a type-1 transmembrane glycoprotein located on chromosome 11q23.2 and is 
highly conserved 320-323. This membrane glycoprotein contains three Ig-like C2-type domains, 
a transmembrane domain and a short cytoplasmic domain (Figure 19) 316, 321, 322. This 
cytoplasmic domain contains two interaction motifs, namely the 4.1/ezrin/radixin/moesin 
(FERM) domain and the PDZ domain 319, 322, 323 which acts as the docking sites for various 
transmembrane proteins 323 conferring upon CADM1 its ability to play a role in cell-cell 
interactions 316. CADM1 is also present on the surface of dendritic cells and acts as a ligand 
for the class-I-restricted T-cell-associated molecule (CRTAM). Their interaction results in the 
release of cytokines 323. Expression of CADM1 has also been shown to be ubiquitous 322. 
 
   6.1.3 Other CADM Genes: CADM2, CADM3 and NCAM2 
 
Not much is known about CADM2 and CADM3 genes. However, Fukhara et al. (2001) and 
Fukami et al. (2003) have shown great homology between the gene structure of CADM1, 
CADM2 and CADM3, which allowed them to classify these three genes into a unique 
subfamily. Due to these similarities it is also believed that CADM2 and CADM3 play a role in 
cell adhesion. Interestingly however, the expression patterns of these genes differ markedly, 
with CADM2 expressed restrictively in the prostrate, brain and kidney; while CADM3 is 
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exclusively expressed in the brain 318, 322. Neural Cell Adhesion Molecule 2 (NCAM2) gene 
structure was also significantly homologous to that of CADM1, and as mentioned above is a 
member of the Ig superfamily of proteins 322. 
 
 
Figure 19: Structure of CADM1 protein, showing (left to right) the 3 Ig domains; the transmembrane 
domain and the short cytoplasmic domain 320. The PDZ (post synaptic density protein (PSD95), 
Drosophila disc large tumour suppressor (DlgA), and zonula occludens-1 protein (zo-1)) domain is a 
common structural domain found in signalling proteins. 
 
   6.1.4 Disease Mechanisms – CADM family 
      6.1.4.1 Cancers 
 
CADM1 has been shown to play a role in various cancers, including non-small cell lung 
cancer, hepatocellular carcinoma, pancreatic cancer, prostate cancer, breast cancer and 
gastric cancers 317, 321, 322. Various studies have shown that truncation of the cytoplasmic 
domain of CADM1 results in tumour formation and that restoration of CADM1 protein levels 
to normal results in tumour suppression 324, 325, and that the loss of one allele and 
suppression of the other allele by promoter methylation or mutation is frequently observed 
in the various cancers mentioned above 321, 326, 327. These studies have thus highlighted the 
tumour suppressor ability of CADM1. The study conducted by Fukhara et al. (2001) also 
showed that lower expression of CADM2 and CADM3 in various human glioma and prostate 
cancer cell lines is indicative of the important role of these genes in tumour suppression. 
However, the mechanism whereby this unique gene family is able to suppress tumour 
formation still eludes us. 
 
      6.1.4.2 TB 
 
In a recent GWAS for TB in West Africans, there was an indication that CADM1 may alter 
susceptibility to TB (unpublished). Polymorphisms associated with other CADM members 
and the highly homologous NCAM2 gene were also found to play a role in TB susceptibility. 
The authors postulated that CADM1 could play an important role in antigen cross-
presentation between dendritic cells (DC) and natural killer (NK) cells. CADM1 has been 
found to be present on the surface of a subset of DCs and through its interaction with 
CRTAM on the surface of NK cells; the cytokine IL-22 is released 323. IL-22 is known to induce 
the epithelial innate immune response in the respiratory system, resulting in the release of 
anti-microbials including beta-defensins, which have been shown to have anti-mycobacterial 
activity. Therefore by altering NK and CD8 T cell activity, CADM1 could play a role in TB 
susceptibility by enhancing the mucosal innate immunity. 
 
The Wellcome Trust Case Control Consortium (WTCCC) and The African Tuberculosis 
Genetics Group conducted the first two independent GWAS for TB, and subsequently the 
data was pooled, analysed and recently published 55. One of the draw-cards for GWAS is 
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that they are not hypothesis based, and therefore allow for the identification of novel genes 
and pathways. In the early analysis of the WTCCC TB GWAS, CADM1 polymorphisms were 
found to alter susceptibility in West Africans (unpublished). Polymorphisms in other CADM 
genes, CADM2 and CADM3, were also found to be associated with susceptibility to TB (Table 
20). We were therefore interested in identifying whether or not these genes, previously not 
considered as susceptibility factors, could alter susceptibility to TB in the SAC population. 
 
Table 20: CADM polymorphisms investigated as TB susceptibility variants in the SAC population. 
Gene Polymorphism Location 
CADM1 
rs1460911 5’ UTR/upstream 
rs1563899 5’ UTR/upstream 
rs1563900 5’ UTR/upstream 
rs2446890 5’ UTR/upstream 
rs2515327 5’ UTR/upstream 
CADM2 rs2324979 3’ UTR/downtream 
CADM3 
rs12057331 5’ UTR/upstream 
rs12068892 5’ UTR/upstream 
rs16841729 5’ UTR/upstream 
NCAM2 rs8184921 intron 1 
 
6.2 Results 
 
   6.2.1 Genotype Analysis 
      6.2.1.1 CADM1 
 
All of the polymorphisms investigated by TaqMan® genotyping had a call rate ≥ 95% and 
were in HWE. P < 0.05 was considered statistically significant. However, none of the 
polymorphisms that were investigated were found to be significantly associated with 
susceptibility to TB (Table 21). 
 
Table 21: Statistical analysis of CADM1 polymorphisms. 
SNP 
Allele 
Genotype frequencies 
Pgen
† Pallele
* 
OR 
[95%CI]$ 
Cases Controls 
1‡ 2 11 12 22 HWE# 11 12 22 HWE 
rs1460911 T C 0.22 0.47 0.31 0.26 0.20 0.48 0.32 0.69 0.72 0.52 0.94 
[0.77-1.14] 
rs1563899 A G 0.16 0.46 0.38 0.11 0.15 0.42 0.43 0.053 0.44 0.41 1.09 
[0.89-1.33] 
rs1563900 C T 0.16 0.46 0.38 0.52 0.16 0.42 0.42 0.054 0.53 0.54 1.07 
[0.87-1.31] 
rs2446890 G A 0.14 0.46 0.40 0.74 0.15 0.41 0.44 0.058 0.37 0.38 0.91 
[0.74-1.12] 
rs2515327 C A 0.11 0.45 0.44 0.78 0.12 0.39 0.49 0.067 0.15 0.52 0.93 
[0.75-1.15] 
‡
Minor allele in controls. 
† 
P value from a genotype-based Χ
2
-test, significant if P<0.05. 
*
 P value from an allele-based Fisher’s exact test, significant if P<0.05. 
#
Hardy-Weinberg Equilibrium. 
$
Odds Ratio and [95% Confidence Interval] 
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      6.2.1.2 CADM2 
 
The CADM2 polymorphism investigated by TaqMan® genotyping had a call rate of 96.4% 
and was in HWE. P < 0.05 was considered statistically significant. The polymorphism was 
however not associated with susceptibility to TB (Table 22). 
 
Table 22: Statistical analysis of CADM2 polymorphisms. 
SNP 
Allele 
Genotype frequencies 
Pgen
† Pallele
* 
OR 
[95%CI]$ 
Cases Controls 
1‡ 2 11 12 22 HWE# 11 12 22 HWE 
rs2324979 C G 0.02 0.24 0.74 0.76 0.01 0.25 0.74 0.17 0.69 1 1.01 
[0.76-1.34] 
‡
Minor allele in controls. 
† 
P value from a genotype-based Χ
2
-test, significant if P<0.05. 
*
 P value from an allele-based Fisher’s exact test, significant if P<0.05. 
#
Hardy-Weinberg Equilibrium. 
$
Odds Ratio and [95% Confidence Interval] 
 
      6.2.1.3 CADM3 
 
Three CADM3 polymorphisms were investigated using TaqMan® genotyping, with call rates 
≥ 92% and all were in HWE. P < 0.05 was considered statistically significant. Although none 
of the genotypes were found to be significantly associated with TB susceptibility, we did find 
a weak association with the G-allele of rs12057331 (OR 0.67, 95% CI 0.49-0.98) and 
susceptibility to TB. The two remaining polymorphisms were not found to be significantly 
associated with TB susceptibility (Table 23). 
 
Table 23: Statistical analysis of CADM3 polymorphisms. 
SNP 
Allele 
Genotype frequencies 
Pgen
† Pallele
* 
OR 
[95%CI]$ 
Cases Controls 
1‡ 2 11 12 22 HWE# 11 12 22 HWE 
rs12057331 G A 0.01 0.20 0.79 0.19 0.01 0.14 0.85 0.83 0.08 0.04 0.70 
[0.49-0.98] 
rs12068892 T C 0.01 0.20 0.79 0.18 0.01 0.14 0.85 0.83 0.12 0.06 0.72 
[0.50-1.02] 
rs16841729 A G 0.01 0.20 0.79 0.22 0.01 0.14 0.85 0.87 0.11 0.05 1.42 
[1.00-2.01] 
‡
Minor allele in controls. 
† 
P value from a genotype-based Χ
2
-test, significant if P<0.05. 
*
 P value from an allele-based Fisher’s exact test, significant if P<0.05. 
#
Hardy-Weinberg Equilibrium. 
$
Odds Ratio and [95% Confidence Interval] 
 
The rs12057331 polymorphism of CADM3 was further investigated in susceptibility to TBM 
using TaqMan® genotyping and had a call rate of 90% and was in HWE. P < 0.05 was 
considered statistically significant. The polymorphism however was not associated with 
susceptibility to TBM (Table 24). 
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Table 24: Statistical analysis of the CADM3 polymorphism, rs12057331, and susceptibility to TBM. 
SNP 
Allele 
Genotype frequencies 
Pgen
† Pallele
* 
OR 
[95%CI]$ 
Cases Controls 
1‡ 2 11 12 22 HWE# 11 12 22 HWE 
rs12057331 G A 0.03 0.23 0.74 0.56 0.03 0.18 0.79 0.30 0.82 0.27 0.64 
[0.31-1.32] 
‡
Minor allele in controls. 
† 
P value from a genotype-based Χ
2
-test, significant if P<0.05. 
*
 P value from an allele-based Fisher’s exact test, significant if P<0.05. 
#
Hardy-Weinberg Equilibrium. 
$
Odds Ratio and [95% Confidence Interval] 
      
      6.2.1.4 NCAM2 
 
The NCAM2 polymorphism investigated by TaqMan® genotyping had a call rate of 98.5% 
and was in HWE. P < 0.05 was considered statistically significant. The polymorphism 
however was not associated with susceptibility to TB (Table 25). 
 
Table 25: Statistical analysis of NCAM2 polymorphisms. 
SNP 
Allele 
Genotype frequencies 
Pgen
† Pallele
* 
OR 
[95%CI]$ 
Cases Controls 
1‡ 2 11 12 22 HWE# 11 12 22 HWE 
rs8184921 T C 0.13 0.44 0.43 0.52 0.13 0.44 0.43 0.71 1 0.84 0.97 
[0.80-1.20] 
‡
Minor allele in controls. 
† 
P value from a genotype-based Χ
2
-test, significant if P<0.05. 
*
 P value from an allele-based Fisher’s exact test, significant if P<0.05. 
#
Hardy-Weinberg Equilibrium. 
$
Odds Ratio and [95% Confidence Interval] 
 
   6.2.2 Linkage Disequilibrium and Haplotype Analysis 
      6.2.2.1 CADM1 
 
The LD structure of the five CADM1 polymorphisms were all shown to be in strong LD 
(Figure 20), as identified by Haploview. However, of the five proposed haplotypes identified 
by the Cocaphase program, none were found to be significantly associated with 
susceptibility to TB in the SAC population (Table 26). 
 
      6.2.2.2 CADM3 
 
The three CADM3 polymorphisms were found to be in complete LD (Figure 21) with each 
other. However, Cocaphase could not predict any haplotypes based on the data generated 
by typing of the CADM3 polymorphisms. 
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Figure 20: Plot of LD between the CADM1 markers in the SAC population, generated by Haploview v4.1. The 5’ 
and 3’ ends of the genes are indicated and r
2
 values (%) are indicated on the squares.  The colours of the 
squares represent D’ values, with red being D’ = 1 and blue D’ = 0. 
 
Table 26: Haplotype analysis for CADM1 polymorphisms. 
Haplotypes* Frequency 
P value OR 
rs
1
4
6
0
9
1
1
 
rs
1
5
6
3
8
9
9
 
rs
1
5
6
3
9
0
0
 
rs
2
4
4
6
8
9
0
 
rs
2
5
1
5
3
2
7
 
Cases Controls 
C G T A A 0.53 0.55 0.44 0.56 
T A C A A 0.09 0.01 0.58 0.44 
T A C G A 0.031 0.027 0.61 0.66 
T A C G C 0.33 0.32 0.7 0.59 
T G T A A 0.08 0.08 0.95 0.59 
Global significance# 0.171 
*
Estimated haplotypes, as produced by Cocaphase. 
#
Permutation test P value calculated from 10 000 permuations in Cocaphase, to correct for multiple testing 
while taking into account the correlation between markers and haplotypes. 
 
 
Figure 21: Plot of LD between the CADM3 markers in the SAC population, generated by Haploview v4.1. The 5’ 
and 3’ ends of the genes are indicated and r
2
 values (%) are indicated on the squares.  The colours of the 
squares represent D’ values, with red being D’ = 1 and blue D’ = 0. 
5’ 3’ 
5’ 3’ 
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6.3 Discussion 
 
In the first TB GWAS conducted by The Wellcome Case Control Consortium polymorphisms 
associated with CADM1 were found to alter susceptibility to TB in the Gambian population 
(unpublished). Polymorphisms associated with CADM2, CADM3 and the structurally similar 
NCAM2 genes were also found to be associated with susceptibility to TB during the “first 
stage” of genotyping in the GWAS. We were therefore interested in investigating whether or 
not these polymorphisms would also alter susceptibility to TB in the SAC population, in a TB 
endemic region. 
 
In 2005, Boles et al. demonstrated the importance of CADM1 in immuno-surveillance 
through its interaction with CRTAM 317. CRTAM had been found to be expressed on the 
surface of activated NK cells and T cells. This CRTAM-CADM1 interaction was then 
subsequently shown to promote cytotoxicity of NK cells and CD8+ T cell secretion of IFN-γ in 
vitro. Therefore, it has been suggested that CADM1 could act as a molecular target and play 
a role in distinguishing tumour cells from normal cells. In the TB GWAS, the authors 
postulated that this CRTAM-CADM1 interaction could also alter susceptibility to TB. They 
argued that the binding of CRTAM to CADM1 on antigen presenting cells results in the 
release of IL-22 323. This cytokine is then able to induce the epithelial innate immunity by 
facilitating the secretion of anti-microbials (beta-defensins), some of which have defined 
anti-mycobacterial activity 328-331. Therefore, by enhancing the mucosal innate immunity 
CADM1 could potentially alter susceptibility to TB. 
 
In the TB GWAS that was conducted, five polymorphisms were found to alter susceptibility 
to TB in the Gambian population (P = 1.38 x 10-5 – 2.03 x 10-6). However, during the 
replication phase of the GWAS, which was conducted in three populations; Guinea-Conakry, 
Guinea-Bassau and Malawi, only three SNPs identified during the initial genotyping phase 
were found to be significantly associated with TB susceptibility, and this was only true in the 
Guinea-Conakry population. In this study, we aimed to validate the findings of the initial 
genotyping phase in the SAC population. Here we did not find any of the polymorphisms 
identified in the TB GWAS to be significantly associated with susceptibility to TB. We also did 
not observe any association between the CADM2 and NCAM2 polymorphisms and 
susceptibility to TB. 
 
On the other hand, for the CADM3 polymorphisms, we did observe a weak association with 
the G-allele of rs12057331 polymorphism and susceptibility to TB. Haplotype analysis using 
Cocaphase did not identify any haplotypes based on the CADM3 genotyping data. However, 
we do not believe that this association is true but rather an artefact. Both Fukhara et al. 
(2001) and Fukhami et al. (2003) have shown that CADM3 is expressed exclusively in brain 
and neurogenic cells; however, because an association was identified in the West African TB 
GWAS, we were interested in the CADM family. Since our TB cases were predominantly 
pulmonary TB individuals, the association identified becomes highly unlikely. We therefore 
investigated the rs12057331 polymorphism in a smaller cohort consisting of TBM cases. 
However, still no association was observed. After further investigation of polymorphism 
locations and the gene structure surrounding these SNPs, interesting observations were 
noted. Firstly, these polymorphisms occur in the 5’ flanking region of the CADM3 gene and 
secondly, they are approximately 50 kilo bases (kb) - 60 kb from either CADM3 gene or the 
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absent in melanoma 2 (AIM2) gene. Also, the Duffy blood group, chemokine receptor 
(DARC) gene has been shown to overlap with the 3’ region of CADM3. AIM2 is a member of 
the IFI20X/IFI16 family and is known to play a role in tumourigenic reversion and may 
control cell proliferation. AIM2 expression has also been shown to be induced by IFN-γ 332. 
The DARC protein on the other hand is a glycosylated membrane protein and is a non-
specific receptor for several chemokines. The encoded protein is also the receptor for the 
human malarial parasites, Plasmodium vivax and Plasmodium knowlesi 333. DARC 
polymorphisms have also been shown to alter susceptibility to HIV/AIDS 334. It is therefore 
likely that the association identified could hold true, if the polymorphisms in fact regulate 
either AIM2 or DARC. Further research is therefore required. 
 
The recently published GWAS that was conducted in two West African populations by the 
WTCCC and the African TB Genetics Consortium, identified a polymorphism, rs4331426 (P = 
6.8 x 10-9, OR[95%] = 1.19[1.13 – 1.27]), in a gene poor region on chromosome 18q11.2 to 
be associated with susceptibility to TB 55. It is therefore evident that the CADM1 locus that 
was identified in the initial WTCCC TB GWAS (unpublished) was no longer significantly 
associated with susceptibility to TB when the data of the African TB Genetics Consortium 
GWAS was included, indicating that it was probably an artifactual finding. It is therefore not 
surprising that our case-control study did not find association with this locus and the genes 
within it.  
 
There are currently two schools of thought regarding the use and applicability of GWAS in 
elucidating novel and the true underlying disease genetic risk factors. On the one hand, due 
to its ability to interrogate the entire genome and its hypothesis-free basis, some 
researchers believe that the use of GWAS will lead to the discovery of the genetic factors 
that predispose individuals to disease, including complex diseases. Others however, believe 
that due to GWAS being driven by the CDCV hypothesis, they will not be able to successfully 
identify the genetic factors that predispose individuals to infectious diseases, as 
susceptibility to these diseases may be due to the presence of several rare variants. Based 
on the current literature, there is support for both schools of thought. GWAS have been 
successfully employed in the identification of susceptibility variants for various complex 
diseases, including Crohn’s disease, diabetes and prostate cancer and even in some 
infectious diseases (HIV, Kawasaki disease, chronic hepatitis B and leprosy) 103, 104, 107, 108, 335. 
However, the current TB GWAS may lend support to those who do not believe that the 
CDCV hypothesis is appropriate. Another limiting factor for GWAS in African populations is 
the unavailability of microarray chips that contain SNP information relevant to these 
populations, as current microarray chips are based on European populations. It is known 
that African populations such as the West African populations used for the TB GWAS, have 
shorter stretches of LD, perhaps making them less likely to yield results in this type of 
enquiry336. 
 
Therefore, until the current limitations of GWAS are addressed, GWAS may not be the best 
scientific tool to elucidate the genetic factors that alter susceptibility to TB and other 
methods such as admixture mapping, copy number variation and searching for rare variants 
may be better suited for the task at hand. 
 
 
 
 
 
 
 
 
 
 
Chapter 7: Conclusions 
 
 
 
 
 
Most great people have attained their greatest success just one step beyond their 
greatest failure. 
Napoleon Hill 
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The work presented in this thesis provides further support for the hypothesis that host 
genetics plays an important role in TB disease outcome, and adds to the growing amount of 
evidence for this conclusion. In this study we investigated the role of five genes previously 
not considered to play a role in TB susceptibility. 
 
Genome-wide association studies offer researchers a means to interrogate the entire 
genome for the presence of disease susceptibility factors, and are able to identify novel 
variants and pathways without being limited by our understanding of the disease pathology. 
However, their use in non-European populations, such as African populations who have a 
high disease burden, is still limited. The main reason for this is that the current SNP-chips 
used in GWAS are only able to cover approximately 46% of all SNPs currently available for 
the Yoruba population in the HapMap database. 
 
ANXA11, a gene found in a GWAS on sarcoidosis, a granulomatous disease related to TB, 
also appeared to be implicated in TB, illustrating the possibility of using diseases with 
common pathways to aid in elucidating the causes of both. We identified the 3’ UTR 
polymorphism in ANXA11 as potentially altering the risk of developing TB. Previous studies 
on the role of NRAMP1 have also identified polymorphisms in its 3’ UTR that altered 
susceptibility to TB in West African and Asian populations, amongst others. Given the 
importance of the 3’ UTR in post-transcriptional regulation due to the presence of a number 
of regulatory sequences (the polyadenylation signal and binding sites for various proteins 
and mRNA); it is not surprising that polymorphisms in this region are being implicated in 
disease susceptibility. 
 
Whether or not apoptosis is beneficial to the host or the invading pathogen, the cellular 
process seems to be central to the outcome of disease. Another cellular process, autophagy, 
has also been shown to be important in the progress of disease, especially when the 
invading pathogen is able to suppress the apoptosis pathway. Future research should focus 
on the various molecules involved in these processes and how they affect susceptibility to 
TB. 
 
In summary, an association between a 3’ UTR ANXA11 polymorphism that could alter 
susceptibility to TB was shown in this study, the biological mechanism of which still eludes 
us. It is possible that this polymorphism is not the actual causal variant but is in LD with it. It 
would therefore be important to genotype other polymorphisms in the 3’ region of ANXA11, 
including the fifteen novel SNPs identified in this study. Investigating variation in the 
promoter region of this gene could also yield interesting results. None of the polymorphisms 
investigated in the CADM genes were found to be associated with susceptibility to TB. 
 
In conclusion, a better understanding of the role that hosts genetics plays in disease 
susceptibility can only aid us in our fight of eradicating TB disease from society. The concept 
of genetically-based personalized medicine is fast becoming a reality. However, translation 
of the findings in this field to clinically relevant information is still in the future. 
Understanding how host genetics influences disease outcomes could allow us to identify 
those individuals who are at greater risk of developing disease. It could also allow us to 
design new vaccines and treatment regimens. For decades, TB has been treated by the use 
of various antibiotics, with no true success in eradicating the disease. Maybe a new tactic is 
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required, one that involves boosting the immune response in those individuals who seem to 
be unable to overcome the disease, leading to better results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
References 
 1.  Daniel TM (2006) The history of tuberculosis. Respir Med 100 (11):1862-1870 
 2.  Mathema B, Kurepina NE, Bifani PJ, and Kreiswirth BN (2006) Molecular epidemiology of 
tuberculosis: current insights. Clin Microbiol Rev 19 (4):658-685 
 3.  Leão SC and Portaels F (2007) History. In: Palomino JC, Leão SC, Ritacco V (eds) 
Tuberculosis 2007: From Basic Science to Patient Care., pp 25-49 
 4.  Pease AS (1940) Some remarks on the diagnosis and treatment of tuberculosis in antiquity. 
Isis 31:380-393 
 5.  Bates JH and Stead WW (1993) The history of tuberculosis as a global epidemic. Med Clin 
North Am 77 (6):1205-1217 
 6.  Daniel TM (1997) Captain of Death: the story of Tuberculosis. University of Rochester 
Press. New York, 
 7.  Canetti G, Rist N, and Grosset J (1964) Primary drug resistance in tuberculosis. Am Rev 
Respir Dis 90:792-799 
 8.  World Health Organization. WHO report 2009: Global Tuberculosis Control 2009 - 
epidemiology, strategy, financing. WHO/HTM/TB/2009.411. 2009.  Geneva.  
 9.  Health Statistics.  2008.  
 10.  U.S.Global Health Policy. Adult HIV/AIDS Prevalence Rate (Aged 15-49) 2007-2008. 
http://www.globalhealthfacts.org/topic.jsp?i=3 . 2009.  
 11.  World Health Organization. WHO Report 2008: Global tuberculosis control - surveillance, 
planning, financing. WHO/HTM/TB/2008.393. 2008. Geneva.  
 12.  Frieden TR, Sterling TR, Munsiff SS, Watt CJ, and Dye C (2003) Tuberculosis. Lancet 362 
(9387):887-899 
 13.  Greenwood D, Slack RCB, and Peutherer JF (1997) Medical Microbiology - A guide to 
microbial infections: pathogenesis, immunity, laboratory diagnosis and control. Churchill 
Livingstone, London 
 14.  Knechel NA (2009) Tuberculosis: pathophysiology, clinical features, and diagnosis. Crit Care 
Nurse 29 (2):34-43 
 15.  Kaufmann SH and McMichael AJ (2005) Annulling a dangerous liaison: vaccination 
strategies against AIDS and tuberculosis. Nat Med 11 (4 Suppl):S33-S44 
 16.  Pieters J (2001) Entry and survival of pathogenic mycobacteria in macrophages. Microbes 
Infect 3 (3):249-255 
 17.  Smith I (2003) Mycobacterium tuberculosis pathogenesis and molecular determinants of 
virulence. Clin Microbiol Rev 16 (3):463-496 
69 
 
 18.  Frieden TR, Sterling TR, Munsiff SS, Watt CJ, and Dye C (2003) Tuberculosis. Lancet 362 
(9387):887-899 
 19.  Kaufmann SH (2001) How can immunology contribute to the control of tuberculosis? Nat 
Rev Immunol 1 (1):20-30 
 20.  Centre for Disease Control. TB Treatment.  2010.  
 21.  Centers for Disease Control and Prevention (CDC) (2006) Emergence of Mycobacterium 
tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. 
MMWR Morb Mortal Wkly Rep 55 (11):301-305 
 22.  Victor TC, Warren R, Beyers N, and van Helden PD (1997) Transmission of multidrug-
resistant strains of Mycobacterium tuberculosis in a high incidence community. Eur J Clin 
Microbiol Infect Dis 16 (7):548-549 
 23.  Victor TC, Streicher EM, Kewley C, Jordaan AM, van der Spuy GD, Bosman M, Louw H, 
Murray M, Young D, van Helden PD, and Warren RM (2007) Spread of an emerging 
Mycobacterium tuberculosis drug-resistant strain in the western Cape of South Africa. Int J 
Tuberc Lung Dis 11 (2):195-201 
 24.  Johnson MD and Decker CF (2006) Tuberculosis and HIV Infection. Dis Mon 52 (11-12):420-
427 
 25.  Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, and Ellner J (1995) Accelerated 
course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care 
Med 151 (1):129-135 
 26.  Comstock GW (1978) Tuberculosis in twins: a re-analysis of the Prophit survey. Am Rev 
Respir Dis 117 (4):621-624 
 27.  Kallmann FJ and Reisner D (1943) Twin studies on the significance of genetic factors in 
tuberculosis. Am Rev Tuberc 47:549-547 
 28.  Simonds B (2004) Tuberculosis in twins. Pitman Medical Publishing Company, 
 29.  Bellamy R (2003) Susceptibility to mycobacterial infections: the importance of host 
genetics. Genes Immun 4 (1):4-11 
 30.  Hill AV (1999) Genetics and genomics of infectious disease susceptibility. Br Med Bull 55 
(2):401-413 
 31.  Hoal EG (2002) Human genetic susceptibility to tuberculosis and other mycobacterial 
diseases. IUBMB Life 53 (4-5):225-229 
 32.  Möller M, de Wit E, and Hoal EG (2010) Past, present and future directions in human 
genetic susceptibility to tuberculosis. FEMS Immunol Med Microbiol 58 (1):3-26 
 33.  Diehl K and Von Verschuer O (1936) Der Erbeinfluss bei der Tuberkulose. Gustav Fischer, 
London 
 34.  Uehlinger E and Küinsch M (1938) Über Zwillingstuberkulose. Beitrage zur Klinik der 
Tuberkulose 92 (4):275-370 
70 
 
 35.  Harvald H and Hauge M (1965) Hereditary factors elucidated by twin studies. In: Neel JV, 
Shaw MW, Schull WL (eds) Genetics and the epidemiology of chronic diseases. S 
Department of Health, Education and Welfare, US Public Health Service, Division of 
Chronic Diseases, Washington, pp 61-76 
 36.  van der Eijk EA, Van D, V, Vandenbroucke JP, and van Dissel JT (2007) Heredity versus 
environment in tuberculosis in twins: the 1950s United Kingdom Prophit Survey Simonds 
and Comstock revisited. Am J Respir Crit Care Med 176 (12):1281-1288 
 37.  Alcaïs A and Abel L (2004) Application of genetic epidemiology to dissecting host 
susceptibility/resistance to infection illustrated with the study of common mycobacterial 
infections. In: Bellamy R (ed) Susceptibility to infectious diseases - The importance of host 
genetics. Cambridge University Press, Cambridge, pp 7-33 
 38.  Motulsky AG (1960) Metabolic polymorphisms and the role of infectious diseases in 
human evolution. Human Biology 32:28-62 
 39.  Serpa JA, Teeter LD, Musser JM, and Graviss EA (2009) Tuberculosis disparity between US-
born blacks and whites, Houston, Texas, USA. Emerg Infect Dis 15 (6):899-904 
 40.  Dubos R and Dubos J (1952) The White Plague: Tuberculosis, Man and Society. Little, 
Brown & Co., Boston 
 41.  Farmer P, Robin S, Ramilus SL, and Kim JY (1991) Tuberculosis, poverty, and "compliance": 
lessons from rural Haiti. Semin Respir Infect 6 (4):254-260 
 42.  Farmer P (1997) Social scientists and the new tuberculosis. Soc Sci Med 44 (3):347-358 
 43.  Cegielski JP and McMurray DN (2004) The relationship between malnutrition and 
tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc 
Lung Dis 8 (3):286-298 
 44.  Schaible UE and Kaufmann SH (2007) Malnutrition and infection: complex mechanisms and 
global impacts. PLoS Med 4 (5):e115 
 45.  Finch PJ, Millard FJ, and Maxwell JD (1991) Risk of tuberculosis in immigrant Asians: 
culturally acquired immunodeficiency? Thorax 46 (1):1-5 
 46.  Strachan DP, Powell KJ, Thaker A, Millard FJ, and Maxwell JD (1995) Vegetarian diet as a 
risk factor for tuberculosis in immigrant south London Asians. Thorax 50 (2):175-180 
 47.  Chanarin I and Stephenson E (1988) Vegetarian diet and cobalamin deficiency: their 
association with tuberculosis. J Clin Pathol 41 (7):759-762 
 48.  Finch PJ, Ang L, Eastwood JB, and Maxwell JD (1992) Clinical and histological spectrum of 
osteomalacia among Asians in south London. Q J Med 83 (302):439-448 
 49.  Yang S, Smith C, Prahl JM, Luo X, and Deluca HF (1993) Vitamin D deficiency suppresses 
cell-mediated immunity in vivo. Arch Biochem Biophys 303 (1):98-106 
 50.  Rehm J and Parry CD. Alcohol consumption and infectious diseases in South Africa. The 
Lancet (in press) 
71 
 
 51.  Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lonnroth K, Patra J, Poznyak V, 
and Popova S (2009) The association between alcohol use, alcohol use disorders and 
tuberculosis (TB). A systematic review. BMC Public Health 9:450 
 52.  Rehm J, Baliunas D, Borges GL, Graham K, Irving H, Kehoe T, Parry CD, Patra J, Popova S, 
Poznyak V, Roerecke M, Room R, Samokhvalov AV, and Taylor B (2010) The relation 
between different dimensions of alcohol consumption and burden of disease: an 
overview. Addiction 105 (5):817-843 
 53.  Siddiqi K, Khan A, Ahmad M, and Rehman SU (2010) An intervention to stop smoking 
among patients suspected of TB - evaluation of an integrated approach. BMC Public Health 
10 (1):160 
 54.  Clementi M and Di Gianantonio E (2006) Genetic susceptibility to infectious diseases. 
Reprod Toxicol 21 (4):345-349 
 55.  Thye T, Vannberg FO, Wong SH, Owusu-Dabo E, Osei I, Gyapong J, Sirugo G et al (2010) 
Genome-wide association analyses identifies a susceptibility locus for tuberculosis on 
chromosome 18q11.2. Nat Genet 42 (9):739-741 
 56.  Richards EJ (2006) Inherited epigenetic variation--revisiting soft inheritance. Nat Rev Genet 
7 (5):395-401 
 57.  Abel L and Dessein AJ (1997) The impact of host genetics on susceptibility to human 
infectious diseases. Curr Opin Immunol 9 (4):509-516 
 58.  Cervino AC, Lakiss S, Sow O, Bellamy R, Beyers N, Hoal-Van Helden E, van Helden P, 
McAdam KP, and Hill AV (2002) Fine mapping of a putative tuberculosis-susceptibility 
locus on chromosome 15q11-13 in African families. Hum Mol Genet 11 (14):1599-1603 
 59.  Bellamy R, Beyers N, McAdam KP, Ruwende C, Gie R, Samaai P, Bester D, Meyer M, Corrah 
T, Collin M, Camidge DR, Wilkinson D, Hoal-Van Helden E, Whittle HC, Amos W, van Helden 
P, and Hill AV (2000) Genetic susceptibility to tuberculosis in Africans: a genome-wide 
scan. Proc Natl Acad Sci U S A 97 (14):8005-8009 
 60.  Neyrolles O and Quintana-Murci L (2009) Sexual inequality in tuberculosis. PLoS Med 6 
(12):e1000199 
 61.  Davila S, Hibberd ML, Hari DR, Wong HE, Sahiratmadja E, Bonnard C, Alisjahbana B, 
Szeszko JS, Balabanova Y, Drobniewski F, van CR, Van D, V, Nejentsev S, Ottenhoff TH, and 
Seielstad M (2008) Genetic association and expression studies indicate a role of toll-like 
receptor 8 in pulmonary tuberculosis. PLoS Genet 4 (10):e1000218 
 62.  Stein CM, Zalwango S, Malone LL, Won S, Mayanja-Kizza H, Mugerwa RD, Leontiev DV, 
Thompson CL, Cartier KC, Elston RC, Iyengar SK, Boom WH, and Whalen CC (2008) Genome 
scan of M. tuberculosis infection and disease in Ugandans. PLoS ONE 3 (12):e4094 
 63.  Cobat A, Gallant CJ, Simkin L, Black GF, Stanley K, Hughes J, Doherty TM, Hanekom WA, 
Eley B, Jais JP, Boland-Auge A, van HP, Casanova JL, Abel L, Hoal EG, Schurr E, and Alcais A 
(2009) Two loci control tuberculin skin test reactivity in an area hyperendemic for 
tuberculosis. J Exp Med 206 (12):2583-2591 
72 
 
 64.  Möller M and Hoal EG (2010) Current findings, challenges and novel approaches in human 
genetic susceptibility to tuberculosis. Tuberculosis (Edinb ) 
 65.  Miller EN, Jamieson SE, Joberty C, Fakiola M, Hudson D, Peacock CS, Cordell HJ, Shaw MA, 
Lins-Lainson Z, Shaw JJ, Ramos F, Silveira F, and Blackwell JM (2004) Genome-wide scans 
for leprosy and tuberculosis susceptibility genes in Brazilians. Genes Immun 5 (1):63-67 
 66.  Baghdadi JE, Orlova M, Alter A, Ranque B, Chentoufi M, Lazrak F, Archane MI, Casanova JL, 
Benslimane A, Schurr E, and Abel L (2006) An autosomal dominant major gene confers 
predisposition to pulmonary tuberculosis in adults. J Exp Med 203 (7):1679-1684 
 67.  Cooke GS, Campbell SJ, Bennett S, Lienhardt C, McAdam KP, Sirugo G, Sow O, Gustafson P, 
Mwangulu F, van HP, Fine P, Hoal EG, and Hill AV (2008) Mapping of a novel susceptibility 
locus suggests a role for MC3R and CTSZ in human tuberculosis. Am J Respir Crit Care Med 
178 (2):203-207 
 68.  Mahasirimongkol S, Yanai H, Nishida N, Ridruechai C, Matsushita I, Ohashi J, Summanapan 
S, Yamada N, Moolphate S, Chuchotaworn C, Chaiprasert A, Manosuthi W, Kantipong P, 
Kanitwittaya S, Sura T, Khusmith S, Tokunaga K, Sawanpanyalert P, and Keicho N (2009) 
Genome-wide SNP-based linkage analysis of tuberculosis in Thais. Genes Immun 10 (1):77-
83 
 69.  Lander ES and Schork NJ (1994) Genetic dissection of complex traits. Science 265 
(5181):2037-2048 
 70.  Burgner D, Jamieson SE, and Blackwell JM (2006) Genetic susceptibility to infectious 
diseases: big is beautiful, but will bigger be even better? Lancet Infect Dis 6 (10):653-663 
 71.  Risch N and Merikangas K (1996) The future of genetic studies of complex human diseases. 
Science 273 (5281):1516-1517 
 72.  Daly AK and Day CP (2001) Candidate gene case-control association studies: advantages 
and potential pitfalls. Br J Clin Pharmacol 52 (5):489-499 
 73.  Wilkening S, Chen B, Bermejo JL, and Canzian F (2009) Is there still a need for candidate 
gene approaches in the era of genome-wide association studies? Genomics 93 (5):415-419 
 74.  Gambaro G, Anglani F, and D'Angelo A (2000) Association studies of genetic 
polymorphisms and complex disease. Lancet 355 (9200):308-311 
 75.  Ardlie KG, Kruglyak L, and Seielstad M (2002) Patterns of linkage disequilibrium in the 
human genome. Nat Rev Genet 3 (4):299-309 
 76.  Newport MJ and Nejentsev S (2004) Genetics of susceptibility to tuberculosis in humans. 
Monaldi Arch Chest Dis 61 (2):102-111 
 77.  Newport MJ (2009) Why hasn't human genetics told us more about tuberculosis? Int J 
Tuberc Lung Dis 13 (9):1049-1050 
 78.  Spielman RS, McGinnis RE, and Ewens WJ (1993) Transmission test for linkage 
disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). 
Am J Hum Genet 52 (3):506-16 
73 
 
 79.  Lombard Z, Brune AE, Hoal EG, Babb C, van Helden PD, Epplen JT, and Bornman L (2006) 
HLA class II disease associations in southern Africa. Tissue Antigens 67 (2):97-110 
 80.  Janeway C, Travers P, Walport M, and Shlomchik M (2001) Immunobiology: the immune 
system in health and disease. Fifth ed. Garland Science, New York 
 81.  Khomenko AG, Litvinov VI, Chukanova VP, and Pospelov LE (1990) Tuberculosis in patients 
with various HLA phenotypes. Tubercle 71 (3):187-192 
 82.  Meyer T, Baynes R, Bothwell T, Jenkins T, Jooste P, Dutoit E, Martell R, and Jacobs P (1990) 
Phenotypic-Expression of the Hla Linked Iron-Loading Gene in Males Over the Age of 40 
Years - A Population Study Using Serial Serum Ferritin Estimations. Journal of Internal 
Medicine 227 (6):397-406 
 83.  Ravikumar M, Dheenadhayalan V, Rajaram K, Lakshmi SS, Kumaran PP, Paramasivan CN, 
Balakrishnan K, and Pitchappan RM (1999) Associations of HLA-DRB1, DQB1 and DPB1 
alleles with pulmonary tuberculosis in south India. Tuber Lung Dis 79 (5):309-317 
 84.  Selvaraj P, Uma H, Reetha AM, Kurian SM, Xavier T, Prabhakar R, and Narayanan PR (1998) 
HLA antigen profile in pulmonary tuberculosis patients & their spouses. Indian J Med Res 
107:155-158 
 85.  Vejbaesya S, Chierakul N, Luangtrakool K, Srinak D, and Stephens HA (2002) Associations 
of HLA class II alleles with pulmonary tuberculosis in Thais. Eur J Immunogenet 29 (5):431-
434 
 86.  Malo D, Vogan K, Vidal S, Hu J, Cellier M, Schurr E, Fuks A, Bumstead N, Morgan K, and 
Gros P (1994) Haplotype mapping and sequence analysis of the mouse Nramp gene predict 
susceptibility to infection with intracellular parasites. Genomics 23 (1):51-61 
 87.  North RJ, LaCourse R, Ryan L, and Gros P (1999) Consequence of Nramp1 deletion to 
Mycobacterium tuberculosis infection in mice. Infect Immun 67 (11):5811-5814 
 88.  Vidal SM, Malo D, Vogan K, Skamene E, and Gros P (1993) Natural resistance to infection 
with intracellular parasites: isolation of a candidate for Bcg. Cell 73 (3):469-485 
 89.  Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, and Hill AV (1998) Variations in 
the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 338 
(10):640-644 
 90.  Hoal EG, Lewis L-A, Jamieson SE, Tanzer F, Rossouw M, Victor T, Hillerman R, Beyers N, 
Blackwell JM, and van Helden PD (2004) SLC11A1 (NRAMP1) but not SLC11A2 (NRAMP2) 
polymorphisms are associated with susceptibility to tuberculosis in a high-incidence 
community in South Africa. Int J Tuberc Lung Dis 8 (12):1464-1471 
 91.  Li HT, Zhang TT, Zhou YQ, Huang QH, and Huang J (2006) SLC11A1 (formerly NRAMP1) 
gene polymorphisms and tuberculosis susceptibility: a meta-analysis. Int J Tuberc Lung Dis 
10 (1):3-12 
 92.  Holmskov U, Thiel S, and Jensenius JC (2003) Collections and ficolins: humoral lectins of 
the innate immune defense. Annu Rev Immunol 21:547-578 
74 
 
 93.  Turner MW (2003) The role of mannose-binding lectin in health and disease. Mol Immunol 
40 (7):423-429 
 94.  Summerfield JA, Sumiya M, Levin M, and Turner MW (1997) Association of mutations in 
mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 
314 (7089):1229-1232 
 95.  Hoal-van Helden EG, Epstein J, Victor TC, Hon D, Lewis LA, Beyers N, Zurakowski D, 
Ezekowitz AB, and van Helden PD (1999) Mannose-binding protein B allele confers 
protection against tuberculous meningitis. Pediatr Res 45 (4 Pt 1):459-464 
 96.  Cosar H, Ozkinay F, Onay H, Bayram N, Bakiler AR, Anil M, Can D, and Ozkinay C (2008) Low 
levels of mannose-binding lectin confers protection against tuberculosis in Turkish 
children. Eur J Clin Microbiol Infect Dis 27 (12):1165-1169 
 97.  Soborg C, Madsen HO, Andersen AB, Lillebaek T, Kok-Jensen A, and Garred P (2003) 
Mannose-binding lectin polymorphisms in clinical tuberculosis. J Infect Dis 188 (5):777-782 
 98.  The International HapMap Consortium (2003) The International HapMap Project. Nature 
426 (6968):789-796 
 99.  The International HapMap Consortium (2005) A haplotype map of the human genome. 
Nature 437 (7063):1299-1320 
 100.  The International HapMap Consortium (2007) A second generation human haplotype map 
of over 3.1 million SNPs. Nature 449 (7164):851-861 
 101.  Balding DJ (2006) A tutorial on statistical methods for population association studies. Nat 
Rev Genet 7 (10):781-791 
 102.  Hirschhorn JN and Daly MJ (2005) Genome-wide association studies for common diseases 
and complex traits. Nat Rev Genet 6 (2):95-108 
 103.  Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K et al (2007) A 
whole-genome association study of major determinants for host control of HIV-1. Science 
317 (5840):944-947 
 104.  Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, Ling L, Wright VJ, Thalamuthu A, 
Odam M, Shimizu C, Burns JC, Levin M, Kuijpers TW, and Hibberd ML (2009) A genome-
wide association study identifies novel and functionally related susceptibility Loci for 
Kawasaki disease. PLoS Genet 5 (1):e1000319 
 105.  Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, 
Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita 
W, Nakamura Y, and Matsuda K (2009) A genome-wide association study identifies 
variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41 
(5):591-595 
 106.  Wong SH, Hill AV, and Vannberg FO (2010) Genomewide association study of leprosy. N 
Engl J Med 362 (15):1446-1447 
 107.  Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, Inwald D, Nadel S, Betts H, 
Carrol ED, de GR, Hermans PW, Hazelzet J, Emonts M, Lim CC, Kuijpers TW, Martinon-
75 
 
Torres F, Salas A, Zenz W, Levin M, and Hibberd ML (2010) Genome-wide association study 
identifies variants in the CFH region associated with host susceptibility to meningococcal 
disease. Nat Genet 42 (9):772-776 
 108.  Zhang FR, Huang W, Chen SM, Sun LD, Liu H, Li Y, Cui Y et al (2009) Genomewide 
association study of leprosy. N Engl J Med 361 (27):2609-2618 
 109.  Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, 
Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, 
Daly MJ, and Altshuler D (2002) The structure of haplotype blocks in the human genome. 
Science 296 (5576):2225-9 
 110.  Jeffreys AJ, Kauppi L, and Neumann R (2001) Intensely punctate meiotic recombination in 
the class II region of the major histocompatibility complex. Nat Genet 29 (2):217-222 
 111.  Patil N, Berno AJ, Hinds DA, Barrett WA, Doshi JM, Hacker CR, Kautzer CR, Lee DH, 
Marjoribanks C, McDonough DP, Nguyen BT, Norris MC, Sheehan JB, Shen N, Stern D, 
Stokowski RP, Thomas DJ, Trulson MO, Vyas KR, Frazer KA, Fodor SP, and Cox DR (2001) 
Blocks of limited haplotype diversity revealed by high-resolution scanning of human 
chromosome 21. Science 294 (5547):1719-1723 
 112.  Levenstien MA, Ott J, and Gordon D (2006) Are molecular haplotypes worth the time and 
expense? A cost-effective method for applying molecular haplotypes. PLoS Genet 2 
(8):e127 
 113.  Abecasis GR, Ghosh D, and Nichols TE (2005) Linkage disequilibrium: ancient history drives 
the new genetics. Hum Hered 59 (2):118-124 
 114.  Weiss KM and Clark AG (2002) Linkage disequilibrium and the mapping of complex human 
traits. Trends Genet 18 (1):19-24 
 115.  Flynn JL (2006) Lessons from experimental Mycobacterium tuberculosis infections. 
Microbes Infect 8 (4):1179-1188 
 116.  Vidal S, Tremblay ML, Govoni G, Gauthier S, Sebastiani G, Malo D, Skamene E, Olivier M, 
Jothy S, and Gros P (1995) The Ity/Lsh/Bcg locus: natural resistance to infection with 
intracellular parasites is abrogated by disruption of the Nramp1 gene. J Exp Med 182 
(3):655-666 
 117.  Cellier M, Govoni G, Vidal S, Kwan T, Groulx N, Liu J, Sanchez F, Skamene E, Schurr E, and 
Gros P (1994) Human natural resistance-associated macrophage protein: cDNA cloning, 
chromosomal mapping, genomic organization, and tissue-specific expression. J Exp Med 
180 (5):1741-1752 
 118.  Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, 
and Bloom BR (1995) Tumor necrosis factor-alpha is required in the protective immune 
response against Mycobacterium tuberculosis in mice. Immunity 2 (6):561-572 
 119.  Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, and Orme IM (1993) 
Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178 
(6):2243-2247 
76 
 
 120.  Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, and Bloom BR (1993) An essential role 
for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 
178 (6):2249-2254 
 121.  Kamijo R, Le J, Shapiro D, Havell EA, Huang S, Aguet M, Bosland M, and Vilcek J (1993) 
Mice that lack the interferon-gamma receptor have profoundly altered responses to 
infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. 
J Exp Med 178 (4):1435-1440 
 122.  Flynn JL, Goldstein MM, Triebold KJ, Koller B, and Bloom BR (1992) Major 
histocompatibility complex class I-restricted T cells are required for resistance to 
Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 89 (24):12013-12017 
 123.  Ladel CH, Daugelat S, and Kaufmann SH (1995) Immune response to Mycobacterium bovis 
bacille Calmette Guerin infection in major histocompatibility complex class I- and II-
deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J 
Immunol 25 (2):377-384 
 124.  Ladel CH, Hess J, Daugelat S, Mombaerts P, Tonegawa S, and Kaufmann SH (1995) 
Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against 
Mycobacterium bovis bacillus Calmette Guerin: studies with T cell receptor-deficient 
mutant mice. Eur J Immunol 25 (3):838-846 
 125.  Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, Le J, Koh SI, Kimura 
T, Green SJ, and . (1994) Requirement for transcription factor IRF-1 in NO synthase 
induction in macrophages. Science 263 (5153):1612-1615 
 126.  Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, and Kaufmann SH (1997) Lethal 
tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 65 (11):4843-4849 
 127.  Cooper AM, Magram J, Ferrante J, and Orme IM (1997) Interleukin 12 (IL-12) is crucial to 
the development of protective immunity in mice intravenously infected with 
mycobacterium tuberculosis. J Exp Med 186 (1):39-45 
 128.  Sanjeevi CB, Narayanan PR, Prabakar R, Charles N, Thomas BE, Balasubramaniam R, and 
Olerup O (1992) No association or linkage with HLA-DR or -DQ genes in south Indians with 
pulmonary tuberculosis. Tuber Lung Dis 73 (5):280-284 
 129.  Teran-Escandon D, Teran-Ortiz L, Camarena-Olvera A, Gonzalez-Avila G, Vaca-Marin MA, 
Granados J, and Selman M (1999) Human leukocyte antigen-associated susceptibility to 
pulmonary tuberculosis: molecular analysis of class II alleles by DNA amplification and 
oligonucleotide hybridization in Mexican patients. Chest 115 (2):428-433 
 130.  Amirzargar AA, Yalda A, Hajabolbaghi M, Khosravi F, Jabbari H, Rezaei N, Niknam MH, 
Ansari B, Moradi B, and Nikbin B (2004) The association of HLA-DRB, DQA1, DQB1 alleles 
and haplotype frequency in Iranian patients with pulmonary tuberculosis. Int J Tuberc 
Lung Dis 8 (8):1017-1021 
 131.  Dubaniewicz A, Moszkowska G, Szczerkowska Z, and Hoppe A (2003) Analysis of DQB1 
allele frequencies in pulmonary tuberculosis: preliminary report. Thorax 58 (10):890-891 
77 
 
 132.  Lombard Z, Dalton DL, Venter PA, Williams RC, and Bornman L (2006) Association of HLA-
DR, -DQ, and vitamin D receptor alleles and haplotypes with tuberculosis in the Venda of 
South Africa. Hum Immunol 67 (8):643-654 
 133.  Goldfeld AE, Delgado JC, Thim S, Bozon MV, Uglialoro AM, Turbay D, Cohen C, and Yunis EJ 
(1998) Association of an HLA-DQ allele with clinical tuberculosis. JAMA 279 (3):226-228 
 134.  Delgado JC, Baena A, Thim S, and Goldfeld AE (2006) Aspartic acid homozygosity at codon 
57 of HLA-DQ beta is associated with susceptibility to pulmonary tuberculosis in 
Cambodia. J Immunol 176 (2):1090-1097 
 135.  Bothamley GH, Beck JS, Schreuder GM, D'Amaro J, de Vries RR, Kardjito T, and Ivanyi J 
(1989) Association of tuberculosis and M. tuberculosis-specific antibody levels with HLA. J 
Infect Dis 159 (3):549-555 
 136.  Singh SP, Mehra NK, Dingley HB, Pande JN, and Vaidya MC (1983) Human leukocyte 
antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association 
with HLA-DR types. J Infect Dis 148 (4):676-681 
 137.  Brahmajothi V, Pitchappan RM, Kakkanaiah VN, Sashidhar M, Rajaram K, Ramu S, 
Palanimurugan K, Paramasivan CN, and Prabhakar R (1991) Association of pulmonary 
tuberculosis and HLA in south India. Tubercle 72 (2):123-132 
 138.  Rajalingam R, Singal DP, and Mehra NK (1997) Transporter associated with antigen-
processing (TAP) genes and susceptibility to tuberculoid leprosy and pulmonary 
tuberculosis. Tissue Antigens 49 (2):168-172 
 139.  Pospelov LE, Matrakshin AG, Chernousova LN, Tsoi KN, Afanasjev KI, Rubtsova GA, and 
Yeremeyev VV (1996) Association of various genetic markers with tuberculosis and other 
lung diseases in Tuvinian children. Tuber Lung Dis 77 (1):77-80 
 140.  Cox RA, Downs M, Neimes RE, Ognibene AJ, Yamashita TS, and Ellner JJ (1988) 
Immunogenetic analysis of human tuberculosis. J Infect Dis 158 (6):1302-1308 
 141.  Chandanayingyong D, Maranetra N, and Bovornkitti S (1988) HLA antigen profiles in Thai 
tuberculosis patients. Asian Pac J Allergy Immunol 6 (2):77-80 
 142.  Ruggiero G, Cosentini E, Zanzi D, Sanna V, Terrazzano G, Matarese G, Sanduzzi A, Perna F, 
and Zappacosta S (2004) Allelic distribution of human leucocyte antigen in historical and 
recently diagnosed tuberculosis patients in Southern Italy. Immunology 111 (3):318-322 
 143.  Pospelova LE, Matrashkin AG, Larionova EE, Eremeev VV, and Mes'ko EM (2005) [The 
association of tuberculosis with the specificities of the HLA gene DRB1 in different regions 
of Tuva]. Probl Tuberk Bolezn Legk (7):23-25 
 144.  Kim HS, Park MH, Song EY, Park H, Kwon SY, Han SK, and Shim YS (2005) Association of 
HLA-DR and HLA-DQ Genes With Susceptibility to Pulmonary Tuberculosis in Koreans: 
Preliminary Evidence of Associations With Drug Resistance, Disease Severity, and Disease 
Recurrence. Hum Immunol 66 (10):1074-81 
 145.  Wang J, Song C, and Wang S (2001) [Association of HLA-DRB1 genes with pulmonary 
tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 24 (5):302-305 
78 
 
 146.  Dubaniewicz A, Lewko B, Moszkowska G, Zamorska B, and Stepinski J (2000) Molecular 
subtypes of the HLA-DR antigens in pulmonary tuberculosis. Int J Infect Dis 4 (3):129-133 
 147.  Sriram U, Selvaraj P, Kurian SM, Reetha AM, and Narayanan PR (2001) HLA-DR2 subtypes 
& immune responses in pulmonary tuberculosis. Indian J Med Res 113:117-124 
 148.  Blackwell JM (2001) Genetics and genomics in infectious disease susceptibility. Trends Mol 
Med 7 (11):521-526 
 149.  Hawkins BR, Higgins DA, Chan SL, Lowrie DB, MITCHISON DA, and Girling DJ (1988) HLA 
typing in the Hong Kong Chest Service/British Medical Research Council study of factors 
associated with the breakdown to active tuberculosis of inactive pulmonary lesions. Am 
Rev Respir Dis 138 (6):1616-1621 
 150.  Chu SF, Tam CM, Wong HS, Kam KM, Lau YL, and Chiang AK (2007) Association between 
RANTES functional polymorphisms and tuberculosis in Hong Kong Chinese. Genes Immun 8 
(6):475-479 
 151.  Möller M, Nebel A, Valentonyte R, van Helden PD, Schreiber S, and Hoal EG (2009) 
Investigation of chromosome 17 candidate genes in susceptibility to TB in a South African 
population. Tuberculosis (Edinb ) 89 (2):189-194 
 152.  Thye T, Nejentsev S, Intemann CD, Browne EN, Chinbuah MA, Gyapong J, Osei I, Owusu-
Dabo E, Zeitels LR, Herb F, Horstmann RD, and Meyer CG (2009) MCP-1 promoter variant -
362C associated with protection from pulmonary tuberculosis in Ghana, West Africa. Hum 
Mol Genet 18 (2):381-388 
 153.  Flores-Villanueva PO, Ruiz-Morales JA, Song CH, Flores LM, Jo EK, Montano M, Barnes PF, 
Selman M, and Granados J (2005) A functional promoter polymorphism in monocyte 
chemoattractant protein-1 is associated with increased susceptibility to pulmonary 
tuberculosis. J Exp Med 202 (12):1649-1658 
 154.  Gomez LM, Anaya JM, Sierra-Filardi E, Cadena J, Corbi A, and Martin J (2006) Analysis of 
DC-SIGN (CD209) functional variants in patients with tuberculosis. Hum Immunol 67 
(10):808-811 
 155.  Ben-Ali M, Barreiro LB, Chabbou A, Haltiti R, Braham E, Neyrolles O, Dellagi K, Gicquel B, 
Quintana-Murci L, and Barbouche MR (2007) Promoter and neck region length variation of 
DC-SIGN is not associated with susceptibility to tuberculosis in Tunisian patients. Hum 
Immunol 68 (11):908-912 
 156.  Olesen R, Wejse C, Velez DR, Bisseye C, Sodemann M, Aaby P, Rabna P, Worwui A, 
Chapman H, Diatta M, Adegbola RA, Hill PC, Ostergaard L, Williams SM, and Sirugo G 
(2007) DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with 
pulmonary tuberculosis risk in West Africans. Genes Immun 8 (6):456-467 
 157.  Selvaraj P, Alagarasu K, Swaminathan S, Harishankar M, and Narendran G (2009) CD209 
gene polymorphisms in South Indian HIV and HIV-TB patients. Infect Genet Evol 9 (2):256-
262 
 158.  Barreiro LB, Neyrolles O, Babb CL, Tailleux L, Quach H, McElreavey K, Helden PD, Hoal EG, 
Gicquel B, and Quintana-Murci L (2006) Promoter Variation in the DC-SIGN Encoding Gene 
CD209 Is Associated with Tuberculosis. PLoS Medicine 3 (2):e20 
79 
 
 159.  Vannberg FO, Chapman SJ, Khor CC, Tosh K, Floyd S, Jackson-Sillah D, Crampin A, Sichali L, 
Bah B, Gustafson P, Aaby P, McAdam KP, Bah-Sow O, Lienhardt C, Sirugo G, Fine P, and Hill 
AV (2008) CD209 genetic polymorphism and tuberculosis disease. PLoS ONE 3 (1):e1388 
 160.  Tang NL, Fan HP, Chang KC, Ching JK, Kong KP, Yew WW, Kam KM, Leung CC, Tam CM, 
Blackwell J, and Chan CY (2009) Genetic association between a chemokine gene CXCL-10 
(IP-10, interferon gamma inducible protein 10) and susceptibility to tuberculosis. Clin Chim 
Acta 406 (1-2):98-102 
 161.  Martineau AR, Leandro AC, Anderson ST, Newton SM, Wilkinson KA, Nicol MP, Pienaar 
SM, Skolimowska KH, Rocha MA, Rolla VC, Levin M, Davidson RN, Bremner SA, Griffiths CJ, 
Eley BS, Bonecini-Almeida MG, and Wilkinson RJ (2009) Association between Gc genotype 
and susceptibility to TB is dependent on vitamin D status. Eur Respir J doi: 
10.1183/09031936.00087009 
 162.  Lio D, Marino V, Serauto A, Gioia V, Scola L, Crivello A, Forte GI, Colonna-Romano G, 
Candore G, and Caruso C (2002) Genotype frequencies of the +874T-->A single nucleotide 
polymorphism in the first intron of the interferon-gamma gene in a sample of Sicilian 
patients affected by tuberculosis. Eur J Immunogenet 29 (5):371-374 
 163.  Etokebe GE, Bulat-Kardum L, Johansen MS, Knezevic J, Balen S, Matakovic-Mileusnic N, 
Matanic D, Flego V, Pavelic J, Beg-Zec Z, and Dembic Z (2006) Interferon-gamma gene 
(T874A and G2109A) polymorphisms are associated with microscopy-positive tuberculosis. 
Scand J Immunol 63 (2):136-141 
 164.  Lopez-Maderuelo D, Arnalich F, Serantes R, Gonzalez A, Codoceo R, Madero R, Vazquez JJ, 
and Montiel C (2003) Interferon-gamma and interleukin-10 gene polymorphisms in 
pulmonary tuberculosis. Am J Respir Crit Care Med 167 (7):970-975 
 165.  Cooke GS, Campbell SJ, Sillah J, Gustafson P, Bah B, Sirugo G, Bennett S, McAdam KP, Sow 
O, Lienhardt C, and Hill AV (2006) Polymorphism within the interferon-gamma/receptor 
complex is associated with pulmonary tuberculosis. Am J Respir Crit Care Med 174 (3):339-
343 
 166.  Ding S, Li L, and Zhu X (2008) Polymorphism of the interferon-gamma gene and risk of 
tuberculosis in a southeastern Chinese population. Hum Immunol 69 (2):129-133 
 167.  Rossouw M, Nel HJ, Cooke GS, van Helden PD, and Hoal EG (2003) Association between 
tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene. 
Lancet 361 (9372):1871-1872 
 168.  Sallakci, Nilgun, Coskun, Mesut, Berber, Zafer, Gurkan, Fuat, Kocamaz, Halil, Uysal, Gulnar, 
Bhuju, Sabin, Yavuzer, Ugur, Singh, Mahavir, and Yegin, Olcay. Interferon- gene+874T-A 
polymorphism is associated with tuberculosis and gamma interferon response. 
Tuberculosis . 2007.  
 169.  Vidyarani M, Selvaraj P, Prabhu AS, Jawahar MS, Adhilakshmi AR, and Narayanan PR 
(2006) Interferon gamma (IFNgamma) & interleukin-4 (IL-4) gene variants & cytokine levels 
in pulmonary tuberculosis. Indian J Med Res 124 (4):403-410 
 170.  Moran A, Ma X, Reich RA, and Graviss EA (2007) No association between the +874T/A 
single nucleotide polymorphism in the IFN-gamma gene and susceptibility to TB. Int J 
Tuberc Lung Dis 11 (1):113-115 
80 
 
 171.  Tso HW, Ip WK, Chong WP, Tam CM, Chiang AK, and Lau YL (2005) Association of 
interferon gamma and interleukin 10 genes with tuberculosis in Hong Kong Chinese. Genes 
Immun 6 (4):358-363 
 172.  Henao MI, Montes C, Paris SC, and Garcia LF (2006) Cytokine gene polymorphisms in 
Colombian patients with different clinical presentations of tuberculosis. Tuberculosis 
(Edinburgh, Scotland) 86 (1):11-19 
 173.  Pacheco AG, Cardoso CC, and Moraes MO (2008) IFNG +874T/A, IL10 -1082G/A and TNF -
308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis 
study. Hum Genet 123 (5):477-484 
 174.  Akahoshi M, Ishihara M, Remus N, Uno K, Miyake K, Hirota T, Nakashima K, Matsuda A, 
Kanda M, Enomoto T, Ohno S, Nakashima H, Casanova JL, Hopkin JM, Tamari M, Mao XQ, 
and Shirakawa T (2004) Association between IFNA genotype and the risk of sarcoidosis. 
Hum Genet 114 (5):503-509 
 175.  Sahiratmadja E, Baak-Pablo R, de Visser AW, Alisjahbana B, Adnan I, van Crevel R, Marzuki 
S, van Dissel JT, Ottenhoff TH, and Van D, V (2007) Association of polymorphisms in IL-
12/IFN-gamma pathway genes with susceptibility to pulmonary tuberculosis in Indonesia. 
Tuberculosis (Edinb ) 87 (4):303-311 
 176.  Kusuhara K, Yamamoto K, Okada K, Mizuno Y, and Hara T (2007) Association of IL12RB1 
polymorphisms with susceptibility to and severity of tuberculosis in Japanese: a gene-
based association analysis of 21 candidate genes. Int J Immunogenet 34 (1):35-44 
 177.  Thye T, Browne EN, Chinbuah MA, Gyapong J, Osei I, Owusu-Dabo E, Brattig NW, Niemann 
S, Rusch-Gerdes S, Horstmann RD, and Meyer CG (2009) IL10 haplotype associated with 
tuberculin skin test response but not with pulmonary TB. PLoS ONE 4 (5):e5420 
 178.  Ansari A, Talat N, Jamil B, Hasan Z, Razzaki T, Dawood G, and Hussain R (2009) Cytokine 
gene polymorphisms across tuberculosis clinical spectrum in Pakistani patients. PLoS ONE 
4 (3):e4778 
 179.  Vollstedt S, Yuliwulandari R, Okamoto K, Lien LT, Keicho N, Rochani JT, Wikaningrum R, 
and Tokunaga K (2009) No evidence for association between the interferon regulatory 
factor 1 (IRF1) gene and clinical tuberculosis. Tuberculosis (Edinb ) 89 (1):71-76 
 180.  Soborg C, Andersen AB, Range N, Malenganisho W, Friis H, Magnussen P, Temu MM, 
Changalucha J, Madsen HO, and Garred P (2007) Influence of candidate susceptibility 
genes on tuberculosis in a high endemic region. Mol Immunol 44 (9):2213-2220 
 181.  Garcia-Laorden MI, Pena MJ, Caminero JA, Garcia-Saavedra A, Campos-Herrero MI, 
Caballero A, and Rodriguez-Gallego C (2006) Influence of mannose-binding lectin on HIV 
infection and tuberculosis in a Western-European population. Mol Immunol 43 (14):2143-
2150 
 182.  El Sahly HM, Reich RA, Dou SJ, Musser JM, and Graviss EA (2004) The effect of mannose 
binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic 
groups. Scand J Infect Dis 36 (2):106-108 
 183.  Bellamy R, Ruwende C, McAdam KP, Thursz M, Sumiya M, Summerfield J, Gilbert SC, 
Corrah T, Kwiatkowski D, Whittle HC, and Hill AV (1998) Mannose binding protein 
81 
 
deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans. 
QJM 91 (1):13-18 
 184.  Druszczynska M, Strapagiel D, Kwiatkowska S, Kowalewicz-Kulbat M, Rozalska B, Chmiela 
M, and Rudnicka W (2006) Tuberculosis bacilli still posing a threat. Polymorphism of genes 
regulating anti-mycobacterial properties of macrophages. Pol J Microbiol 55 (1):7-12 
 185.  Capparelli R, Iannaccone M, Palumbo D, Medaglia C, Moscariello E, Russo A, and Iannelli D 
(2009) Role played by human mannose-binding lectin polymorphisms in pulmonary 
tuberculosis. The Journal of infectious diseases 199 (5):666-672 
 186.  Selvaraj P, Narayanan PR, and Reetha AM (1999) Association of functional mutant 
homozygotes of the mannose binding protein gene with susceptibility to pulmonary 
tuberculosis in India. Tuber Lung Dis 79 (4):221-227 
 187.  Liu W, Zhang F, Xin ZT, Zhao QM, Wu XM, Zhang PH, de VS, Richardus JH, Habbema JD, 
Yang H, and Cao WC (2006) Sequence variations in the MBL gene and their relationship to 
pulmonary tuberculosis in the Chinese Han population. Int J Tuberc Lung Dis 10 (10):1098-
1103 
 188.  Gomez LM, Anaya JM, Vilchez JR, Cadena J, Hinojosa R, Velez L, Lopez-Nevot MA, and 
Martin J (2007) A polymorphism in the inducible nitric oxide synthase gene is associated 
with tuberculosis. Tuberculosis (Edinb ) 87 (4):288-294 
 189.  Velez DR, Hulme WF, Myers JL, Weinberg JB, Levesque MC, Stryjewski ME, Abbate E, 
Estevan R, Patillo SG, Gilbert JR, Hamilton CD, and Scott WK (2009) NOS2A, TLR4, and 
IFNGR1 interactions influence pulmonary tuberculosis susceptibility in African-Americans. 
Hum Genet 126 (5):643-653 
 190.  Xiao J, Sun L, Jiao W, Li Z, Zhao S, Li H, Jin J, Jiao A, Guo Y, Jiang Z, Mokrousov I, and Shen A 
(2009) Lack of association between polymorphisms in the P2X7 gene and tuberculosis in a 
Chinese Han population. FEMS Immunol Med Microbiol 55 (1):107-111 
 191.  Li CM, Campbell SJ, Kumararatne DS, Bellamy R, Ruwende C, McAdam KP, Hill AV, and 
Lammas DA (2002) Association of a polymorphism in the P2X7 gene with tuberculosis in a 
Gambian population. J Infect Dis 186 (10):1458-1462 
 192.  Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Goldberg H, Marks GB, Wiley JS, and 
Britton WJ (2007) A polymorphism in the P2X7 gene increases susceptibility to 
extrapulmonary tuberculosis. Am J Respir Crit Care Med 175 (4):360-366 
 193.  Nino-Moreno P, Portales-Perez D, Hernandez-Castro B, Portales-Cervantes L, Flores-Meraz 
V, Baranda L, Gomez-Gomez A, cuna-Alonzo V, Granados J, and Gonzalez-Amaro R (2007) 
P2X7 and NRAMP1/SLC11 A1 gene polymorphisms in Mexican mestizo patients with 
pulmonary tuberculosis. Clin Exp Immunol 148 (3):469-477 
 194.  Mokrousov I, Sapozhnikova N, and Narvskaya O (2008) Mycobacterium tuberculosis co-
existence with humans: making an imprint on the macrophage P2X7 receptor gene? 
Journal of Medical Microbiology 57:581-584 
 195.  Lamsyah H, Rueda B, Baassi L, Elaouad R, Bottini N, Sadki K, and Martin J (2009) 
Association of PTPN22 gene functional variants with development of pulmonary 
tuberculosis in Moroccan population. Tissue Antigens 74 (3):228-232 
82 
 
 196.  Malik S, Abel L, Tooker H, Poon A, Simkin L, Girard M, Adams GJ, Starke JR, Smith KC, 
Graviss EA, Musser JM, and Schurr E (2005) Alleles of the NRAMP1 gene are risk factors for 
pediatric tuberculosis disease. Proc Natl Acad Sci U S A 102 (34):12183-12188 
 197.  Vejbaesya S, Chierakul N, Luangtrakool P, and Sermduangprateep C (2007) NRAMP1 and 
TNF-alpha polymorphisms and susceptibility to tuberculosis in Thais. Respirology 12 
(2):202-206 
 198.  El Baghdadi J, Remus N, Benslimane A, El Annaz H, Chentoufi M, Abel L, and Schurr E 
(2003) Variants of the human NRAMP1 gene and susceptibility to tuberculosis in Morocco. 
Int J Tuberc Lung Dis 7 (6):599-602 
 199.  Leung KH, Yip SP, Wong WS, Yiu LS, Chan KK, Lai WM, Chow EY, Lin CK, Yam WC, and Chan 
KS (2007) Sex- and age-dependent association of SLC11A1 polymorphisms with 
tuberculosis in Chinese: a case control study. BMC Infect Dis 7:19 
 200.  Ryu S, Park YK, Bai GH, Kim SJ, Park SN, and Kang S (2000) 3'UTR polymorphisms in the 
NRAMP1 gene are associated with susceptibility to tuberculosis in Koreans. Int J Tuberc 
Lung Dis 4 (6):577-580 
 201.  Jin J, Sun L, Jiao W, Zhao S, Li H, Guan X, Jiao A, Jiang Z, and Shen A (2009) SLC11A1 
(Formerly NRAMP1) gene polymorphisms associated with pediatric tuberculosis in China. 
Clin Infect Dis 48 (6):733-738 
 202.  Awomoyi A, Sirugo G, Newport MJ, and Tishkoff S (2006) Global distribution of a novel 
trinucleotide microsatellite polymorphism (ATA)n in intron 8 of the SLC11A1 gene and 
susceptibility to pulmonary tuberculosis. Int J Immunogenet 33 (1):11-15 
 203.  Qu YB, Tang YX, Zhang ZB, Zhu R, Liu J, Gu SY, Lu GL, and Xia ZL (2006) [Relationship 
between single nucleotide polymorphisms of NRAMP1 gene and susceptibility to 
pulmonary tuberculosis in workers exposed to silica dusts]. Zhonghua Lao Dong Wei Sheng 
Zhi Ye Bing Za Zhi 24 (9):531-533 
 204.  Delgado JC, Baena A, Thim S, and Goldfeld AE (2002) Ethnic-specific genetic associations 
with pulmonary tuberculosis. J Infect Dis 186 (10):1463-1468 
 205.  Liu W, Zhang CY, Tian L, Li CZ, Wu XM, Zhao QM, Zhang PH, Yang SM, Yang H, and Cao WC 
(2003) [A case-control study on natural-resistance-associated macrophage protein 1 gene 
polymorphisms and susceptibility to pulmonary tuberculosis]. Zhonghua Yu Fang Yi Xue Za 
Zhi 37 (6):408-411 
 206.  Zhang W, Shao L, Weng X, Hu Z, Jin A, Chen S, Pang M, and Chen ZW (2005) Variants of the 
natural resistance-associated macrophage protein 1 gene (NRAMP1) are associated with 
severe forms of pulmonary tuberculosis. Clin Infect Dis 40 (9):1232-1236 
 207.  Liu W, Cao WC, Zhang CY, Tian L, Wu XM, Habbema JD, Zhao QM, Zhang PH, Xin ZT, Li CZ, 
and Yang H (2004) VDR and NRAMP1 gene polymorphisms in susceptibility to pulmonary 
tuberculosis among the Chinese Han population: a case-control study. Int J Tuberc Lung Dis 
8 (4):428-434 
 208.  Abe T, Iinuma Y, Ando M, Yokoyama T, Yamamoto T, Nakashima K, Takagi N, Baba H, 
Hasegawa Y, and Shimokata K (2003) NRAMP1 polymorphisms, susceptibility and clinical 
features of tuberculosis. J Infect 46 (4):215-220 
83 
 
 209.  Taype CA, Castro JC, Accinelli RA, Herrera-Velit P, Shaw MA, and Espinoza JR (2006) 
Association between SLC11A1 polymorphisms and susceptibility to different clinical forms 
of tuberculosis in the Peruvian population. Infect Genet Evol 6 (5):361-367 
 210.  Awomoyi AA, Marchant A, Howson JM, McAdam KP, Blackwell JM, and Newport MJ (2002) 
Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to 
tuberculosis. J Infect Dis 186 (12):1808-1814 
 211.  Ma X, Dou S, Wright JA, Reich RA, Teeter LD, El Sahly HM, Awe RJ, Musser JM, and Graviss 
EA (2002) 5' dinucleotide repeat polymorphism of NRAMP1 and susceptibility to 
tuberculosis among Caucasian patients in Houston, Texas. Int J Tuberc Lung Dis 6 (9):818-
823 
 212.  Gao PS, Fujishima S, Mao XQ, Remus N, Kanda M, Enomoto T, Dake Y, Bottini N, Tabuchi 
M, Hasegawa N, Yamaguchi K, Tiemessen C, Hopkin JM, Shirakawa T, and Kishi F (2000) 
Genetic variants of NRAMP1 and active tuberculosis in Japanese populations. International 
Tuberculosis Genetics Team. Clin Genet 58 (1):74-76 
 213.  Puzyrev VP, Freidin MB, Rudko AA, Strelis AK, and Kolokolova OV (2002) [Polymorphisms 
of the candidate genes for genetic susceptibility to tuberculosis in the Slavic population of 
Siberia: a pilot study]. Mol Biol (Mosk) 36 (5):788-791 
 214.  Liaw YS, Tsai-Wu JJ, Wu CH, Hung CC, Lee CN, Yang PC, Luh KT, and Kuo SH (2002) 
Variations in the NRAMP1 gene and susceptibility of tuberculosis in Taiwanese. Int J 
Tuberc Lung Dis 6 (5):454-460 
 215.  Cervino AC, Lakiss S, Sow O, and Hill AV (2000) Allelic association between the NRAMP1 
gene and susceptibility to tuberculosis in Guinea-Conakry. Ann Hum Genet 64 (Pt 6):507-
512 
 216.  Duan HF, Zhou XH, Ma Y, Li CY, Chen XY, Gao WW, and Zheng SH (2003) [A study on the 
association of 3'UTR polymorphisms of NRAMP1 gene with susceptibility to tuberculosis in 
Hans]. Zhonghua Jie He He Hu Xi Za Zhi 26 (5):286-289 
 217.  Tosh K, Campbell SJ, Fielding K, Sillah J, Bah B, Gustafson P, Manneh K, Lisse I, Sirugo G, 
Bennett S, Aaby P, McAdam KP, Bah-Sow O, Lienhardt C, Kramnik I, and Hill AV (2006) 
Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in 
West Africa. Proc Natl Acad Sci U S A 103 (27):10364-10368 
 218.  Babb C, Keet EH, van Helden PD, and Hoal EG (2007) SP110 polymorphisms are not 
associated with pulmonary tuberculosis in a South African population. Hum Genet 121 (3-
4):521-522 
 219.  Szeszko JS, Healy B, Stevens H, Balabanova Y, Drobniewski F, Todd JA, and Nejentsev S 
(2006) Resequencing and association analysis of the SP110 gene in adult pulmonary 
tuberculosis. Hum Genet 121 (2):155-160 
 220.  Thye T, Browne EN, Chinbuah MA, Gyapong J, Osei I, Owusu-Dabo E, Niemann S, Rusch-
Gerdes S, Horstmann RD, and Meyer CG (2006) No associations of human pulmonary 
tuberculosis with Sp110 variants. J Med Genet 43 (7):e32 
84 
 
 221.  Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, Frodsham AJ et al (2007) 
A Mal functional variant is associated with protection against invasive pneumococcal 
disease, bacteremia, malaria and tuberculosis. Nat Genet 39 (4):523-528 
 222.  Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, and Anaya 
JM (2008) TIRAP (MAL) S180L polymorphism is a common protective factor against 
developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 8 (5):541-
544 
 223.  Nejentsev S, Thye T, Szeszko JS, Stevens H, Balabanova Y, Chinbuah AM, Hibberd M, Van D, 
V, Alisjahbana B, van CR, Ottenhoff TH, Png E, Drobniewski F, Todd JA, Seielstad M, and 
Horstmann RD (2008) Analysis of association of the TIRAP (MAL) S180L variant and 
tuberculosis in three populations. Nat Genet 40 (3):261-262 
 224.  Hawn TR, Dunstan SJ, Thwaites GE, Simmons CP, Thuong NT, Lan NT, Quy HT, Chau TT, 
Hieu NT, Rodrigues S, Janer M, Zhao LP, Hien TT, Farrar JJ, and Aderem A (2006) A 
polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is 
associated with susceptibility to meningeal tuberculosis. J Infect Dis 194 (8):1127-1134 
 225.  Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, and Musser JM (2007) Full-exon resequencing 
reveals toll-like receptor variants contribute to human susceptibility to tuberculosis 
disease. PLoS ONE 2 (12):e1318 
 226.  Yim JJ, Lee HW, Lee HS, Kim YW, Han SK, Shim YS, and Holland SM (2006) The association 
between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene 
and tuberculosis among Koreans. Genes Immun 7 (2):150-155 
 227.  Ogus AC, Yoldas B, Ozdemir T, Uguz A, Olcen S, Keser I, Coskun M, Cilli A, and Yegin O 
(2004) The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis 
disease. Eur Respir J 23 (2):219-223 
 228.  Velez DR, Wejse C, Stryjewski ME, Abbate E, Hulme WF, Myers JL, Estevan R, Patillo SG, 
Olesen R, Tacconelli A, Sirugo G, Gilbert JR, Hamilton CD, and Scott WK (2009) Variants in 
toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, 
African-Americans, and West Africans. Hum Genet DOI: 10.1007/s00439-009-0741-7 
 229.  Newport MJ, Allen A, Awomoyi AA, Dunstan SJ, McKinney E, Marchant A, and Sirugo G 
(2004) The toll-like receptor 4 Asp299Gly variant: no influence on LPS responsiveness or 
susceptibility to pulmonary tuberculosis in The Gambia. Tuberculosis (Edinb ) 84 (6):347-
352 
 230.  Möller M, Flachsbart F, Till A, Thye T, Horstmann RD, Meyer CG, Osei I, van Helden PD, 
Hoal E, Schreiber S, Nebel A, and Franke A (2010) A functional haplotype in the 3'UTR of 
TNFRSF1B is associated with TB in two African populations. Am J Respir Crit Care Med 
181:388-393 
 231.  Selvaraj P, Kurian SM, Chandra G, Reetha AM, Charles N, and Narayanan PR (2004) Vitamin 
D receptor gene variants of BsmI, ApaI, TaqI, and FokI polymorphisms in spinal 
tuberculosis. Clin Genet 65 (1):73-76 
 232.  Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, Wright D, Latif M, and 
Davidson RN (2000) Influence of vitamin D deficiency and vitamin D receptor 
85 
 
polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control 
study. Lancet 355 (9204):618-621 
 233.  Liu W, Zhang CY, Wu XM, Tian L, Li CZ, Zhao QM, Zhang PH, Yang SM, Yang H, Zhang XT, 
and Cao WC (2003) [A case-control study on the vitamin D receptor gene polymorphisms 
and susceptibility to pulmonary tuberculosis]. Zhonghua Liu Xing Bing Xue Za Zhi 24 
(5):389-392 
 234.  Roth DE, Soto G, Arenas F, Bautista CT, Ortiz J, Rodriguez R, Cabrera L, and Gilman RH 
(2004) Association between Vitamin D Receptor Gene Polymorphisms and Response to 
Treatment of Pulmonary Tuberculosis. J Infect Dis 190 (5):920-927 
 235.  Bornman L, Campbell SJ, Fielding K, Bah B, Sillah J, Gustafson P, Manneh K, Lisse I, Allen A, 
Sirugo G, Sylla A, Aaby P, McAdam KP, Bah-Sow O, Bennett S, Lienhardt C, and Hill AV 
(2004) Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: 
a case-control and family study. J Infect Dis 190 (9):1631-1641 
 236.  Bellamy R, Ruwende C, Corrah T, McAdam KP, Thursz M, Whittle HC, and Hill AV (1999) 
Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin 
D receptor gene. J Infect Dis 179 (3):721-724 
 237.  de WE, Delport W, Rugamika CE, Meintjes A, Moller M, van Helden PD, Seoighe C, and 
Hoal EG (2010) Genome-wide analysis of the structure of the South African Coloured 
Population in the Western Cape. Hum Genet 128 (2):145-153 
 238.  Healy DG (2006) Case-control studies in the genomic era: a clinician's guide. Lancet Neurol 
5 (8):701-707 
 239.  Barreiro LB, Neyrolles O, Babb CL, van Helden PD, Gicquel B, Hoal EG, and Quintana-Murci 
L (2007) Length Variation of DC-SIGN and L-SIGN Neck-Region has no Impact on 
Tuberculosis Susceptibility. Human Immunology 68 (2):106-112 
 240.  Western Cape Department of Health. TB Statistics: Cape Town.  2006.  
 241.  Kritzinger FE, den BS, Verver S, Enarson DA, Lombard CJ, Borgdorff MW, Gie RP, and 
Beyers N (2009) No decrease in annual risk of tuberculosis infection in endemic area in 
Cape Town, South Africa. Trop Med Int Health 14 (2):136-142 
 242.  Munch Z, Van Lill SWP, Booysen CN, Zietsman HL, Enarson DA, and Beyers N (2003) 
Tuberculosis transmission patterns in a high-incidence area: a spatial analysis. 
International Journal of Tuberculosis and Lung Disease 7 (3):271-277 
 243.  Holland PM, Abramson RD, Watson R, and Gelfand DH (1991) Detection of specific 
polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus 
aquaticus DNA polymerase. Proc Natl Acad Sci U S A 88 (16):7276-7280 
 244.  De la Vega FM, Lazaruk KD, Rhodes MD, and Wenz MH (2005) Assessment of two flexible 
and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the 
SNPlex Genotyping System. Mutat Res 573 (1-2):111-35 
 245.  Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. 
Genet Anal 14 (5-6):143-149 
86 
 
 246.  www.servicexs.com/plaatjes/TaqMan_AD_SNP_assay.jpg. TaqMan SNP Assay.  2010.  
 247.  www.kapabiosystems .com/public/files/images/products/next-generation/kapa-
probe/image1-modal.png. TaqMan Cluster Plot.  2010.  
 248.  Hardy GH (2003) Mendelian proportions in a mixed population. 1908. Yale J Biol Med 76 
(2):79-80 
 249.  Weinberg W (1908) On the demonstration of heredity in man. Naturkunde in 
Wurttemberg, Stuttgart 64:368-382 
 250.  Raven, Johnson, Losos, and Singer (2005) Genes Within Populations.  Biology. Mc Graw-Hill 
Higher Education, 
 251.  Xu J, Turner A, Little J, Bleecker ER, and Meyers DA (2002) Positive results in association 
studies are associated with departure from Hardy-Weinberg equilibrium: hint for 
genotyping error? Hum Genet 111 (6):573-4 
 252.  Wigginton JE, Cutler DJ, and Abecasis GR (2005) A note on exact tests of Hardy-Weinberg 
equilibrium. Am J Hum Genet 76 (5):887-93 
 253.  Fisher RA (1922) On the interpretation of X2 from contingency tables, and the calculation 
of P. Royal Statistical Society 85 (1):87-94 
 254.  Dudbridge F (2003) Pedigree disequilibrium tests for multilocus haplotypes. Genet 
Epidemiol 25 (2):115-121 
 255.  Barrett JC, Fry B, Maller J, and Daly MJ (2005) Haploview: analysis and visualization of LD 
and haplotype maps. Bioinformatics (Oxford, England) 21 (2):263-265 
 256.  Cuervo AM, Gomes AV, Barnes JA, and Dice JF (2000) Selective Degredation of Annexins by 
Chaperone-mediated Autophagy. The Journal of Biological Chemistry 275 (43):33329-
33335 
 257.  Duncan R, Carpenter B, Main LC, Telfer C, and Murray GI (2008) Characterisation of protein 
expression profiling of annexins in colorectal cancer. British Journal of Cancer 98:426-433 
 258.  Moss SE and Morgan RO (2004) The annexins. Genome Biol 5 (4):219 
 259.  Futter CE and White IJ (2007) Annexins and endocytosis. Traffic 8 (8):951-958 
 260.  Gruenberg J and Emans N (1993) Annexins in membrane traffic. Trends Cell Biol 3 (7):224-
227 
 261.  Gerke V, Creutz CE, and Moss SE (2005) Annexins: Linking Ca2+ Signalling to Membrane 
Dynamics. Nature Reviews Molecular Cell Biology 6:449-461 
 262.  Rescher U and Gerke V (2004) Annexins - unique membrane binding proteins with diverse 
functions. Journal of Cell Science 117:2631-2639 
 263.  Gerke V and Moss SE (2002) Annexins: from structure to function. Physiol Rev 82 (2):331-
371 
87 
 
 264.  Hannon R, Croxtall JD, Getting SJ, Roviezzo F, Yona S, Paul-Clark MJ, Gavins FN, Perretti M, 
Morris JF, Buckingham JC, and Flower RJ (2003) Aberrant inflammation and resistance to 
glucocorticoids in annexin 1-/- mouse. Federation of American Societies for Experimental 
Biology Journal 17 (2):253-255 
 265.  Srivastava M, Atwater I, Glasman M, Leighton X, Goping G, Caohuy H, Miller G, Pichel J, 
Westphal H, Mears D, Rojas E, and Pollard HB (1999) Defects in inositol 1,4,5-
trisphosphate receptor expression, Ca(2+) signaling, and insulin secretion in the anx7(+/-) 
knockout mouse. PNAS 96 (24):13783-13788 
 266.  Herr C, Smyth N, Ullrich S, Yun F, Sasse P, Hescheler J, Fleischmann B, Lasek K, Brixius K, 
Fässler R, Schröder R, and Noegel AA (2001) Loss of annexin A7 leads to alterations in 
frequency-induced shortening of isolated murine cardiomyocytes. Molecular and Cellular 
Biology 21 (13):4119-4128 
 267.  Tomas A, Futter C, and Moss SE (2004) Annexin 11 is required for midbody formation and 
completion of the terminal phase of cytokinesis. J Cell Biol 165 (6):813-822 
 268.  Lecona E, Turnay J, Olmo N, Guzman-Aranguez A, Morgan RO, Fernandez M-P, and Lizarbe 
MA (2003) Structural amd functional characterization of recombinant mouse annexin A11: 
influence of calcium binding. Biochem J 373:437-449 
 269.  Song J, Shih I, Chan DW, and Zhang Z (2009) Suppression of annexin A11 in ovarian cancer: 
implications in chemoresistance. Neoplasia 11 (6):605-14, 1 
 270.  Bances P, Fernandez M-R, Rodriguez-Garcia M-I, Morgan RO, and Fernandez M-P (2000) 
Annexin A11 (ANXA11) Gene Structure as the Progenitor of Paralogous Annexins and 
Source of Orthologous cDNA Isoforms. Genomics 69:95-103 
 271.  Tomas A and Moss SE (2003) Calcium- and cell cycle-dependent association of annexin 11 
with the nuclear envelope. J Biol Chem 278:20210-20216 
 272.  Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt 
SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR, Liotta LA, Emmert-Buck 
MR, and Petricoin EF3 (2000) Loss of annexin 1 correlates with early onset of 
tumorigenesis in esophageal and prostate carcinoma. Cancer Research 15 (60):6293-6297 
 273.  Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, and Sharma MC (2006) Angiogenesis-
associated protein annexin II in breast cancer: selective expression in invasive breast 
cancer and contribution to tumor invasion and progression. Experimental and Molecular 
Pathology 81 (2):146-156 
 274.  Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehrle 
W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi 
OP, Srivastava S, and Pollard HB (2001) ANX7, a candidate tumor suppressor gene for 
prostate cancer. PNAS 98 (8):4575-4580 
 275.  Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, and Rubin MA (2003) Dysregulation of the 
annexin family protein family is associated with prostate cancer progression. The 
American Journal of Pathology 162 (1):255-261 
88 
 
 276.  Song J, Shih I, Salani R, Chan DW, and Zhang Z (2007) Annexin XI is associated with 
cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer 
Res 13 (22 Pt 1):6842-6849 
 277.  Hofmann S, Franke A, Fischer A, Jacobs G, Nothnagel M, Gaede KI, Schurmann M, Muller-
Quernheim J, Krawczak M, Rosenstiel P, and Schreiber S (2008) Genome-wide association 
study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet 40 
(9):1103-1106 
 278.  Fabrellas EF (2007) Epidemiology of Sarcoidosis. Arch Bronconeumol 43 (2):92-100 
 279.  Newman LS, Rose CS, and Maier LA (1997) Sarcoidosis. N Engl J Med 336 (17):1224-1234 
 280.  American Thoracic Society (1999) Statement on sarcoidosis. Joint Statement of the 
American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World 
Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the 
ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir 
Crit Care Med 160 (2):736-755 
 281.  Iannuzzi MC (2004) Clara cell protein in sarcoidosis: another job for the respiratory tract 
protector? Am J Respir Crit Care Med 169 (2):143-144 
 282.  McGrath DS, Goh N, Foley PJ, and du Bois RM (2001) Sarcoidosis: genes and microbes--soil 
or seed? Sarcoidosis Vasc Diffuse Lung Dis 18 (2):149-164 
 283.  Noppen M (1999) Tuberculosis and sarcoidosis. Chest 115 (5):1480 
 284.  Litinsky I, Elkayam O, Flusser G, Segal R, Yaron M, and Caspi D (2002) Sarcoidosis: TB or not 
TB? Ann Rheum Dis 61 (5):385-6 
 285.  Nicodemus KK, Liu W, Chase GA, Tsai YY, and Fallin MD (2005) Comparison of type I error 
for multiple test corrections in large single-nucleotide polymorphism studies using 
principal components versus haplotype blocking algorithms. BMC Genet 6 Suppl 1:S78 
 286.  Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, 
Kessing BD et al (2004) A high-density admixture map for disease gene discovery in African 
Americans. Am J Hum Genet 74 (5):1001-13 
 287.  Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, Hirbo JB, Awomoyi 
AA, Bodo JM, Doumbo O, Ibrahim M, Juma AT, Kotze MJ, Lema G, Moore JH, Mortensen H, 
Nyambo TB, Omar SA, Powell K, Pretorius GS, Smith MW, Thera MA, Wambebe C, Weber 
JL, and Williams SM (2009) The genetic structure and history of Africans and African 
Americans. Science 324 (5930):1035-1044 
 288.  Mattick, J. Video Q&A: Non-coding RNAs and eukaryotic evolution - a personal view. 8(67). 
2010.  BMC Biology.  
 289.  Bird A (2007) Perceptions of epigenetics. Nature 447 (7143):396-398 
 290.  Bird A (2002) DNA methylation patterns and epigenetic memory. Genes & Development 16 
(1):6-21 
89 
 
 291.  Holliday R and Pugh JE (1975) DNA modification mechanisms and gene activity during 
development. Science 187 (4173):226-232 
 292.  Esteller M (2008) Epigenetics in Cancer. The New England Journal of Medicine 358 
(11):1148-1159 
 293.  Kornfeld H, Mancino G, and Colizzi V (1999) The role of macrophage cell death in 
tuberculosis. Cell Death and Differentiation 6:71-78 
 294.  Lee J, Hartman M, and Kornfeld H (2009) Macrophage apoptosis in tuberculosis. Yonsei 
Med J 50 (1):1-11 
 295.  Zychlinsky A (1993) Programmed cell death in infectious diseases. Trends Microbiol 1:114-
117 
 296.  Keane J, Balcewicz-Sablinska K, Remold HG, Chupp GL, Meek BB, Fenton MJ, and Kornfeld 
H (1997) Infection by Mycobacterium tuberculosis promotes human alveolar macrophage 
apoptosis. Infect Immun 65:298-304 
 297.  Balcewicz-Sablinska MK, Keane J, Kornfeld H, and Remold HG (1998) Pathogenic 
Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, 
resulting in inactivation of TNF-alpha. J Immunol 161 (5):2636-2641 
 298.  Sly LM, Hingley-Wilson SM, Reiner NE, and McMaster WR (2003) Survival of 
Mycobacterium tuberculosis in host macrophages involves resistance to apoptosis 
dependent upon induction of antiapoptotic Bcl-2 family member Mcl-1. Journal of 
immunology (Baltimore, Md : 1950) 170:430-437 
 299.  Spira A, Carrol JD, Liu G, Aziz Z, Shah V, and Kornefeld H (2003) Apoptosis genes in human 
alveolar macrophages infected with virulent or attenuated Mycobacterium tuberculosis: A 
pivotal role for tumor necrosis factor. Am J Respir Cell Mol Biol 29:545-551 
 300.  Molloy A, Laochumroonvorapong P, and Kaplan G (1994) Apoptosis, but not necrosis, of 
infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J Exp 
Med 180:1499-1509 
 301.  Oddo M, Renno T, Attinger A, Baker T, MacDonald HR, and Meylan PR (1998) Fas ligand-
induced apoptosis of infected human macrophages reduces the viability on intracellular 
Mycobacterium tuberculosis. Journal of immunology (Baltimore, Md : 1950) 160:5448-
5454 
 302.  Riendeau CJ and Kornfeld H (2003) THP-1 cell apoptosis in response to Mycobacterial 
infection. Infect Immun 71:254-259 
 303.  Velmurugan K, Chen B, Miller JL, Azogue S, Gurses S, and Hsu T (2007) Mycobacterium 
tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS 
Pathog 3:e110 
 304.  Fratazzi C, Arbeit RD, Carini C, and Remold HG (1997) Programmed cell death of 
Mycobacterium avium serovar 4-infected human macrophages prevents mycobacteria 
from spreading and induces mycobacterial growth inhibition by freshly added, uninfected 
macrophages. Journal of immunology (Baltimore, Md : 1950) 158:4320-4327 
90 
 
 305.  Lee J, Remold HG, Ieong MH, and Kornfeld H (2006) Macrophage apoptosis in response to 
high intracellular burden of Mycobacterium tuberculosis is mediated by a novel caspase-
independent pathway. J Immunol 176 (7):4267-4274 
 306.  Piacentini M and Colizzi V. <<Tissue>> transglutaminase: apoptosis versus autoimmunity. 
Immunol Today (in press) 
 307.  Briken V and Miller JL (2008) Living on the edge: inhibition of host cell apoptosis by 
Mycobacterium tuberculosis. Future Microbiol 3:415-422 
 308.  Gordon PB, Hoyvik H, and Seglen PO (1992) Prelysosomal and lysosomal connections 
between autophagy and endocytosis. Biochem J 283 ( Pt 2):361-369 
 309.  Jing X and Tang XM (1999) The convergent point of the endocytic and autophagic 
pathways in leydig cells. Cell Research 9:243-253 
 310.  Liou W, Geuze HJ, Geelen MJ, and Slot JW (1997) The autophagic and endocytic pathways 
converge at the nascent autophagic vacuoles. J Cell Biol 136 (1):61-70 
 311.  Deretic V, Singh S, Master S, Harris J, Roberts E, Kyei G, Davis A, de Haro S, Naylor J, Lee H-
H, and Vergne I (2006) Mycobacterium tuberculosis inhibition of phagolysosome 
biogenesis and autophagy as a host defence mechanism. Cellular Microbiology 8 (5):719-
727 
 312.  Levine B (2005) Eating oneself and uninvited guests: autophagy-related pathways in 
cellular defense. Cell 120 (2):159-162 
 313.  Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, and Deretic V (2004) 
Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis 
survival in infected macrophages. Cell 119 (6):753-766 
 314.  Ogawa M, Yoshimori T, Suzuki T, Sagara H, Mizushima N, and Sasakawa C (2005) Escape of 
intracellular Shigella from autophagy. Science 307 (5710):727-731 
 315.  Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, and Munz C (2005) 
Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307 
(5709):593-596 
 316.  Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, Nomoto A, and Murakami 
Y (2002) The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 
277 (34):31014-31019 
 317.  Boles KS, Barchet W, Diacovo T, Cella M, and Colonna M (2005) The tumor suppressor 
TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor 
CRTAM. Blood 106 (3):779-786 
 318.  Kakunaga S, Ikeda W, Itoh S, guchi-Tawarada M, Ohtsuka T, Mizoguchi A, and Takai Y 
(2005) Nectin-like molecule-1/TSLL1/SynCAM3: a neural tissue-specific immunoglobulin-
like cell-cell adhesion molecule localizing at non-junctional contact sites of presynaptic 
nerve terminals, axons and glia cell processes. J Cell Sci 118 (Pt 6):1267-1277 
 319.  Shingai T, Ikeda W, Kakunaga S, Morimoto K, Takekuni K, Itoh S, Satoh K, Takeuchi M, Imai 
T, Monden M, and Takai Y (2003) Implications of nectin-like molecule-
91 
 
2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein 
localization in epithelial cells. J Biol Chem 278 (37):35421-35427 
 320.  Biederer T, Sara Y, Mozhayeva M, Atasoy D, Liu X, Kavalali ET, and Sudhof TC (2002) 
SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 297 
(5586):1525-1531 
 321.  Fukami T, Satoh H, Williams YN, Masuda M, Fukuhara H, Maruyama T, Yageta M, 
Kuramochi M, Takamoto S, and Murakami Y (2003) Isolation of the mouse Tsll1 and Tsll2 
genes, orthologues of the human TSLC1-like genes 1 and 2 (TSLL1 and TSLL2). Gene 323:11-
18 
 322.  Fukuhara H, Kuramochi M, Nobukuni T, Fukami T, Saino M, Maruyama T, Nomura S, Sekiya 
T, and Murakami Y (2001) Isolation of the TSLL1 and TSLL2 genes, members of the tumor 
suppressor TSLC1 gene family encoding transmembrane proteins. Oncogene 20 (38):5401-
5407 
 323.  Galibert L, Diemer GS, Liu Z, Johnson RS, Smith JL, Walzer T, Comeau MR, Rauch CT, 
Wolfson MF, Sorensen RA, Van der Vuurst de Vries AR, Branstetter DG, Koelling RM, 
Scholler J, Fanslow WC, Baum PR, Derry JM, and Yan W (2005) Nectin-like protein 2 defines 
a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated 
molecule. J Biol Chem 280 (23):21955-21964 
 324.  Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, 
Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH, and Murakami Y (2001) TSLC1 is a 
tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27 (4):427-430 
 325.  Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T, Arai Y, Gomyou H, Tanigami A, 
Ohki M, Cabin D, Frischmeyer P, Hunt P, and Reeves RH (1998) Localization of tumor 
suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. Proc 
Natl Acad Sci U S A 95 (14):8153-8158 
 326.  Allinen M, Peri L, Kujala S, Lahti-Domenici J, Outila K, Karppinen SM, Launonen V, and 
Winqvist R (2002) Analysis of 11q21-24 loss of heterozygosity candidate target genes in 
breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes 
Cancer 34 (4):384-389 
 327.  Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV, Hruban R, Offerhaus JG, and 
Goggins M (2002) Aberrant methylation of the 5' CpG island of TSLC1 is common in 
pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol 
Ther 1 (3):293-296 
 328.  Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, and Kornfeld H (2002) Beta-
chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect 
Immun 70 (4):1684-1693 
 329.  Whittington HA, Armstrong L, Uppington KM, and Millar AB (2004) Interleukin-22: a 
potential immunomodulatory molecule in the lung. Am J Respir Cell Mol Biol 31 (2):220-
226 
 330.  Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K, Volk HD, Sterry W, and Sabat R 
(2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, 
92 
 
cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J 
Immunol 36 (5):1309-1323 
 331.  Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, and Ouyang W 
(2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and 
acanthosis. Nature 445 (7128):648-651 
 332.  Asefa B, Klarmann KD, Copeland NG, Gilbert DJ, Jenkins NA, and Keller JR (2004) The 
interferon-inducible p200 family of proteins: a perspective on their roles in cell cycle 
regulation and differentiation. Blood Cells Mol Dis 32 (1):155-167 
 333.  Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ, Ogborne K, Hadley TJ, 
Lu ZH, Hesselgesser J, and Horuk R (1995) The Duffy antigen/receptor for chemokines 
(DARC) is expressed in endothelial cells of Duffy negative individuals who lack the 
erythrocyte receptor. J Exp Med 181 (4):1311-1317 
 334.  He W, Neil S, Kulkarni H, Wright E, Agan BK, Marconi VC, Dolan MJ, Weiss RA, and Ahuja 
SK (2008) Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from 
red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 4 
(1):52-62 
 335.  Davila S and Hibberd ML (2009) Genome-wide association studies are coming for human 
infectious diseases. Genome Med 1 (2):19 
 336.  de Bakker PIW and Telenti A. Infectious diseases not immune to genome-wide association. 
Nature Genetics (in press) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addenda 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
 
 ADDENDUM 1: BUFFERS, SOLUTIONS AND GELS 
 
0.5M EDTA 
93.06 g EDTA 
400 ml distilled water 
Adjust the pH to 8.0 using approximately 10g NaOH pellets 
Make up to 500 ml with distilled water 
Autoclave and store at room temperature 
 
1M Tris 
121g Tris 
800ml distilled water 
Adjust the pH to 8.0 with concentrated HCl 
Make up to 1 litre with distilled water 
Store at room temperature 
 
2X Reducing SDS sample buffer 
3.4 ml Tris (1M, pH 6.8) 
2 ml Glycerol 
3 ml of SDS (20%) 
500µl Bromophenol blue 
200µl EDTA (0.5M) 
1 ml β-Mercaptoethanol 
Store at -20 degrees 
 
10% Ammonium persulphate (APS) 
1 g APS 
Make up to 10 ml with distilled water 
Store at 4 degrees 
 
10% Sodium Dodecyl Sulfate (SDS) 
1 g SDS 
Make up to 10 ml with distilled water 
Store at room temperature 
 
20X Sodium boride (SB) buffer 
19.1 g di-sodium tetraborate  
Make up to 500 ml with distilled water 
Store at room temperature 
 
20% Sodium Dodecyl Sulfate (SDS) 
2 g SDS 
Make up to 10 ml with distilled water 
Store at room temperature 
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Agarose gel (1.5%) 
3 g agarose 
200 ml SB buffer (1X) 
 
Blocking buffer 
200 ml TBS-T wash buffer 
10% fat free milk powder 
1% BSA 
 
Luria broth (LB) 
10 g tryptone 
5 g NaCl 
5 g yeast extract 
Make up to 1 litre with distilled water 
Autoclave and store at room temperature 
 
Running Buffer  
3 g Tris 
14.4 g Glycine 
10 ml SDS (10%) 
Make up to 1 litre with distilled water 
Store at room temperature or 4 degrees 
 
Separating gel (12%) 
2.5 ml Acrylamide/bisacrylamide (40%) 
2.5 ml Tris-HCl (1.5M, pH 8.8)  
0.1 ml SDS (10%) 
4.85 ml distilled water 
10 µl TEMED 
50 µl APS (10%) 
 
Stacking gel (3%) 
0.4 ml Acrylamide/bisacrylamide (40%) 
0.75 ml Tris-HCl (1M, pH 6.8) 
50 µl SDS (10%) 
4 ml distilled water 
10 µl TEMED 
25 µl APS (10%) 
 
TBS-T Wash Buffer  
10 ml Tris (1M pH 7.6) 
8 g NaCl 
1 ml Tween 20 
Make up to 1 litre with distilled water 
Store at room temperature or 4 degrees 
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TE 
1.21 g Tris-HCl 
0.372 g EDTA 
Add 800 ml distilled water 
Adjust the pH to 8.0 with concentrated HCl 
Make up to 1 litre with distilled water 
Autoclave and store at room temperature 
 
Transfer buffer 
3.03 g Tris 
14.4 g Glycine 
200 ml methanol 
Make up to 1 litre with distilled water 
Store at 4 degrees 
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ADDENDUM 2: REAGENTS 
 
Reagent Supplier  
   
10-250 kDa PageRuler Prestained protein ladder Fermentas Canada 
10X PCR buffer with 1.5mM MgCl2 Southern Cross Biotechnologies South Africa 
100 bp DNA ladder Whitehead Scientific  South Africa 
Acetone Sigma-Aldrich South Africa 
Acrylamide/bisacrylamide (40%) Sigma-Aldrich South Africa 
Agarose Whitehead Scientific  South Africa 
Ammonium persulphate (APS) Sigma-Aldrich South Africa 
Antibody_primary GeneTex®, Inc. USA 
Antibody_secondary Santa Cruz Biotechnology Inc. USA 
BCG Division of Molecular Biology and Human 
Genetics, Stellenbosch University 
South Africa 
β-Mercaptoethanol Sigma-Aldrich South Africa 
Bioline dNTPs (4x 25μmol solutions) Celtic Diagnostics South Africa 
Bromophenol blue Sigma-Aldrich South Africa 
BSA Sigma-Aldrich South Africa 
Chloroform Sigma-Aldrich South Africa 
DEPC water Ambion USA 
Dc Protein Assay Bio-Rad South Africa 
E.coli FastMedia™ LB Agar Amp IPTG/X-Gal Fermantas Canada 
E.coli JM109 Promega USA 
ECl detection fluid Amersham Biosciences UK 
EDTA Sigma-Aldrich South Africa 
Ethanol Merck South Africa 
Ethidium bromide (10 mg/ml) Sigma-Aldrich South Africa 
ExoSAPit USB Corporation USA 
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Reagent Supplier  
   
Fat free milk powder Pick ‘n Pay South Africa 
GIBCO® GlutaMAX™ media Invitrogen USA 
Glycerol Sigma-Aldrich South Africa 
Glycine Sigma-Aldrich South Africa 
Histopaque H8889 Sigma-Aldrich South Africa 
Human AB Serum (10%) Sigma-Aldrich South Africa 
Imprint™ DNA Modification Kit Sigma-Aldrich South Africa 
Isopropanol Sigma-Aldrich South Africa 
LightCycler® FastStart DNA Master SYBR Green I Kit Roche South Africa 
Nucleon BACC3 Kit for blood and cell cultures Amersham Biosciences UK 
Orange loading dye solution Inqaba Biotechnology South Africa 
Methanol Sigma-Aldrich South Africa 
Middlebrook oleic-albumin-dextrose-catalase (OADC) BD Scientific USA 
Middlebrook 7H9 broth BD Scientific USA 
Middlebrook 7H11 Agar  BD Scientific USA 
PCR primers UCT South Africa 
pGEM-T Easy vector Promega USA 
Phenol Sigma-Aldrich South Africa 
Promega 10X ligase buffer Whitehead Scientific South Africa 
Promega PureYield Plasmid Midiprep System Whitehead Scientific South Africa 
Promega T4 DNA ligase Whitehead Scientific South Africa 
Promega Wizard Plus SV Miniprep Kit Whitehead Scientific South Africa 
Promega Wizard SV Gel and PCR Clean-up System Whitehead Scientific South Africa 
RPMI-1640 Sigma-Aldrich South Africa 
Sodium Dodecyl Sulphate (SDS) Sigma-Aldrich South Africa 
Sodium Chloride (NaCl) Sigma-Aldrich South Africa 
Shrimp alkaline phosphatase Amersham Biosciences Germany 
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Reagent Supplier  
   
Super-therm GOLD Hotstart TAQ DNA polymerase Southern Cross Biotechnology South Africa 
T4 DNA ligase Promega USA 
TaqMan SNP Genotyping Assay Mix Applied Biosystems South Africa 
TaqMan SNP Genotyping assays Applied Biosystems South Africa 
TEMED Sigma-Aldrich South Africa 
Transcriptor First Strand cDNA Synthesis Kit Roche Germany 
Tris Sigma-Aldrich South Africa 
TRIzol® reagent Invitrogen USA 
Tween 20 Sigma-Aldrich South Africa 
Wizard Plus SV Miniprep Kit Promega USA 
Wizard SV Gel and PCR Clean-Up System Promega USA 
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ADDENDUM 3: EQUIPMENT 
 
Equipment Supplier  
   
1ml/cc insulin syringe Supra Latex South Africa 
6 well tissue culture dishes Nunc Denmark 
96 deepwell storage plates Eppendorf Germany 
ABI Prism 9700 HT Sequence Detection System Applied Biosystems Germany 
Autoflow CO2 water jacketed incubator Thermofisher Scientific USA 
BD Falcon tubes (15ml and 50ml) Scientific Group South Africa 
Cell scraper Corning Incorporated USA 
Consort electrophoresis power supply Sigma-Aldrich South Africa 
Disposable serological  pipettes (10ml) Corning Incorporated USA 
Easypet Eppendorf Germany 
EpMotion 5070 Eppendorf Germany 
EpTips Motion Filter 1-50ul Merck South Africa 
Eppendorf 0.5, 1.5 and 2 ml tubes Merck South Africa 
Eppendorf Centrifuge 5810R Merck South Africa 
Eppendorf Mastercycler Merck South Africa 
G-box Syngene UK 
GeneAmp PCR system 9700 Applied Biosystems Germany 
Hybond-P PVDF GE Healthcare USA 
Hypercasette™ Amersham Life Sciences England 
Hyper Processor Amersham Pharmacia Biotech USA 
LightCycler 1.5 system Roche Germany 
LightCycler® Capillary Roche Germany 
Magnetic stirrer Velp Scientifica Italy 
Medical X-ray film Agfa South Africa 
MicroAmp 384-well reaction plates Applied Biosystems South Africa 
 1
00
 
 
 
Equipment 
 
Supplier 
 
 
   
MicroAmp TM Optical Adhesive Covers Applied Biosystems South Africa 
milli-PORE milli-PORE USA 
Nanodrop ND-1000 Spectrophotometer Inqaba Biotechnology South Africa 
Orbital Shaker Incubator LM-530 Yih Der Japan 
Petri dishes Nunc Denmark 
Pipettes (2µl, 20µl, 200µl, 1000µl) Eppendorf Germany 
Pipette tips Whitehead Scientific South Africa 
Protein gel apparatus Bio-Rad South Africa 
qPCR capillaries Roche South Africa 
Single and multi-channel pipettes Eppendorf Germany 
Ultrospec 4051 LKB Biochrom UK 
Vacuette Heparin tubes Greiner Bio-One Austria 
Vortex mixer VM-1000 Digisystem lab. Instruments, inc. Taiwan 
Western blot apparatus Bio-Rad South Africa 
Western blotting filter paper Thermo Scientific USA 
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ADDENDUM 4: SOFTWARE PACKAGES 
 
 
Bioedit Sequence Alignment Editor v7.05 Ibis Therapeutics, USA 
Cocaphase MRC Human Genome Mapping Project, UK 
Epi Info 2000 Centres for Disease Control and Prevention, 
USA 
Haploview v4.1. Daly lab, Broad Institute, USA 
Nanodrop v3.0.1 Inqaba Biotechnology, South Africa 
Prism 5.02 GraphPad Software, Inc., California, USA 
Sequencher v4.2 Gene Codes Corporaration, USA 
SDS 2.0 Applied Biosystems, Germany 
 
 
 
 
ADDENDUM 5: ONLINE RESOURCES 
 
 
BiQ Analyzer software package biq-analyzer.bioinf.mpi-inf.mpg.de/ 
BLAST www.ncbi.nlm.nih.gov/BLAST 
CHIP Bioinformatics snpper.chip.org/bio/snpper-enter 
dbSNP www.ncbi.nlm.nih.gov/SNP 
HapMap www.hapmap.org 
Human BLAT search genome.ucsc.edu/cgi-bin/hgBlat 
PubMed www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed 
 
 
 
